Method for artificially producing human tissue-specific stem / progenitor cells

Abstract

A method for artificially producing human tissue-specific stem cells (iTS cells) / human tissue-specific progenitor cells (iTP cells). [Solution] A method for producing human tissue-specific stem / progenitor cells, comprising: an initialization step of initializing human somatic cells with reprogramming factors; and a selection step of selecting, from the cell population initialized by the initialization step, cells expressing markers selectively expressed in human tissue stem / progenitor cells derived from the human somatic cells. iTS / iTP cells produced by the present invention have a certain degree of self-renewal ability and are capable of tissue-specific differentiation induction. Furthermore, iTS / iTP cells are superior to ES / iPS cells in that they have higher establishment efficiency and differentiation induction efficiency and do not form teratomas.

Description

[Technical Field]

[0001] The present invention relates to a method for artificially producing human tissue-specific stem / progenitor cells. [Background technology]

[0002] Embryonic stem cells (hereinafter referred to as "ES cells") and induced pluripotent stem cells (hereinafter referred to as "iPS cells") are cells with the ability to self-replicate and differentiate. ES / iPS cells are theoretically capable of creating any cell or organ, making them the mainstream of development in the field of regenerative medicine. However, there are still several issues with ES / iPS cells that have yet to be resolved. One of the problems is the possibility of teratomas forming when ES / iPS cells themselves are transplanted into a living organism. Another problem is that an efficient method for inducing differentiation from ES / iPS cells into target cells has not yet been established. Because of these issues, although ES / iPS cells are highly useful and have many hidden possibilities, they are not necessarily a fully established technology and are still in the development stage.

[0003] Incidentally, the inventor has previously succeeded in artificially producing mouse pancreatic-specific stem cells (induced tissue-specific stem cells from pancreatic tissue, hereinafter also referred to as "iTS-P cells") (Patent Document 1). This technology involves extracting islet cells from mouse pancreatic tissue, reprogramming them with reprogramming factors (OCT3 / 4, SOX2, KLF4, c-MYC), and selecting cells that express Pdx1 to create mouse iTS-P cells. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2012 / 044486 Brochure DISCLOSURE OF THE INVENTION [Problem to be solved by the invention]

[0005] Induced tissue-specific stem cells (iTS cells) or induced tissue-specific progenitor cells (hereinafter referred to as "iTP cells") have a certain degree of self-renewal ability and can be induced to differentiate in a tissue-specific manner. Furthermore, iTS / iTP cells are superior to ES / iPS cells in that they have higher establishment and differentiation induction efficiencies and do not form teratomas. However, there have been no reports on human iTS / iTP cells.

[0006] Therefore, the objective of the present invention is to develop human iTS / iTP cells. [Means for solving the problem]

[0007] As a result of extensive research, the inventors discovered that human iTS / iTP cells can be obtained by initializing somatic cells derived from human tissue and selecting them using tissue markers, thereby completing the invention.

[0008] The present invention comprises the following configurations.

[0009] The method for producing human mesenchymal tissue-specific stem / progenitor cells of the present invention comprises the steps of: Human adipose-derived mesenchymal stem cells that had lost their proliferation ability due to subculture were Reprogramming factors (OCT4, SOX2, KLF4, GLIS1) were introduced into the embryonic stem cells. After the gene is introduced, Has proliferation ability From the cell group, 5 or more times Subculture By doing so, NANOG, OCT 4 , SOX2 gene expression Significantly higher than ES / iPS cells Low, CD29, CD90, CD44, CD73, CD105, CD55, CD59, CD71, CD166, IGF1, HGF, FGF2, VEGFA, EGF genes but Expression is doing Cells obtain , It is characterized by: [Effects of the Invention]

[0013] The present invention makes it possible to provide human iTS / iTP cells. [Brief explanation of the drawings]

[0014] [Figure 1] (A) Diagram showing the method for generating pancreatic-derived human iTS / iTP cells. (B) Diagram showing the differentiation process from iPS cells to insulin-producing cells and expression markers. [Figure 2] (A) Magnified photographs of each cell type (GTE: Gut Endoderm). (B) Diagram showing the number of colonies of each cell type produced by each reprogramming factor. (C) Diagram showing PDX1 mRNA expression in each cell type. (D) Diagram showing the incorporation of the introduced gene (plasmid) into the chromosome. [Figure 3] (A) Diagram of PDX1 mRNA expression in each cell type. (B) Diagram of chromosomal incorporation of the introduced gene (plasmid). [Figure 4] (A) ES cell marker expression in each cell type. (B) Endoderm cell marker expression in each cell type. (C) Pancreatic cell marker expression in each cell type. [Figure 5] (A) ES cell marker expression in each cell type. (B) Endoderm cell marker expression in each cell type. (C) Pancreatic cell marker expression in each cell type. [Figure 6](A) Diagram showing the results of examining the proliferation ability of each cell. (B) Diagram showing the results of inducing differentiation of iTP cells and examining the expression of insulin protein and C-peptide. (C) Diagram showing the results of examining insulin mRNA expression in each cell after differentiation induction. (D) Diagram showing the results of examining the insulin expression level in each cell when glucose loading was performed. (E) Diagram showing the stimulation index in each cell. [Figure 7] A diagram showing the methylation status of each marker promoter region in each cell. [Figure 8] (A) Diagram showing the results of gene analysis using microarrays for each cell. (B) Diagram showing the results of gene cluster analysis using microarrays for each cell. [Figure 9] (A) A diagram showing albumin mRNA expression in each cell type when induced to differentiate into hepatocytes. (B) A diagram showing α1-AT mRNA expression in each cell type when induced to differentiate into hepatocytes. (C) A diagram showing PECAM1 mRNA expression in each cell type when induced to differentiate into mesodermal cells. (D) A diagram showing MIXL1 mRNA expression in each cell type when induced to differentiate into mesodermal cells. (E) A diagram showing ZIC1 mRNA expression in each cell type when induced to differentiate into neuroectodermal cells. (F) A diagram showing SOX1 mRNA expression in each cell type when induced to differentiate into neuroectodermal cells. [Figure 10] A diagram showing the method for producing human mesenchymal cell-derived iTS / iTP cells. [Figure 11] (A) Diagram showing the culture status of each cell. (B) Diagram showing the results of vector detection by RT-PCR analysis. (C) Diagram showing the mRNA expression of each ES cell marker in each cell. (D) Diagram showing the proliferation status of hADSC and hiTS-M cells. (E) Diagram showing the expression of TERT mRNA in each cell. [Figure 12] The expression of surface antigens in each cell type was examined by flow cytometry. [Figure 13](A) Diagram of the mRNA expression of hADSC-specific markers in each cell type. (B) Diagram of the mRNA expression of each marker in each cell type. (C) Diagram of the protein expression of hADSC-specific markers in each cell type by flow cytometry. (D) Diagram of the protein expression of hADSC-specific markers in each cell type by immunostaining. [Figure 14] (A) Oil red staining results when hiTS-M cells were induced to differentiate using an adipocyte differentiation-inducing medium. (B) Alizarin Red S staining results when hiTS-M cells were induced to differentiate using an osteoblast differentiation-inducing medium. (C) Expression levels of the osteoblast marker RUNX2 mRNA in each cell type. [Figure 15] A diagram showing the methylation status of each marker promoter region in each cell. [Figure 16] (A) Diagram showing the results of gene analysis using microarrays for each cell. (B) Diagram showing the results of gene cluster analysis using microarrays for each cell. DETAILED DESCRIPTION OF THE INVENTION

[0015] The present invention is characterized by comprising an initialization step of initializing human somatic cells using initialization factors, and a selection step of selecting cells from the group of cells initialized by the initialization step that express markers that are selectively expressed in human tissue stem cells / human tissue progenitor cells derived from the human somatic cells. That is, human somatic cells are reprogrammed with reprogramming factors, and the resulting cell populations are selected based on the expression of tissue-specific markers.

[0016] In the present invention, the human somatic cells are not particularly limited as long as they can be collected from a human and can be obtained in accordance with legally and ethically appropriate procedures, and any human somatic cells can be used. Such human somatic cells can be derived, for example, from pancreatic tissue, liver tissue, mesenchymal cells, kidney tissue, ureteral tissue, bladder tissue, lung and tracheal tissue, brain and nervous tissue, retinal tissue, corneal tissue, pharyngeal and oral epithelium, esophageal epithelium, gastric and intestinal epithelium, bile duct and gallbladder tissue, spleen tissue, lymph gland and lymphatic tissue, blood (bone marrow cells), skeletal muscle tissue, smooth muscle tissue, adipose tissue, cardiac tissue, vascular tissue, thyroid tissue, parathyroid gland, adrenal tissue, prostate tissue, gonadal tissue, uterine tissue, skin tissue, hair root tissue, mammary gland, thymus, placental tissue, umbilical cord tissue, amniotic tissue, sweat gland tissue, and bone tissue.

[0017] In the present invention, the reprogramming step is a step of reprogramming human somatic cells with reprogramming factors to obtain a cell population. The reprogramming step does not need to be particularly limited as long as it is possible to obtain such a reprogrammed somatic cell population, and any appropriate method can be adopted depending on the somatic cells.

[0018] In the reprogramming step, genes for reprogramming factors are introduced into human somatic cells. The gene introduction does not need to be particularly limited as long as it is possible to introduce genes for reprogramming factors into human somatic cells, and various techniques can be adopted depending on the human somatic cells. For gene transfer, physical / chemical methods or biological methods can be selected and used as appropriate.

[0019] Examples of physical and chemical methods include the calcium phosphate method, the DEAE-dextran method, the lipofection method, the electroporation method, and the microinjection method, and preferably, the electroporation method can be used. Biological techniques include those that use viral vectors, such as adenoviral vectors, retroviral vectors, and lentiviral vectors.

[0020] The reprogramming factors used for gene transfer do not need to be particularly limited as long as they are capable of reprogramming human somatic cells, and any reprogramming factor suitable for human somatic cells can be used. Typically, four reprogramming factors known as Yamanaka factors, OCT3 / 4, SOX2, KLF4, and c-MYC, can be used. Furthermore, these four reprogramming factors can be appropriately supplemented or substituted with L-MYC, Nanog, LIN28, SV40LT, p53 shRNA, GLIS1, and other factors. In the case of pancreatic cells, six reprogramming factors can be used: OCT4, p53 shRNA, SOX2, KLF4, L-MYC, and LIN28, as shown in Experimental Example I. In the case of mesenchymal cells, four reprogramming factors can be used: OCT4, SOX2, KLF4, and GLIS1, as shown in Experimental Example II.

[0021] Cell populations transfected with reprogramming factors can be cultured and passaged by commonly used methods to produce colonies. For example, transfected cell populations can be seeded on feeder cells and the medium changed as needed, and this process can be repeated until colonies are obtained. Colonies can also be produced using feeder-free medium such as Matrigel.

[0022] In the present invention, the selection step is a step of selecting cells that express a marker (hereinafter referred to as "tissue-specific marker") that is selectively expressed in human tissue stem cells / human tissue progenitor cells derived from human somatic cells from the cell population (colony) obtained by the reprogramming step. The selection step does not need to be particularly limited as long as it allows selection of human tissue stem cells / human tissue progenitor cells, and various techniques can be adopted. Tissue-specific markers may include mRNA, proteins, etc., which may be used alone or in combination depending on the target human tissue stem cells / human tissue progenitor cells. Furthermore, tissue-specific markers may be used alone or in combination of two or more types.

[0023] As the tissue-specific marker, one or more of the markers shown in Markers 1 to 20733 can be selected. In other words, since these are not expressed in ES / iPS cells, the inventors have found them to be suitable markers for human tissue stem cells / human tissue progenitor cells. The markers are A1BG antisense RNA 1 (A1BG-AS1, marker 1), APOBEC1 complementation factor (A1CF, marker 2), APOBEC1 complementation factor (A1CF, marker 3), alpha-2-macroglobulin (A2M, marker 4), A2M antisense RNA 1 (head to head) (A2M-AS1, marker 5), alpha-2-macroglobulin-like 1 (A2ML1, marker 6), alpha-2-macroglobulin-like 1 (A2ML1, marker 7), alpha-2-macroglobulin pseudogene 1 (A2MP1, marker 8), alpha 1,4-galactosyltransferase (A4GALT, marker 9), alpha-1,4-N-acetylglucosaminyltransferase (A4GNT, marker 10), uncharacterized LOC100506677 (AA06, marker 11), and acetoacetyl-CoA synthetase pseudogene. 1 (AACSP1, marker 12), arylacetamide deacetylase (AADAC, marker 13), arylacetamide deacetylase-like 2 (AADACL2, marker 14), arylacetamide deacetylase pseudogene 1 (AADACP1, marker 15), AP2 associated kinase 1 (AAK1, marker 16), AP2 associated kinase 1 (AAK1, marker 17), AP2 associated kinase 1 (AAK1, marker 18), AP2 associated kinase 1 (AAK1, marker 19), AP2 associated kinase 1 (AAK1, marker 20), adipogenesis associated,Mth938 domain containing (AAMDC, marker 21), aralkylamine N-acetyltransferase (AANAT, marker 22), aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT, marker 23), apoptosis-associated transcript in bladder cancer (AATBC, marker 24), 4-aminobutyrate aminotransferase (ABAT, marker 25), ATP binding cassette subfamily A member 1 (ABCA1, marker 26), ATP binding cassette subfamily A member 1 (ABCA1, marker 27), ATP binding cassette subfamily A member 12 (ABCA12, marker 28), ATP binding cassette subfamily A member 13 (ABCA13, marker 29), ATP binding cassette subfamily A member 13 (ABCA13, marker 30), ATP binding cassette subfamily A member 13 (ABCA13, marker 31), ATP binding cassette subfamily A member 17, pseudogene (ABCA17P, marker 32), ATP binding cassette subfamily A member 2 (ABCA2, marker 33), ATP binding cassette subfamily A member 2 (ABCA2, marker 34), ATP binding cassette subfamily A member 2 (ABCA2, marker 35), ATP binding cassette subfamily A member 4 (ABCA4, marker 36), ATP binding cassette subfamily A member 4 (ABCA4, marker 37),ATP binding cassette subfamily A member 5(ABCA5, marker 38),ATP binding cassette subfamily A member 6(ABCA6, marker 39),ATP binding cassette subfamily A member 8(ABCA8, marker 40),ATP binding cassette subfamily A member 8(ABCA8, marker 41),ATP binding cassette subfamily A member 8(ABCA8, marker 42),ATP binding cassette subfamily A member 9(ABCA9, marker 43),ATP binding cassette subfamily A member 9(ABCA9, marker 44),ATP binding cassette subfamily A member 9(ABCA9, marker 45),ATP binding cassette subfamily B member 1(ABCB1, marker 46),ATP binding cassette subfamily B member 1(ABCB1, marker 47),ATP binding cassette subfamily B member 1 / / / ATP binding cassette subfamily B member 4(ABCB1 / / / ABCB4, marker 48),ATP binding cassette subfamily B member 11(ABCB11, marker 49),ATP binding cassette subfamily B member 11 (ABCB11, marker 50), ATP binding cassette subfamily B member 4 (ABCB4, marker 51), ATP binding cassette subfamily B member 4 (ABCB4, marker 52), ATP binding cassette subfamily B member 5 (ABCB5, marker 53),ATP binding cassette subfamily B member 5(ABCB5,マーカー54),ATP binding cassette subfamily B member 5(ABCB5,マーカー55),ATP binding cassette subfamily B member 5(ABCB5,マーカー56),ATP binding cassette subfamily B member 6 (Langereis blood group)(ABCB6,マーカー57),ATP binding cassette subfamily B member 8(ABCB8,マーカー58),ATP binding cassette subfamily B member 8 / / / acid sensing ion channel 3(ABCB8 / / / ASIC3,マーカー59),ATP binding cassette subfamily B member 9(ABCB9,マーカー60),ATP binding cassette subfamily B member 9(ABCB9,マーカー61),ATP binding cassette subfamily B member 9(ABCB9,マーカー62),ATP binding cassette subfamily C member 11(ABCC11,マーカー63),ATP binding cassette subfamily C member 11(ABCC11,マーカー64),ATP binding cassette subfamily C member 12(ABCC12,マーカー65),ATP binding cassette subfamily C member 12(ABCC12,マーカー66),ATP binding cassette subfamily C member 13, pseudogene(ABCC13,マーカー67),ATP binding cassette subfamily C member 13, pseudogene(ABCC13,マーカー68),ATP binding cassette subfamily C member 13,pseudogene(ABCC13, marker 69),ATP binding cassette subfamily C member 13, pseudogene(ABCC13, marker 70),ATP binding cassette subfamily C member 2(ABCC2, marker 71),ATP binding cassette subfamily C member 3(ABCC3, marker 72),ATP binding cassette subfamily C member 3(ABCC3, marker 73),ATP binding cassette subfamily C member 3(ABCC3, marker 74),ATP binding cassette subfamily C member 3(ABCC3, marker 75),ATP binding cassette subfamily C member 3(ABCC3, marker 76),ATP binding cassette subfamily C member 4(ABCC4, marker 77),ATP binding cassette subfamily C member 6 / / / multidrug resistance-associated protein 6(ABCC6 / / / LOC105369239, marker 78), ATP binding cassette subfamily C member 6 / / / multidrug resistance-associated protein 6(ABCC6 / / / LOC105369239, marker 79), ATP binding cassette subfamily C member 6 pseudogene 1 (functional) (ABCC6P1, marker 80), ATP binding cassette subfamily C member 8 (ABCC8, marker 81), ATP binding cassette subfamily C member 8 (ABCC8, marker 82), ATP binding cassette subfamily C member 9 (ABCC9, marker 83),ATP binding cassette subfamily C member 9 (ABCC9, marker 84), ATP binding cassette subfamily C member 9 (ABCC9, marker 85), ATP binding cassette subfamily C member 9 (ABCC9, marker 86), ATP binding cassette subfamily C member 9 (ABCC9, marker 87), ATP binding cassette subfamily D member 1 (ABCD1, marker 88), ATP binding cassette subfamily D member 1 pseudogene 2 (ABCD1P2, marker 89), ATP binding cassette subfamily D member 2 (ABCD2, marker 90), ATP binding cassette subfamily D member 4 (ABCD4, marker 91), ATP binding cassette subfamily F member 2 (ABCF2, marker 92), ATP binding cassette subfamily G member 1 (ABCG1, marker 93), ATP binding cassette subfamily G member 1 (ABCG1, marker 94), ATP binding cassette subfamily G member 1 (ABCG1, marker 95), ATP binding cassette subfamily G member 1 (ABCG1, marker 96), ATP binding cassette subfamily G member 4 (ABCG4, marker 97), ATP binding cassette subfamily G member 5 (ABCG5, marker 98), ATP binding cassette subfamily G member 8 (ABCG8, marker 99), abhydrolase domain containing 1 (ABHD1, marker 100), abhydrolase domain containing 1 (ABHD1,Marker 101), abhydrolase domain containing 1 (ABHD1, marker 102), abhydrolase domain containing 11 (ABHD11, marker 103), abhydrolase domain containing 11 (ABHD11, marker 104), abhydrolase domain containing 12B (ABHD12B, marker 105), abhydrolase domain containing 12B (ABHD12B, marker 106), abhydrolase domain containing 15 (ABHD15, marker 107), abhydrolase domain containing 16A (ABHD16A, marker 108), abhydrolase domain containing 16B (ABHD16B, marker 109), abhydrolase domain containing 17B (ABHD17B, marker 110), abhydrolase domain containing 2 (ABHD2, marker 111), abhydrolase domain containing 4 (ABHD4, marker 112), abhydrolase domain containing 5 (ABHD5, marker 113), abhydrolase domain containing 6 (ABHD6, marker 114), abl-interactor 1 (ABI1, marker 115), abl-interactor 2 (ABI2, marker 116), ABI family, member 3 (NESH) binding protein (ABI3BP, marker 117), ABI family, member 3 (NESH) binding protein (ABI3BP, marker 118), actin binding LIM protein family, member 2 (ABLIM2, marker 119), actin binding LIM protein family, member 2 (ABLIM2, marker 120), actin binding LIM protein family, member 2 (ABLIM2,Marker 121), actin binding LIM protein family, member 2 (ABLIM2, marker 122), actin binding LIM protein family, member 3 (ABLIM3, marker 123), ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (ABO, marker 124), ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (ABO, marker 125), ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (ABO, marker 126), actin binding Rho activating protein (ABRA, marker 127), actin binding Rho activating protein (ABRA, marker 128), ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1, marker 129), ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1, marker 130), ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1, marker 131), ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1, marker 132), ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1, marker 133),ankyrin repeat and BTB (POZ) domain containing 2 (ABTB2, marker 134), acetyl-CoA carboxylase beta (ACACB, marker 135), acetyl-CoA carboxylase beta (ACACB, marker 136), acyl-CoA dehydrogenase family, member 10 (ACAD10, marker 137), acyl-CoA dehydrogenase, long chain (ACADL, marker 138), acyl-CoA dehydrogenase, long chain (ACADL, marker 139), acyl-CoA dehydrogenase, C-2 to C-3 short chain (ACADS, marker 140), aggrecan (ACAN, marker 141), aggrecan (ACAN, marker 142), aggrecan (ACAN, marker 143), ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 (ACAP1, marker 144), ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 (ACAP1, marker 145), ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2, marker 146), ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 (ACAP3, marker 147), acetyl-CoA acetyltransferase 1 (ACAT1, marker 148), acetyl-CoA acetyltransferase 1 (ACAT1, marker 149), acyl-CoA binding domain containing 4 (ACBD4, marker 150), angiotensin I converting enzyme (ACE, marker 151), angiotensin I converting enzyme (ACE, marker 152), alkaline ceramidase 1 (ACER1, marker 153),alkaline ceramidase 3 (ACER3, marker 154), alkaline ceramidase 3 (ACER3, marker 155), acetylcholinesterase (Yt blood group) (ACHE, marker 156), acetylcholinesterase (Yt blood group) (ACHE, marker 157), atypical chemokine receptor 1 (Duffy blood group) (ACKR1, marker 158), atypical chemokine receptor 1 (Duffy blood group) / / / cell adhesion molecule 3 (ACKR1 / / / CADM3, marker 159), atypical chemokine receptor 2 (ACKR2, marker 160), atypical chemokine receptor 2 (ACKR2, marker 161), atypical chemokine receptor 2 (ACKR2, marker 162), atypical chemokine receptor 3 (ACKR3, marker 163), atypical chemokine receptor 4 (ACKR4, marker 164), aminocarboxymuconate semialdehyde decarboxylase (ACMSD, marker 165), aconitase 1, soluble (ACO1, marker, 166), acyl-CoA thioesterase 11 (ACOT11, marker 167), acyl-CoA thioesterase 11 (ACOT11, marker 168), acyl-CoA thioesterase 11 (ACOT11, marker 169), acyl-CoA thioesterase 12 (ACOT12, marker 170), acyl-CoA thioesterase 6 (ACOT6, marker 171), acyl-CoA oxidase 1, palmitoyl (ACOX1, marker 172), acyl-CoA oxidase 1, palmitoyl (ACOX1, marker 173), acyl-CoA oxidase-like (ACOXL, marker 174), acid phosphatase 1, soluble (ACP1, marker 175), acid phosphatase 6, lysophosphatidic (ACP6, marker 176), acid Phosphatase, prostate (ACPP, marker 177), acid phosphatase, prostate (ACPP, marker 178), acrosin (ACR, marker 179), acrosin binding protein (ACRBP, marker 180), acrosin binding protein (ACRBP, marker 181), acrosin binding protein (ACRBP, marker 182), acrosomal vesicle protein 1 (ACRV1, marker 183), acrosomal vesicle protein 1 (ACRV1, marker 184), acrosomal vesicle protein 1 (ACRV1, marker 185), acrosomal vesicle protein 1 (ACRV1, marker 186), acrosomal vesicle protein 1 (ACRV1, marker 187), acrosomal vesicle protein 1 (ACRV1, marker 188), acyl-CoA synthetase bubblegum family member 1 (ACSBG1, marker 189),Acyl-CoA synthetase bubblegum family member 1 (ACSBG1, marker 190), acyl-CoA synthetase bubblegum family member 2 (ACSBG2, marker 191), acyl-CoA synthetase family member 3 (ACSF3, marker 192), acyl-CoA synthetase family member 3 (ACSF3, marker 193), acyl-CoA synthetase family member 3 (ACSF3, marker 194), acyl-CoA synthetase long-chain family member 4 (ACSL4, marker 195), acyl-CoA synthetase long-chain family member 4 (ACSL4, marker 196), acyl-CoA synthetase long-chain family member 5 (ACSL5, marker 197), acyl-CoA synthetase long-chain family member 5 (ACSL5, marker 198), acyl-CoA synthetase long-chain family member 6 (ACSL6, marker 199), acyl-CoA synthetase long-chain family member 6 (ACSL6, marker 200), acyl-CoA synthetase long-chain family member 6 (ACSL6, marker 201), acyl-CoA synthetase long-chain family member 6 (ACSL6, marker 202), acyl-CoA synthetase medium-chain family member 1 (ACSM1, marker 203), acyl-CoA synthetase medium-chain family member 1 (ACSM1, marker 204), acyl-CoA synthetase medium-chain family member 2A (ACSM2A, marker 205),acyl-CoA synthetase medium-chain family member 2A(ACSM2A, marker 206),acyl-CoA synthetase medium-chain family member 2A / / / acyl-CoA synthetase medium-chain family member 2B(ACSM2A / / / ACSM2B, marker 207),acyl-CoA synthetase medium-chain family member 2A / / / acyl-CoA synthetase medium-chain family member 2B(ACSM2A / / / ACSM2B, Marker 208), acyl-CoA synthetase medium-chain family member 2B(ACSM2B, Marker 209), acyl-CoA synthetase medium-chain family member 3(ACSM3, Marker 210), acyl-CoA synthetase medium-chain family member 3(ACSM3, Marker 211), acyl-CoA synthetase medium-chain family member 5 (ACSM5, marker 212), acyl-CoA synthetase medium-chain family member 5 (ACSM5, marker 213), acyl-CoA synthetase medium-chain family member 5 (ACSM5, marker 214), acyl-CoA synthetase short-chain family member 1 (ACSS1, marker 215), acyl-CoA synthetase short-chain family member 1 (ACSS1, marker 216), acyl-CoA synthetase short-chain family member 1 (ACSS1, marker 217), acyl-CoA synthetase short-chain family member 1 (ACSS1, marker 218), actin, alpha 2, smooth muscle,aorta (ACTA2, marker 219), actin, alpha 2, smooth muscle, aorta (ACTA2, marker 220), ACTA2 antisense RNA 1 (ACTA2-AS1, marker 221), actin gamma 1 pseudogene 17 (ACTG1P17, marker 222), actin gamma 1 pseudogene 17 (ACTG1P17, marker 223), actin, gamma 2, smooth muscle, enteric (ACTG2, marker 224), actin-like 10 (ACTL10, marker 225), actin-like 6B (ACTL6B, marker 226), actin-like 6B (ACTL6B, marker 227), actin-like 7A (ACTL7A, marker 228), actin-like 7B (ACTL7B, marker 229), actin-like 8 (ACTL8, marker 230), actin-like 9 (ACTL9, marker 231), actinin, alpha 1 (ACTN1, marker 232), actinin, alpha 2 (ACTN2, marker 233), actinin, alpha 2 (ACTN2, marker 234), actinin, alpha 2 (ACTN2, marker 235), actinin, alpha 2 (ACTN2, marker 236), ARP2 actin-related protein 2 homolog (yeast) (ACTR2, marker 237), ARP2 actin-related protein 2 homolog (yeast) (ACTR2, marker 238), ACTR3B pseudogene 2 (ACTR3BP2, marker 239), ACTR3B pseudogene 2 / / / ACTR3B pseudogene 5 (ACTR3BP2 / / / ACTR3BP5, marker 240), ARP3 actin-related protein 3 homolog C (yeast) (ACTR3C, marker 241), ARP3 actin-related protein 3 homolog C (yeast)(ACTR3C, marker 242),Actin-related protein T2 (ACTRT2, marker 243), activin A receptor type IB (ACVR1B, marker 244), activin A receptor type IB (ACVR1B, marker 245), activin A receptor type IC (ACVR1C, marker 246), activin A receptor type IL (ACVRL1, marker 247), activin A receptor type IL (ACVRL1, marker 248), aminoacylase 1 (ACY1, marker 249), aminoacylase 3 (ACY3, marker 250), aminoacylase 3 (ACY3, marker 251), adenosine deaminase domain containing 1 (ADAD1, marker 252), adenosine deaminase domain containing 1 (ADAD1, marker 253), adenosine deaminase domain containing 2 (ADAD2, marker 254), ADAM metallopeptidase domain 11 (ADAM11, marker 255), ADAM metallopeptidase domain 11 (ADAM11, marker 256), ADAM metallopeptidase domain 12 (ADAM12, marker 257), ADAM metallopeptidase domain 12 (ADAM12, marker 258), ADAM metallopeptidase domain 12 (ADAM12, marker 259), ADAM metallopeptidase domain 12 (ADAM12, marker 260), ADAM metallopeptidase domain 12 (ADAM12, marker 261), ADAM metallopeptidase domain 17 (ADAM17, marker 262), ADAM metallopeptidase domain 18 (ADAM18, marker 263), ADAM metallopeptidase domain 18 (ADAM18, marker 264),ADAM metallopeptidase domain 19 (ADAM19, marker 265), ADAM metallopeptidase domain 2 (ADAM2, marker 266), ADAM metallopeptidase domain 20 (ADAM20, marker 267), ADAM metallopeptidase domain 20 (ADAM20, marker 268), ADAM metallopeptidase domain 21 (ADAM21, marker 269), ADAM metallopeptidase domain 21 (ADAM21, marker 270), ADAM metallopeptidase domain 22 (ADAM22, marker 271), ADAM metallopeptidase domain 22 (ADAM22, marker 272), ADAM metallopeptidase domain 22 (ADAM22, marker 273), ADAM metallopeptidase domain 22 (ADAM22, marker 274), ADAM metallopeptidase domain 22 (ADAM22, marker 275), ADAM metallopeptidase domain 22 (ADAM22, marker 276), ADAM metallopeptidase domain 22 (ADAM22, marker 277), ADAM metallopeptidase domain 23 (ADAM23, marker 278), ADAM metallopeptidase domain 28 (ADAM28, marker 279), ADAM metallopeptidase domain 28 (ADAM28, marker 280), ADAM metallopeptidase domain 28 (ADAM28, marker 281), ADAM metallopeptidase domain 29 (ADAM29, marker 282), ADAM metallopeptidase domain 30 (ADAM30, marker 283), ADAM metallopeptidase domain 30 (ADAM30, marker 284), ADAM metallopeptidase domain 32 (ADAM32,marker 285), ADAM metallopeptidase domain 33 (ADAM33, marker 286), ADAM metallopeptidase domain 3A (pseudogene) (ADAM3A, marker 287), ADAM metallopeptidase domain 3B (pseudogene) (ADAM3B, marker 288), ADAM metallopeptidase domain 5 (pseudogene) (ADAM5, marker 289), ADAM metallopeptidase domain 5 (pseudogene) (ADAM5, marker 290), ADAM metallopeptidase domain 6 (pseudogene) (ADAM6, marker 291), ADAM metallopeptidase domain 7 (ADAM7, marker 292), ADAM metallopeptidase domain 7 (ADAM7, marker 293), ADAM metallopeptidase domain 7 (ADAM7, marker 294), ADAM metallopeptidase domain 8 (ADAM8, marker 295), ADAM metallopeptidase domain 9 (ADAM9, marker 296), ADAM-like decysin 1 (ADAMDEC1, marker 297), ADAM metallopeptidase with thrombospondin type 1 motif 10 (ADAMTS10, marker 298), ADAM metallopeptidase with thrombospondin type 1 motif 12 (ADAMTS12, marker 299), ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13, marker 300), ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13, marker 301), ADAM metallopeptidase with thrombospondin type 1 motif 14 (ADAMTS14,marker 302), ADAM metallopeptidase with thrombospondin type 1 motif 15 (ADAMTS15, marker 303), ADAM metallopeptidase with thrombospondin type 1 motif 17 (ADAMTS17, marker 304), ADAM metallopeptidase with thrombospondin type 1 motif 17 (ADAMTS17, marker 305), ADAM metallopeptidase with thrombospondin type 1 motif 17 (ADAMTS17, marker 306), ADAM metallopeptidase with thrombospondin type 1 motif 2 (ADAMTS2, marker 307), ADAM metallopeptidase with thrombospondin type 1 motif 2 (ADAMTS2, marker 308), ADAM metallopeptidase with thrombospondin type 1 motif 2 (ADAMTS2, marker 309), ADAM metallopeptidase with thrombospondin type 1 motif 20 (ADAMTS20, marker 310), ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5, marker 311), ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6, marker 312), ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6, marker 313), ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6, marker 314), ADAM metallopeptidase with thrombospondin type 1 motif 7 (ADAMTS7, marker 315),ADAM metallopeptidase with thrombospondin type 1 motif 7 (ADAMTS7, marker 316), ADAM metallopeptidase with thrombospondin type 1 motif 7 (ADAMTS7, marker 317), ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8, marker 318), ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8, marker 319), ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9, marker 320), ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9, marker 321), ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9, marker 322), ADAMTS9 antisense RNA 1 (ADAMTS9-AS1, marker 323), ADAMTS9 antisense RNA 1(ADAMTS9-AS1, marker 324), ADAMTS9 antisense RNA 2(ADAMTS9-AS2, marker 325), ADAMTS9 antisense RNA 2(ADAMTS9-AS2, marker 326), ADAMTS9 antisense RNA 2(ADAMTS9-AS2, marker 327), ADAMTS9 antisense RNA 2(ADAMTS9-AS2, marker 328), ADAMTS-like 1(ADAMTSL1, marker 329), ADAMTS-like 1(ADAMTSL1, marker 330), ADAMTS-like 1(ADAMTSL1, marker 331), ADAMTS-like 1(ADAMTSL1, marker 332), ADAMTS-like 1(ADAMTSL1, marker 333), ADAMTS-like 1(ADAMTSL1, marker 334),ADAMTS-like 2 (ADAMTSL2, marker 335), ADAMTS-like 3 (ADAMTSL3, marker 336), ADAMTS-like 3 (ADAMTSL3, marker 337), ADAMTS-like 4 (ADAMTSL4, marker 338), ADAMTS-like 4 (ADAMTSL4, marker 339), ADAMTS-like 5 (ADAMTSL5, marker 340), ArfGAP with dual PH domains 2 (ADAP2, marker 341), adenosine deaminase, RNA-specific, B1 (ADARB1, marker 342), adenosine deaminase, RNA-specific, B1 (ADARB1, marker 343), adenosine deaminase, RNA-specific, B1 (ADARB1, marker 344), adenosine deaminase, RNA-specific, B1 (ADARB1, marker 345), adenosine deaminase, RNA-specific, B2 (inactive) (ADARB2, marker 346), adenosine deaminase, RNA-specific, B2 (inactive) (ADARB2, marker 347), aarF domain containing kinase 2 (ADCK2, marker 348), aarF domain containing, ng kinase 3 (ADCK3, marker 349), aarF domain containing kinase 4 (ADCK4, marker 350), aarF domain containing kinase 5 (ADCK5, marker 351), adenylate cyclase 1 (brain) (ADCY1, marker 352), adenylate cyclase 1 (brain) (ADCY1, marker 353), adenylate cyclase 1 (brain) (ADCY1, marker 354), adenylate cyclase 1 (brain) (ADCY1, marker 355), adenylate cyclase 10 (soluble) (ADCY10, marker 356), adenylate cyclase 10 (soluble) (ADCY10, marker 357), adenylate cyclase 10 (soluble) pseudogene 1 (ADCY10P1, marker 358), adenylate cyclase 10 (soluble) pseudogene 1 (ADCY10P1, marker 359), adenylate cyclase 2 (brain) (ADCY2, marker 360), adenylate cyclase 4 (ADCY4, marker 361), adenylate cyclase 5 (ADCY5, marker 362), adenylate cyclase 5 (ADCY5, marker 363), adenylate cyclase 7 (ADCY7, marker 364), adenylate cyclase 8 (brain) (ADCY8, marker 365), adenylate cyclase 9 (ADCY9, marker 366), adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1, marker 367), adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1, marker 368), adenylate cyclase activating polypeptide 1 (pituitary) receptor type I (ADCYAP1R1,Marker 369), ADD3 antisense RNA 1 (ADD3-AS1, marker 370), ADD3 antisense RNA 1 (ADD3-AS1, marker 371), ADD3 antisense RNA 1 (ADD3-AS1, marker 372), androglobin (ADGB, marker 373), adhesion G protein-coupled receptor A1 (ADGRA1, marker 374), adhesion G protein-coupled receptor B1 (ADGRB1, marker 375), adhesion G protein-coupled receptor B3 (ADGRB3, marker 376), adhesion G protein-coupled receptor B3 (ADGRB3, marker 377), adhesion G protein-coupled receptor D1 (ADGRD1, marker 378), adhesion G protein-coupled receptor D2 (ADGRD2, marker 379), adhesion G protein-coupled receptor E1 (ADGRE1, marker 380), adhesion G protein-coupled receptor E2 (ADGRE2, marker 381), adhesion G protein-coupled receptor E2 (ADGRE2, marker 382), adhesion G protein-coupled receptor E3 (ADGRE3, marker 383), adhesion G protein-coupled receptor E5 (ADGRE5, marker 384), adhesion G protein-coupled receptor F1 (ADGRF1, marker 385), adhesion G protein-coupled receptor F1 (ADGRF1, marker 386), adhesion G protein-coupled receptor F1 (ADGRF1, marker 387), adhesion G protein-coupled receptor F1 (ADGRF1, marker 388),adhesion G protein-coupled receptor F2 (ADGRF2, marker 389), adhesion G protein-coupled receptor F3 (ADGRF3, marker 390), adhesion G protein-coupled receptor F3 (ADGRF3, marker 391), adhesion G protein-coupled receptor F4 (ADGRF4, marker 392), adhesion G protein-coupled receptor F4 (ADGRF4, marker 393), adhesion G protein-coupled receptor F5 (ADGRF5, marker 394), adhesion G protein-coupled receptor F5 (ADGRF5, marker 395), adhesion G protein-coupled receptor G1 (ADGRG1, marker 396), adhesion G protein-coupled receptor G3 (ADGRG3, marker 397), adhesion G protein-coupled receptor G3 (ADGRG3, marker 398), adhesion G protein-coupled receptor G4 (ADGRG4, marker 399), adhesion G protein-coupled receptor G5 (ADGRG5, marker 400), adhesion G protein-coupled receptor G6 (ADGRG6, marker 401), adhesion G protein-coupled receptor G6 (ADGRG6, marker 402), adhesion G protein-coupled receptor G7 (ADGRG7, marker 403), adhesion G protein-coupled receptor L2 (ADGRL2, marker 404), adhesion G protein-coupled receptor L3 (ADGRL3, marker 405), adhesion G protein-coupled receptor V1 (ADGRV1, marker 406),adhesion G protein-coupled receptor V1 (ADGRV1, marker 407), adhesion G protein-coupled receptor V1 (ADGRV1, marker 408), adhesion G protein-coupled receptor V1 (ADGRV1, marker 409), alcohol dehydrogenase 1A (class I), alpha polypeptide (ADH1A, marker 410), alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B, marker 411), alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B, marker 412), alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B, marker 413), alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B, marker 414), alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C, marker 415), alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4, marker 416), alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4, marker 417), alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4, marker 418), alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4, marker 419), alcohol dehydrogenase 6 (class V) (ADH6, marker 420), alcohol dehydrogenase 6 (class V) (ADH6, marker 421), alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide (ADH7,Marker 422), acireductone dioxygenase 1 (ADI1, marker 423), adipogenin (ADIG, marker 424), adipogenin (ADIG, marker 425), adiponectin, C1Q and collagen domain containing (ADIPOQ, marker 426), adipogenesis regulatory factor (ADIRF, marker 427), ADIRF antisense RNA 1 (ADIRF-AS1, marker 428), adrenomedullin 5 (putative) (ADM5, marker 429), adenosine A1 receptor (ADORA1, marker 430), adenosine A1 receptor (ADORA1, marker 431), ADORA2A antisense RNA 1 (ADORA2A-AS1, marker 432), ADORA2A antisense RNA 1 (ADORA2A-AS1, marker 433), adenosine A3 receptor (ADORA3, marker 434), adenosine A3 receptor / / / transmembrane and immunoglobulin domain containing 3 (ADORA3 / / / TMIGD3, marker 435), ADP-ribosylarginine hydrolase (ADPRH, marker 436), ADP-ribosylarginine hydrolase (ADPRH, marker 437), ADP-ribosylarginine hydrolase (ADPRH, marker 438), ADP-ribosylhydrolase like 1 (ADPRHL1, marker 439), ADP-ribosylhydrolase like 1 (ADPRHL1, marker 440), adrenoceptor alpha 1A (ADRA1A, marker 441), adrenoceptor alpha 1A (ADRA1A, marker 442), adrenoceptor alpha 1A (ADRA1A, marker 443), adrenoceptor alpha 1A (ADRA1A, marker 444),adrenoceptor alpha 1A (ADRA1A, marker 445), adrenoceptor alpha 1A (ADRA1A, marker 446), adrenoceptor alpha 1A (ADRA1A, marker 447), adrenoceptor alpha 1B (ADRA1B, marker 448), adrenoceptor alpha 1D (ADRA1D, marker 449), adrenoceptor alpha 1D (ADRA1D, marker 450), adrenoceptor alpha 2B (ADRA2B, marker 451), adrenoceptor beta 1 (ADRB1, marker 452), adrenoceptor beta 1 (ADRB1, marker 453), adrenoceptor beta 1 (ADRB1, marker 454), adrenoceptor beta 2 (ADRB2, marker 455), adrenoceptor beta 3 (ADRB3, marker 456), adrenoceptor beta 3 (ADRB3, marker 457), adrenergic beta receptor kinase 1 (ADRBK1, marker 458), adrenergic beta receptor kinase 2 (ADRBK2, marker 459), adenylosuccinate synthase like 1 (ADSSL1, marker 460), androgen-dependent TFPI-regulating protein (ADTRP, marker 461), AE binding protein 2 (AEBP2, marker 462), AFAP1 antisense RNA 1 (AFAP1-AS1, marker 463), AFAP1 antisense RNA 1 (AFAP1-AS1, marker 464), actin filament associated protein 1-like 1 (AFAP1L1, marker 465), AF4 / FMR2 family, member 2 (AFF2, marker 466), AF4 / FMR2 family, member 3 (AFF3, marker 467), AF4 / FMR2 family, member 3 (AFF3, marker 468),AF4 / FMR2 family, member 3 (AFF3, marker 469), AF4 / FMR2 family, member 3 (AFF3, marker 470), AF4 / FMR2 family, member 3 (AFF3, marker 471), AF4 / FMR2 family, member 3 (AFF3, marker 472), AF4 / FMR2 family, member 4 (AFF4, marker 473), AF4 / FMR2 family, member 4 (AFF4, marker 474), AFG3-like AAA ATPase 1, pseudogene (AFG3L1P, marker 475), AFG3-like AAA ATPase 2 (AFG3L2, marker 476), afamin (AFM, marker 477), arylformamidase (AFMID, marker 478), ankyrin repeat and GTPase domain, Arf GTPase activating protein 11 (AGAP11, marker 479), ankyrin repeat and GTPase domain Arf GTPase activating protein 11(AGAP11, marker 480),ArfGAP with GTPase domain, ankyrin repeat and PH domain 2(AGAP2, marker 481),ArfGAP with GTPase domain, ankyrin repeat and PH domain 2(AGAP2, marker 482),ArfGAP with GTPase domain, ankyrin repeat and PH domain 2(AGAP2, marker 483),AGAP2 antisense RNA 1(AGAP2-AS1, marker 484),ArfGAP with GTPase domain, ankyrin repeat and PH domain 4 / / / ArfGAP with GTPase domain, ankyrin repeat and PH domain 6 / / / ArfGAP with GTPase domain,ankyrin repeat and PH domain 9 / / / BMS1 ribosome biogenesis factor pseudogene 5 / / / arf-GAP with GTPase, ANK repeat and PH domain-containing protein 5-like / / / uncharacterized LOC102724455(AGAP4 / / / AGAP6 / / / AGAP9 / / / BMS1P5 / / / LOC101060581 / / / LOC102724455,マーカー485),ArfGAP with GTPase domain, ankyrin repeat and PH domain 6 / / / ArfGAP with GTPase domain, ankyrin repeat and PH domain 9 / / / BMS1 ribosome biogenesis factor pseudogene 5 / / / uncharacterized LOC102724455(AGAP6 / / / AGAP9 / / / BMS1P5 / / / LOC102724455,マーカー486),ArfGAP with GTPase domain, ankyrin repeat and PH domain 9(AGAP9,マーカー487),ArfGAP with GTPase domain, ankyrin repeat and PH domain 9 / / / BMS1 ribosome biogenesis factor pseudogene 5 / / / uncharacterized LOC102724455(AGAP9 / / / BMS1P5 / / / LOC102724455,マーカー488),ATP / GTP binding protein-like 1(AGBL1,マーカー489),ATP / GTP binding protein-like 2(AGBL2,マーカー490),ATP / GTP binding protein-like 3(AGBL3,マーカー491),ATP / GTP binding protein-like 3(AGBL3,マーカー492),ATP / GTP binding protein-like 4 (AGBL4, marker 493), ATP / GTP binding protein-like 4 (AGBL4, marker 494), advanced glycosylation end product-specific receptor (AGER, marker 495), advanced glycosylation end product-specific receptor (AGER, marker 496), ArfGAP with FG repeats 1 (AGFG1, marker 497), ArfGAP with FG repeats 2 (AGFG2, marker 498), ArfGAP with FG repeats 2 (AGFG2, marker 499), ArfGAP with FG repeats 2 (AGFG2, marker 500), ArfGAP with FG repeats 2 (AGFG2, marker 501), ArfGAP with FG repeats 2 (AGFG2, marker 502), angiogenic factor with G-patch and FHA domains 1 (AGGF1, marker 503), acylglycerol kinase (AGK, marker 504), agmatinase (AGMAT, marker 505), argonaute RISC catalytic component 4 (AGO4, marker 506), 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3, marker 507), 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3, marker 508), 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3, marker 509), anterior gradient 2, protein disulphide isomerase family member (AGR2, marker 510), anterior gradient 2, protein disulphide isomerase family member (AGR2, marker 511),anterior gradient 3, protein disulphide isomerase family member (AGR3, marker 512), agrin (AGRN, marker 513), agrin (AGRN, marker 514), agouti-related neuropeptide (AGRP, marker 515), angiotensinogen (serpin peptidase inhibitor, clade A, member 8) (AGT, marker 516), ATP / GTP binding protein 1 (AGTPBP1, marker 517), angiotensin II receptor, type 1 (AGTR1, marker 518), angiotensin II receptor, type 1 (AGTR1, marker 519), angiotensin II receptor, type 2 (AGTR2, marker 520), angiotensin II receptor, type 2 (AGTR2, marker 521), angiotensin II receptor, type 2 (AGTR2, marker 522), alanine-glyoxylate aminotransferase (AGXT, marker 523), alanine-glyoxylate aminotransferase (AGXT, marker 524), alanine-glyoxylate aminotransferase (AGXT, marker 525), alanine--glyoxylate aminotra, ansferase 2 (AGXT2, marker 526), ​​adenosylhomocysteinase like 1 (AHCYL1, marker 527), AT hook, DNA binding motif, containing 1 (AHDC1, marker 528), AT hook, DNA binding motif, containing 1 (AHDC1, marker 529), Abelson helper integration site 1 (AHI1, marker 530), Abelson helper integration site 1 (AHI1, marker 531), AHNAK nucleoprotein (AHNAK, marker 532), AHNAK nucleoprotein (AHNAK, marker 533), AHNAK nucleoprotein (AHNAK, marker 534), aryl-hydrocarbon receptor repressor (AHRR, marker 535), AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) (AHSA2, marker 536), alpha hemoglobin stabilizing Protein (AHSP, marker 537), activation-induced cytidine deaminase (AICDA, marker 538), activation-induced cytidine deaminase (AICDA, marker 539), allograft inflammatory factor 1 (AIF1, marker 540), allograft inflammatory factor 1 (AIF1, marker 541), allograft inflammatory factor 1 (AIF1, marker 542), allograft inflammatory factor 1 (AIF1, marker 543), apoptosis-inducing factor, mitochondrion-associated, 3 (AIFM3, marker 544), androgen-induced 1 (AIG1, marker 545), androgen-induced 1 (AIG1, marker 546),Absent in melanoma 1-like (AIM1L, marker 547), aryl hydrocarbon receptor interacting protein-like 1 (AIPL1, marker 548), autoimmune regulator (AIRE, marker 549), adherens junctions associated protein 1 (AJAP1, marker 550), adherens junctions associated protein 1 (AJAP1, marker 551), ajuba LIM protein (AJUBA, marker 552), adenylate kinase 1 (AK1, marker 553), adenylate kinase 2 (AK2, marker 554), adenylate kinase 5 (AK5, marker 555), adenylate kinase 7 (AK7, marker 556), adenylate kinase 7 (AK7, marker 557), adenylate kinase 7 (AK7, marker 558), adenylate kinase 8 (AK8, marker 559), adenylate kinase 9 (AK9, marker 560), adenylate kinase 9 (AK9, marker 561), A kinase (PRKA) anchor protein 1 (AKAP1, marker 562), A kinase (PRKA) anchor protein 11 (AKAP11, marker 563), A kinase (PRKA) anchor protein 12 (AKAP12, marker 564), A kinase (PRKA) anchor protein 13 (AKAP13, marker 565), A kinase (PRKA) anchor protein 13 (AKAP13, marker 566), A kinase (PRKA) anchor protein 13 (AKAP13, marker 567), A kinase (PRKA) anchor protein 14 (AKAP14, marker 568), A kinase (PRKA) anchor protein 14 (AKAP14, marker 569),A kinase (PRKA) anchor protein 14(AKAP14, marker 570),A kinase (PRKA) anchor protein 17A(AKAP17A, marker 571),A kinase (PRKA) anchor protein 3(AKAP3, marker 572),A kinase (PRKA) anchor protein 4(AKAP4, marker 573),A kinase (PRKA) anchor protein 5(AKAP5, marker 574),A kinase (PRKA) protein anchor 5(AKAP5, marker 575),A kinase (PRKA) anchor protein 6(AKAP6, marker 576),A kinase (PRKA) anchor protein 6(AKAP6, marker 577),A kinase (PRKA) anchor protein 8-like(AKAP8L, marker 578),A kinase (PRKA) anchor protein 9(AKAP9, marker 579),A kinase (PRKA) anchor protein 9(AKAP9, marker 580), AT-hook transcription factor(AKNA, marker 581), AKNA domain containing 1(AKNAD1, marker 582), AKNA domain containing 1(AKNAD1, marker 583), AKNA domain containing 1(AKNAD1, marker 584), aldo-keto reductase family 1, member C1(AKR1C1, marker 585), aldo-keto reductase family 1, member C1(AKR1C1, marker 586), aldo-keto reductase family 1, member C1(AKR1C1, marker 587), aldo-keto reductase family 1, member C1 / / / aldo-keto reductase family 1, member C2(AKR1C1 / / / AKR1C2, marker 588),Aldo-keto reductase family 1, member C2 (AKR1C2, marker 589), aldo-keto reductase family 1, member C4 (AKR1C4, marker 590), aldo-keto reductase family 1, member C6, pseudogene (AKR1C6P, marker 591), aldo-keto reductase family 1, member D1 (AKR1D1, marker 592), aldo-keto reductase family 1, member E2 (AKR1E2, marker 593), aldo-keto reductase family 1, member E2 (AKR1E2, marker 594), aldo-keto reductase family 1, member E2 (AKR1E2, marker 595), v-akt murine thymoma viral oncogene homolog 2 (AKT2, marker 596), v-akt murine thymoma viral oncogene homolog 2 (AKT2, marker 597), v-akt murine thymoma viral oncogene homolog 3 (AKT3, marker 598), v-akt murine thymoma viral oncogene homolog 3 (AKT3, marker 599), v-akt murine thymoma viral oncogene homolog 3 (AKT3, marker 600), v-akt murine thymoma viral oncogene homolog 3 (AKT3, marker 601), 5'-aminolevulinate synthase 2 (ALAS2, marker 602), 5'-aminolevulinate synthase 2 (ALAS2, marker 603), albumin (ALB, marker 604), albumin (ALB, marker 605), albumin (ALB, marker 606), albumin (ALB, marker 607), albumin (ALB, marker 608),activated leukocyte cell adhesion molecule(ALCAM,マーカー609),aldehyde dehydrogenase 1 family, member A2(ALDH1A2,マーカー610),aldehyde dehydrogenase 1 family, member A2(ALDH1A2,マーカー611),aldehyde dehydrogenase 1 family, member A3(ALDH1A3,マーカー612),aldehyde dehydrogenase 1 family, member L1(ALDH1L1,マーカー613),ALDH1L1 antisense RNA 2(ALDH1L1-AS2,マーカー614),aldehyde dehydrogenase 1 family, member L2(ALDH1L2,マーカー615),aldehyde dehydrogenase 1 family, member L2(ALDH1L2,マーカー616),aldehyde dehydrogenase 3 family, member A1(ALDH3A1,マーカー617),aldehyde dehydrogenase 3 family, member B1(ALDH3B1,マーカー618),aldehyde dehydrogenase 3 family, member B1(ALDH3B1,マーカー619),aldehyde dehydrogenase 3 family, member B1(ALDH3B1,マーカー620),aldehyde dehydrogenase 3 family, member B2(ALDH3B2,マーカー621),aldehyde dehydrogenase 3 family, member B2(ALDH3B2,マーカー622),aldehyde dehydrogenase 5 family, member A1(ALDH5A1,マーカー623),aldehyde dehydrogenase 6 family, member A1(ALDH6A1,マーカー624),aldehyde dehydrogenase 8 family, member A1(ALDH8A1,Marker 625), aldolase A, fructose-bisphosphate pseudogene 2 (ALDOAP2, marker 626), aldolase B, fructose-bisphosphate (ALDOB, marker 627), aldolase B, fructose-bisphosphate (ALDOB, marker 628), aldolase B, fructose-bisphosphate (ALDOB, marker 629), aldolase B, fructose-bisphosphate (ALDOB, marker 630), aldolase B, fructose-bisphosphate (ALDOB, marker 631), aldolase B, fructose-bisphosphate (ALDOB, marker 632), aldolase B, fructose-bisphosphate (ALDOB, marker 633), ALG13, UDP-N-acetylglucosaminyltransferase subunit (ALG13, marker 634), ALG14, UDP-N-acetylglucosaminyltransferase subunit (ALG14, marker 635), ALG2, alpha-1,3 / 1,6-mannosyltransferase (ALG2, marker 636), ALG5, dolichyl-phosphate beta-glucosyltransferase (ALG5, marker 637), anaplastic lymphoma receptor tyrosine kinase (ALK, marker 638), anaplastic lymphoma receptor tyrosine kinase (ALK, marker 639), ALKBH3 antisense RNA 1 (ALKBH3-AS1, marker 640), ALKBH3 antisense RNA 1 (ALKBH3-AS1, marker 641), alkB homolog 7 (ALKBH7, marker 642), alkB homolog 7 (ALKBH7, marker 643), allantoicase (ALLC, marker 644), Alstrom syndrome 1 pseudogene (ALMS1P,Marker 645), ALOX12 antisense RNA 1 (ALOX12-AS1, marker 646), ALOX12 antisense RNA 1 (ALOX12-AS1, marker 647), arachidonate 12-lipoxygenase, 12R type (ALOX12B, marker 648), arachidonate 12-lipoxygenase pseudogene 2 (ALOX12P2, marker 649), arachidonate 15-lipoxygenase (ALOX15, marker 650), arachidonate 15-lipoxygenase, type B (ALOX15B, marker 651), arachidonate 15-lipoxygenase, type B (ALOX15B, marker 652), arachidonate 5-lipoxygenase (ALOX5, marker 653), arachidonate 5-lipoxygenase (ALOX5, marker 654), arachidonate 5-lipoxygenase (ALOX5, marker 655), arachidonate 5-lipoxygenase-activating protein (ALOX5AP, marker 656), arachidonate lipoxygenase 3 (ALOXE3, marker 657), arachidonate lipoxygenase 3 (ALOXE3, marker 658), alkaline phosphatase, intestinal (ALPI, marker 659), alkaline phosphatase, intestinal (ALPI, marker 660), alpha kinase 1 (ALPK1, marker 661), alpha kinase 1 (ALPK1, marker 662), alpha kinase 1 (ALPK1, marker 663), alpha kinase 1 (ALPK1, marker 664), alkaline phosphatase, placental (ALPP, marker 665), alkaline phosphatase, placental like 2 (ALPP, marker 666),marker 666), alkaline phosphatase, placental like 2 (ALPPL2, marker 667), alkaline phosphatase, placental like 2 (ALPPL2, marker 668), ALS2, alsin Rho guanine nucleotide exchange factor (ALS2, marker 669), ALS2 C-terminal like (ALS2CL, marker 670), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 671), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 672), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 673), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 674), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 675), amyotrophic lateral sclerosis 2 chromosome region candidate 11 (ALS2CR11, marker 676), amyotrophic lateral sclerosis 2 chromosome region candidate 12 (ALS2CR12, marker 677), amyotrophic lateral sclerosis 2 chromosome region candidate 12 (ALS2CR12, marker 678), ALX homeobox 1 (ALX1, marker 679), ALX homeobox 3 (ALX3, marker 680), ALX homeobox 4 (ALX4, marker 681), alpha-methylacyl-CoA racemase (AMACR, marker 682),alpha-methylacyl-CoA racemase (AMACR, marker 683), alpha-methylacyl-CoA racemase (AMACR, marker 684), alpha-1-microglobulin / bikunin precursor (AMBP, marker 685), alpha-1-microglobulin / bikunin precursor (AMBP, marker 686), autophagy / beclin-1 regulator 1 (AMBRA1, marker 687), autophagy / beclin-1 regulator 1 (AMBRA1, marker 688), amidohydrolase domain containing 1 (AMDHD1, marker 689), amelogenin, X-linked (AMELX, marker 690), amelogenin, Y-linked (AMELY, marker 691), APC membrane recruitment protein 1 (AMER1, marker 692), APC membrane recruitment protein 2 (AMER2, marker 693), APC membrane recruitment protein 3 (AMER3, marker 694), APC membrane recruitment protein 3 (AMER3, marker 695), APC membrane recruitment protein 3 (AMER3, marker 696), anti-Mullerian hormone (AMH, marker 697), anti-Mullerian hormone receptor, type II (AMHR2, marker 698), adhesion molecule, interacts with CXADR antigen 1 (AMICA1, marker 699), adhesion molecule with Ig-like domain 1 (AMIGO1, marker 700), adhesion molecule with Ig-like domain 3 / / / GDP-mannose pyrophosphorylase B (AMIGO3 / / / GMPPB, marker 701), Alport syndrome,Mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 (AMMECR1, marker 702), amnion-associated transmembrane protein (AMN, marker 703), amnion-associated transmembrane protein (AMN, marker 704), amnion-associated transmembrane protein (AMN, marker 705), angiomotin (AMOT, marker 706), angiomotin-like 1 (AMOTL1, marker 707), adenosine monophosphate deaminase 1 (AMPD1, marker 708), adenosine monophosphate deaminase 3 (AMPD3, marker 709), amylase, alpha 1A (salivary) / / / amylase, alpha 1B (salivary) / / / amylase, alpha 1C (salivary) / / / amylase, alpha 2A (pancreatic) / / / amylase, alpha 2B (pancreatic) / / / amylase, alpha pse, udogene 1 (AMY1A / / / AMY1B / / / AMY1C / / / AMY2A / / / AMY2B / / / AMYP1, marker 710), archaelysin family metallopeptidase 1 (AMZ1, marker 711), anaphase promoting complex subunit 11 (ANAPC11, marker 712), anaphase promoting complex subunit 13 (ANAPC13, marker 713), anaphase promoting complex subunit 5 (ANAPC5, marker 714), angel homolog 1 (Drosophila) (ANGEL1, marker 715), angel homolog 2 (Drosophila) (ANGEL2, marker 716), angiopoietin 1 (ANGPT1, marker 717), angiopoietin 1 (ANGPT1, marker 718), angiopoietin 2 (ANGPT2, marker 719), angiopoietin 2 (ANGPT2, marker 720), angiopoietin 2 (ANGPT2, marker 721), angiopoietin 2 (ANGPT2, marker 722), angiopoietin 4 (ANGPT4, marker 723), angiopoietin-like 1 (ANGPTL1, marker 724), angiopoietin-like 1 (ANGPTL1, marker 725), angiopoietin-like 1 (ANGPTL1, marker 726), angiopoietin-like 2 (ANGPTL2, marker 727), angiopoietin-like 2 (ANGPTL2, marker 728), angiopoietin-like 3 (ANGPTL3, marker 729), angiopoietin-like 3 (ANGPTL3, marker 730), angiopoietin-like 3 (ANGPTL3, marker 731), angiopoietin-like 4 (ANGPTL4, marker 732), angiopoietin-like 6 (ANGPTL6, marker 733), angiopoietin-like 7(ANGPTL7,Marker 734), angiopoietin-like 8 (ANGPTL8, marker 735), anomalous homeobox (ANHX, marker 736), anomalous homeobox (ANHX, marker 737), ankyrin 1, erythrocytic (ANK1, marker 738), ankyrin 1, erythrocytic (ANK1, marker 739), ankyrin 2, neuronal (ANK2, marker 740), ankyrin 2, neuronal (ANK2, marker 741), ankyrin 3, node of Ranvier (ankyrin G) (ANK3, marker 742), ankyrin and armadillo repeat containing (ANKAR, marker 743), ankyrin and armadillo repeat containing (ANKAR, marker 744), ankyrin repeat and death domain containing 1A (ANKDD1A, marker 745), ankyrin repeat and EF-hand domain containing 1 (ANKEF1, marker 746), ankyrin-repeat and fibronectin type III domain containing 1 (ANKFN1, marker 747), ankyrin-repeat and fibronectin type III domain containing 1 (ANKFN1, marker 748), ankyrin-repeat and fibronectin type III domain containing 1 (ANKFN1, marker 749), ankyrin repeat and FYVE domain containing 1 (ANKFY1, marker 750), ankyrin repeat and FYVE domain containing 1 (ANKFY1, marker 751), ANKH inorganic pyrophosphate transport regulator (ANKH, marker 752),ANKH inorganic pyrophosphate transport regulator (ANKH, marker 753), ANKH inorganic pyrophosphate transport regulator (ANKH, marker 754), ANKH inorganic pyrophosphate transport regulator (ANKH, marker 755), ANKH inorganic pyrophosphate transport regulator (ANKH, marker 756), ankyrin repeat and LEM domain containing 1 (ANKLE1, marker 757), ankyrin repeat and LEM domain containing 2 (ANKLE2, marker 758), ankyrin repeat and MYND domain containing 1 (ANKMY1, marker 759), ankyrin repeat and MYND domain containing 1 (ANKMY1, marker 760), ankyrin repeat and MYND domain containing 1 (ANKMY1, marker 761), ankyrin repeat domain 10 (ANKRD10, marker 762), ankyrin repeat domain 10 (ANKRD10, marker 763), ankyrin repeat domain 13A (ANKRD13A, marker 764), ankyrin repeat domain 13C (ANKRD13C, marker 765), ankyrin repeat domain 13 family, member D (ANKRD13D, marker 766), ankyrin repeat domain 17 (ANKRD17, marker 767), ankyrin repeat domain 18A (ANKRD18A, marker 768), ankyrin repeat domain 19, pseudogene (ANKRD19P, marker 769), ankyrin repeat domain 2 (stretch responsive muscle) (ANKRD2, marker 770),ankyrin repeat domain 20 family, member A1 / / / ankyrin repeat domain 20 family, member A11, pseudogene / / / ankyrin repeat domain 20 family, member A2 / / / ankyrin repeat domain 20 family, member A3 / / / ankyrin repeat domain 20 family, member A4 / / / ankyrin repeat domain 20 family, member A5, pseudogene / / / ankyrin repeat domain 20 family, member A7, pseudogene / / / uncharacterized LOC105379426(ANKRD20A1 / / / ANKRD20A11P / / / ANKRD20A2 / / / ANKRD20A3 / / / ANKRD20A4 / / / ANKRD20A5P / / / ANKRD20A7P / / / LOC105379426,マーカー771),ankyrin repeat domain 20 family, member A1 / / / ankyrin repeat domain 20 family, member A12, pseudogene / / / ankyrin repeat domain 20 family, member A2 / / / ankyrin repeat domain 20 family, member A3 / / / ankyrin repeat domain 20 family, member A4 / / / ankyrin repeat domain 20 family, member A8, pseudogene / / / ankyrin repeat domain-containing protein 20A2(ANKRD20A1 / / / ANKRD20A12P / / / ANKRD20A2 / / / ANKRD20A3 / / / ANKRD20A4 / / / ANKRD20A8P / / / LOC102723552,マーカー772),ankyrin repeat domain 20 family, member A1 / / / ankyrin repeat domain 20 family, member A2 / / / ankyrin repeat domain 20 family, member A3 / / / ankyrin repeat domain 20 family, member A4(ANKRD20A1 / / / ANKRD20A2 / / / ANKRD20A3 / / / ANKRD20A4,マーカー773),ankyrin repeat domain 20 family, member A11, pseudogene(ANKRD20A11P,マーカー774),ankyrin repeat domain 20 family, member A12, pseudogene(ANKRD20A12P,マーカー775),ankyrin repeat domain 20 family, member A12, pseudogene(ANKRD20A12P,マーカー776),ankyrin repeat domain 20 family, member A12,pseudogene / / / uncharacterized LOC100289026 / / / putative ankyrin repeat domain-containing protein 20A12 pseudogene / / / putative ankyrin repeat domain-containing protein 20A12 pseudogene / / / uncharacterized LOC102723799 / / / uncharacterized LOC105369263 / / / uncharacterized LOC105374447 / / / putative ankyrin repeat domain-containing protein 20A12 pseudogene(ANKRD20A12P / / / LOC100289026 / / / LOC101060632 / / / LOC101927345 / / / LOC102723799 / / / LOC105369263 / / / LOC105374447 / / / LOC105379272, marker 777), ankyrin repeat domain 20 family, member A5, pseudogene (ANKRD20A5P, marker 778), ankyrin repeat domain 22 (ANKRD22, marker 779), ankyrin repeat domain 22 (ANKRD22, marker 780), ankyrin repeat domain 23 (ANKRD23, marker 781), ankyrin repeat domain 23 / / / ankyrin repeat domain 39 (ANKRD23 / / / ANKRD39, marker 782), ankyrin repeat domain 23 / / / ankyrin repeat domain 39 (ANKRD23 / / / ANKRD39, marker 783), ankyrin repeat domain 24 (ANKRD24, marker 784), ankyrin repeat domain 24 (ANKRD24, marker 785), ankyrin repeat domain 24 (ANKRD24, marker 786),Ankyrin repeat domain 26 pseudogene 3 (ANKRD26P3, marker 787), Ankyrin repeat domain 29 (ANKRD29, marker 788), Ankyrin repeat domain 29 (ANKRD29, marker 789), Ankyrin repeat domain 30A (ANKRD30A, marker 790), Ankyrin repeat domain 30B (ANKRD30B, marker 791), Ankyrin repeat domain 30B (ANKRD30B, marker 792), Ankyrin repeat domain 30B-like / / / Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BL / / / ANKRD30BP2, marker 793), Ankyrin repeat domain 30B pseudogene 2 (ANKRD30BP2, marker 794), Ankyrin repeat domain 30B pseudogene 3 (ANKRD30BP3, marker 795), Ankyrin repeat domain 30B pseudogene 3 (ANKRD30BP3, marker 796), ankyrin repeat domain 30B pseudogene 3 (ANKRD30BP3, marker 797), ankyrin repeat domain 31 (ANKRD31, marker 798), ankyrin repeat domain 33 (ANKRD33, marker 799), ankyrin repeat domain 34A (ANKRD34A, marker 800), ankyrin repeat domain 34C (ANKRD34C, marker 801), ankyrin repeat domain 36 (ANKRD36, marker 802), ankyrin repeat domain 36B pseudogene 2 (ANKRD36BP2, marker 803), ankyrin repeat domain 36B pseudogene 2 (ANKRD36BP2, marker 804), ankyrin repeat domain 36C (ANKRD36C, marker 805),Ankyrin repeat domain 37 (ANKRD37, marker 806), ankyrin repeat domain 40 (ANKRD40, marker 807), ankyrin repeat domain 44 (ANKRD44, marker 808), ankyrin repeat domain 44 (ANKRD44, marker 809), ankyrin repeat domain 44 (ANKRD44, marker 810), ankyrin repeat domain 44 (ANKRD44, marker 811), ankyrin repeat domain 44 (ANKRD44, marker 812), ANKRD44 intronic transcript 1 (ANKRD44-IT1, marker 813), ankyrin repeat domain 45 (ANKRD45, marker 814), ankyrin repeat domain 50 (ANKRD50, marker 815), ankyrin repeat domain 53 (ANKRD53, marker 816), ankyrin repeat domain 53 (ANKRD53, marker 817), ankyrin repeat domain 54 (ANKRD54, marker 818), ankyrin repeat domain 55 (ANKRD55, marker 819), ankyrin repeat domain 60 (ANKRD60, marker 820), ankyrin repeat domain 7 (ANKRD7, marker 821), ankyrin repeat domain 9 (ANKRD9, marker 822), ankyrin repeat and sterile alpha motif domain containing 1B (ANKS1B, marker 823), ankyrin repeat and sterile alpha motif domain containing 1B (ANKS1B, marker 824), ankyrin repeat and sterile alpha motif domain containing 1B (ANKS1B, marker 825),Ankyrin repeat and sterile alpha motif domain containing 1B (ANKS1B, marker 826), ankyrin repeat and sterile alpha motif domain containing 4B (ANKS4B, marker 827), ankyrin repeat and sterile alpha motif domain containing 6 (ANKS6, marker 828), ankyrin repeat and sterile alpha motif domain containing 6 (ANKS6, marker 829), ankyrin repeat and ubiquitin domain containing 1 (ANKUB1, marker 830), ankyrin repeat and ubiquitin domain containing 1 (ANKUB1, marker 831), ankyrin repeat and ubiquitin domain containing 1 (ANKUB1, marker 832), anoctamin 1, calcium-activated chloride channel (ANO1, marker 833), anoctamin 1, calcium-activated chloride channel (ANO1, marker 834), anoctamin 2, calcium-activated chloride channel (ANO2, marker 835), anoctamin 2, calcium-activated chloride channel channel (ANO2, marker 836), anoctamin 3 (ANO3, marker 837), anoctamin 4 (ANO4, marker 838), anoctamin 6 (ANO6, marker 839), anoctamin 7 (ANO7, marker 840), anoctamin 7 pseudogene 1 (ANO7P1, marker 841), anosmin 1 (ANOS1, marker 842), anosmin 2 pseudogene (ANOS2P, marker 843), ANP32A intronic transcript 1 (ANP32A-IT1, marker 844),Acidic nuclear phosphoprotein 32 family member C (ANP32C, marker 845), acidic nuclear phosphoprotein 32 family member D (ANP32D, marker 846), alanyl (membrane) aminopeptidase (ANPEP, marker 847), alanyl (membrane) aminopeptidase (ANPEP, marker 848), alanyl (membrane) aminopeptidase (ANPEP, marker 849), anthrax toxin receptor 1 (ANTXR1, marker 850), anthrax toxin receptor 1 (ANTXR1, marker 851), anthrax toxin receptor 1 (ANTXR1, marker 852), anthrax toxin receptor 2 (ANTXR2, marker 853), anthrax toxin receptor 2 (ANTXR2, marker 854), annexin A10 (ANXA10, marker 855), annexin A11 (ANXA11, Marker 856), annexin A13 (ANXA13, Marker 857), annexin A2 (ANXA2, Marker 858), annexin A2 pseudogene 1 (ANXA2P1, Marker 859), annexin A2 receptor (ANXA2R, Marker 860), annexin A6 (ANXA6, Marker 861), annexin A8 (ANXA8, Marker 862), annexin A8 / / / annexin A8-like 1 / / / long intergenic non-protein coding RNA 842 (ANXA8 / / / ANXA8L1 / / / LINC00842, Marker 863), annexin A8-like 1 / / / long intergenic non-protein coding RNA 842 (ANXA8L1 / / / LINC00842, Marker 864), acyloxyacyl hydrolase (neutrophil)(AOAH, marker 865), amine oxidase,copper containing 1 (AOC1, marker 866), amine oxidase, copper containing 2 (retina-specific) (AOC2, marker 867), amine oxidase, copper containing 3 (AOC3, marker 868), amine oxidase, copper containing 4, pseudogene (AOC4P, marker 869), aldehyde oxidase, 1 (AOX1, marker 870), aldehyde oxidase 2 pseudogene (AOX2P, marker 871), adaptor-related protein complex 1 associated regulatory protein (AP1AR, marker 872), adaptor-related protein complex 1, gamma 2 subunit (AP1G2, marker 873), adaptor-related protein complex 1 sigma 3 subunit (AP1S3, marker 874), adaptor-related protein complex 2, alpha 1 subunit (AP2A1, marker 875), adaptor-related protein complex 2, alpha 1 subunit (AP2A1, marker 876), adaptor-related protein complex 3, beta 2 subunit (AP3B2, marker 877), adaptor-related protein complex 4, beta 1 subunit (AP4B1, marker 878), adaptor-related protein complex 4, beta 1 subunit (AP4B1, marker 879), adaptor-related protein complex 4, epsilon 1 subunit (AP4E1, marker 880), adaptor-related protein complex 4, epsilon 1 subunit (AP4E1, marker 881), adaptor-related protein complex 4, epsilon 1 subunit (AP4E1, marker 882), adaptor-related protein complex 4, sigma 1 subunit (AP4S1, marker 883), adaptor-related protein complex 5, beta 1 subunit (AP5B1, marker 884), apoptotic peptidase activating factor 1 (APAF1, marker 885),amyloid beta (A4) precursor protein-binding, family A, member 1(APBA1, marker 886), amyloid beta (A4) precursor protein-binding, family A, member 1 / / / uncharacterized LOC101929802(APBA1 / / / LOC101929802, marker 887), amyloid beta (A4) precursor protein-binding, family A, member 3(APBA3, marker 888), amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein(APBB1IP, marker 889), amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein(APBB1IP, marker 890), amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein(APBB1IP, marker 891), amyloid beta (A4) precursor protein-binding, family B, member 2 (APBB2, marker 892), amyloid beta (A4) precursor protein-binding, family B, member 2 (APBB2, marker 893), adenomatous polyposis coli (APC, marker 894), adenomatous polyposis coli (APC, marker 895), adenomatosis polyposis coli 2 (APC2, marker 896), adenomatosis polyposis coli 2 (APC2, marker 897),adenomatosis polyposis coli down-regulated 1 / / / uncharacterized LOC100130468 (APCDD1 / / / LOC100130468, marker 898), adenomatosis polyposis coli down-regulated 1-like (APCDD1L, marker 899), APCDD1L antisense RNA 1 (head to head) (APCDD1L-AS1, marker 900), APCDD1L antisense RNA 1 (head to head) (APCDD1L-AS1, marker 901), amyloid P component, serum (APCS, marker 902), acylaminoacyl-peptide hydrolase (APEH, marker 903), APH1A gamma secretase subunit (APH1A, marker 904), APAF1 interacting protein (APIP, marker 905), aprataxin and PNKP like factor (APLF, marker 906), apelin (APLN, marker 907), apelin receptor (APLNR, marker 908), APOA1 antisense RNA (APOA1-AS, marker 909), apolipoprotein AV (APOA5, marker 910), apolipoprotein AV (APOA5, marker 911), apolipoprotein B (APOB, marker 912), apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 (APOBEC1, marker 913), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 (APOBEC2, marker 914), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A / / / APOBEC3A and APOBEC3B deletion hybrid (APOBEC3A / / / APOBEC3A_B,Marker 915), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D (APOBEC3D, Marker 916), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F, Marker 917), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F, Marker 918), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F / / / apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3F / / / APOBEC3G, Marker 919), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G, Marker 920), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 4 (putative) (APOBEC4, Marker 921), apolipoprotein B receptor (APOBR, Marker 922), apolipoprotein C-II (APOC2, Marker 923), apolipoprotein C-II (APOC2, marker 924), apolipoprotein C-II / / / apolipoprotein C-IV / / / APOC4-APOC2 readthrough (NMD candidate) (APOC2 / / / APOC4 / / / APOC4-APOC2, marker 925), apolipoprotein C-II / / / APOC4-APOC2 readthrough (NMD candidate) (APOC2 / / / APOC4-APOC2, marker 926), apolipoprotein C-III (APOC3, marker 927),apolipoprotein C-III (APOC3, marker 928), apolipoprotein D (APOD, marker 929), apolipoprotein E (APOE, marker 930), apolipoprotein F (APOF, marker 931), apolipoprotein H (beta-2-glycoprotein I) (APOH, marker 932), apolipoprotein H (beta-2-glycoprotein I) (APOH, marker 933), apolipoprotein L1 (APOL1, marker 934), apolipoprotein L 2 (APOL2, marker 935), apolipoprotein L 3 (APOL3, marker 936), apolipoprotein L 4 (APOL4, marker 937), apolipoprotein L 4 (APOL4, marker 938), apolipoprotein L 4 (APOL4, marker 939), apolipoprotein L 5 (APOL5, marker 940), apolipoprotein L 6 (APOL6, marker 941), apolipoprotein L, 6 (APOL6, marker 942), apolipoprotein L, 6 (APOL6, marker 943), apolipoprotein L, 6 (APOL6, marker 944), apolipoprotein L domain containing 1 (APOLD1, marker 945), amyloid beta precursor protein (cytoplasmic tail) binding protein 2 (APPBP2, marker 946), Alu-mediated CDKN1A / p21 transcriptional regulator (non-protein coding) (APTR, marker 947), aprataxin (APTX, marker 948), aquaporin 1 (Colton blood group) (AQP1, marker 949), aquaporin 1 (Colton blood group) (AQP1, marker 950), aquaporin 10 (AQP10, marker 951),aquaporin 12A / / / aquaporin 12B (AQP12A / / / AQP12B, marker 952), aquaporin 2 (collecting duct) (AQP2, marker 953), aquaporin 2 (collecting duct) (AQP2, marker 954), aquaporin 2 (collecting duct) (AQP2, marker 955), aquaporin 3 (Gill blood group) (AQP3, marker 956), aquaporin 3 (Gill blood group) (AQP3, marker 957), aquaporin 4 (AQP4, marker 958), aquaporin 4 (AQP4, marker 959), aquaporin 4 (AQP4, marker 960), aquaporin 4 (AQP4, marker 961), aquaporin 4 (AQP4, marker 962), AQP4 antisense RNA 1 (AQP4-AS1, marker 963), AQP4 antisense RNA 1 (AQP4-AS1, marker 964), aquaporin 5 (AQP5, marker 965), aquaporin 6, kidney specific (AQP6, marker 966), aquaporin 6, kidney specific (AQP6, marker 967), aquaporin 7 (AQP7, marker 968), aquaporin 8 (AQP8, marker 969), aquaporin 9 (AQP9, marker 970), aquarius intron-binding spliceosomal factor (AQR, marker 971), A-Raf proto-oncogene, serine / threonine kinase (ARAF, marker 972), ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (ARAP1, marker 973), ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 (ARAP2, marker 974), ArfGAP with RhoGAP domain,ankyrin repeat and PH domain 2 (ARAP2, marker 975), activity-regulated cytoskeleton-associated protein (ARC, marker 976), amphiregulin (AREG, marker 977), amphiregulin (AREG, marker 978), apoptosis-resistant E3 ubiquitin protein ligase 1 (AREL1, marker 979), apoptosis-resistant E3 ubiquitin protein ligase 1 (AREL1, marker 980), ADP-ribosylation factor 1 (ARF1, marker 981), ADP-ribosylation factor 1 (ARF1, marker 982), ADP-ribosylation factor GTPase activating protein 2 (ARFGAP2, marker 983), ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) (ARFGEF2, marker 984), ARFGEF family member 3 (ARFGEF3, marker 985), arginase 1 (ARG1, marker 986), arginase 1 (ARG1, marker 987), arginase 1 (ARG1, marker 988), arginase 1 (ARG1, marker 989), Rho GTPase activating protein 1 (ARHGAP1, marker 990), Rho GTPase activating protein 1 (ARHGAP1, marker 991), Rho GTPase activating protein 15 / / / uncharacterized LOC101928361 (ARHGAP15 / / / LOC101928361, marker 992), Rho GTPase activating protein 18 (ARHGAP18, marker 993), ARHGAP19-SLIT1 readthrough (NMD candidate) (ARHGAP19-SLIT1,マーカー994),Rho GTPase activating protein 20(ARHGAP20,マーカー995),Rho GTPase activating protein 20(ARHGAP20,マーカー996),Rho GTPase activating protein 22(ARHGAP22,マーカー997),Rho GTPase activating protein 22(ARHGAP22,マーカー998),Rho GTPase activating protein 22(ARHGAP22,マーカーー992),GAP intronic transcript 22 1(ARHGAP22-IT1,マーカー1000),ARHGAP22 intronic transcript 1(ARHGAP22-IT1,マーカー1001),Rho GTPase activating protein 23(ARHGAP23,マーーーー1001),Rho GTPase activating protein 23(ARHGAP23,マーカー1003),Rho GTPase activating protein 24(ARHGAP24,マーカー1004),Rho GTPase activating protein 24(ARHGAP24,マーーーー1004),Rho GTPase activating protein 24(ARHGAP24,マーーーー1004), protein 24(ARHGAP24,マーカー1006),Rho GTPase activating protein 25(ARHGAP25,マーカー1007),Rho GTPase activating protein 25(ARHGAP25,マーカー1007),Rho GTPase activating protein 25(ARHGAP25,マーゼーー1008), 25(ARHGAP25,マーカー1009),Rho GTPase activating protein 26(ARHGAP26,マーカー1010),ARHGAP26 antisense RNA 1(ARHGAP26-AS1,マーーーー101), Rho GTPase activating protein 27(ARHGAP27,マーカー1012),Rho GTPase activating protein 27(ARHGAP27,マーカー1013),Rho GTPase activating protein 27(ARHGAP27,マーカー1014),Rho GTPase activating protein 27(ARHGAP27,マーカー1015),Rho GTPase activating protein 27(ARHGAP27,ーーー1015),Rho GTPase activating protein 27(ARHGAP27,ーーー1014), GTPase activating protein 29(ARHGAP29,マーカー1017),Rho GTPase activating protein 29(ARHGAP29,マーカー1018),Rho GTPase activating protein 29(ARHGAP29,ーーーーーー1018), activating protein 30(ARHGAP30,マーカー1020),Rho GTPase activating protein 30(ARHGAP30,マーカー1021),Rho GTPase activating protein 31(ARHGAP31,マーーーー1021),Rho GTPase activating protein 31(ARHGAP31,マーーーー1021), protein 31(ARHGAP31,マーカー1023),Rho GTPase activating protein 33(ARHGAP33,マーカー1024),Rho GTPase activating protein 33(ARHGAP33,マーカー1025),Rho GTPase activating proteinー1025 36(ARHGAP36,マーカー1026),Rho GTPase activating protein 42(ARHGAP42,マーカー1027),Rho GTPase activating protein 42(ARHGAP42,マーカー1028),Rho GTPase activating protein 44(ARHGAP44,マーカー1029),Rho GTPase activating protein 5(ARHGAP5,マーカー1030),Rho GTPase activating protein 6(ARHGAP6,マーカー1031),Rho GTPase activating protein 8(ARHGAP8, マーカー1032),Rho GTPase activating protein 9 (ARHGAP9, marker 1033), Rho GTPase activating protein 9 (ARHGAP9, marker 1034), Rho GTPase activating protein 9 (ARHGAP9, marker 1035), Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB, marker 1036), Rho guanine nucleotide exchange factor 11 (ARHGEF11, marker 1037), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1038), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1039), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1040), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1041), Rho guanine nucleotide exchange factor (GEF) 12(ARHGEF12, marker 1042),Rho guanine nucleotide exchange factor (GEF) 12(ARHGEF12, marker 1043),Rho guanine nucleotide exchange factor (GEF) 12(ARH, Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1044), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1045), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1046), Rho guanine nucleotide exchange factor (GEF) 12 (ARHGEF12, marker 1047), Rho guanine nucleotide exchange factor 15 (ARHGEF15, marker 1048), ARHGEF26 antisense RNA 1 (ARHGEF26-AS1, marker 1049), Rho guanine nucleotide exchange factor 28 (ARHGEF28, marker 1050), Rho guanine nucleotide exchange factor 28 (ARHGEF28, marker 1051), Rho guanine nucleotide exchange factor 28 (ARHGEF28, marker 1052), Rho guanine nucleotide exchange factor 28(ARHGEF28, marker 1053), Rho guanine nucleotide exchange factor 33(ARHGEF33, marker 1054), Rho guanine nucleotide exchange factor 34, pseudogene / / / rho guanine nucleotide exchange factor 5-like / / / olfactory receptor, family 2, subfamily A, member 4 / / / olfactory receptor, family 2, subfamily A, member 7(ARHGEF34P / / / LOC102725117 / / / OR2A4 / / / OR2A7, marker 1055), Rho guanine nucleotide exchange factor 37(ARHGEF37, marker 1056),Rho guanine nucleotide exchange factor 37 (ARHGEF37, marker 1057), Rho guanine nucleotide exchange factor 38 (ARHGEF38, marker 1058), Rho guanine nucleotide exchange factor 4 (ARHGEF4, marker 1059), Rho guanine nucleotide exchange factor 4 (ARHGEF4, marker 1060), Rho guanine nucleotide exchange factor (GEF) 40 (ARHGEF40, marker 1061), Rho guanine nucleotide exchange factor (GEF) 40 (ARHGEF40, marker 1062), Rho guanine nucleotide exchange factor (GEF) 40 (ARHGEF40, marker 1063), Rho guanine nucleotide exchange factor 7 (ARHGEF7, marker 1064), Rho guanine nucleotide exchange factor 7 (ARHGEF7, marker 1065), Rho guanine nucleotide exchange factor 7 (ARHGEF7, marker 1066), Rho guanine nucleotide exchange factor 7 (ARHGEF7, marker 1067), Rho guanine nucleotide exchange factor 7 (ARHGEF7, marker 1068), ARHGEF7 antisense RNA 2 (ARHGEF7-AS2, marker 1069), ARHGEF7 intronic transcript 1 (ARHGEF7-IT1, marker 1070), AT-rich interactive domain 1A (SWI-like) (ARID1A, marker 1071), AT-rich interactive domain 1B (SWI1-like) (ARID1B, marker 1072), AT-rich interactive domain 1B (SWI1-like) (ARID1B,Marker 1073), AT-rich interactive domain 4B (RBP1-like) (ARID4B, marker 1074), AT-rich interactive domain 4B (RBP1-like) (ARID4B, marker 1075), AT-rich interactive domain 5A (MRF1-like) (ARID5A, marker 1076), AT-rich interactive domain 5B (MRF1-like) (ARID5B, marker 1077), AT-rich interactive domain 5B (MRF1-like) (ARID5B, marker 1078), AT-rich interactive domain 5B (MRF1-like) (ARID5B, marker 1079), AT-rich interactive domain 5B (MRF1-like) (ARID5B, marker 1080), ariadne RBR E3 ubiquitin protein ligase 1 (ARIH1, marker 1081), ariadne RBR E3 ubiquitin protein ligase 1 (ARIH1, marker 1082), ariadne homolog 2 opposite strand (ARIH2OS, marker 1083), ADP-ribosylation factor like GTPase 10 (ARL10, marker 1084), ADP-ribosylation factor like GTPase 10 (ARL10, marker 1085), ADP-ribosylation factor like GTPase 10 (ARL10, marker 1086), ADP-ribosylation factor like GTPase 11 (ARL11, marker 1087), ADP-ribosylation factor like GTPase 11 (ARL11, marker 1088), ADP-ribosylation factor like GTPase 14 (ARL14, marker 1089),ADP-ribosylation factor like GTPase 17A / / / ADP-ribosylation factor like GTPase 17B(ARL17A / / / ARL17B,マーカー1090),ADP-ribosylation factor like GTPase 17A / / / ADP-ribosylation factor like GTPase 17A / / / ARL17A / / / ARL17B,マーカー1091),ADP-ribosylation factor like GTPase 17A / / / ADP-ribosylation factor like GTPase 17B / / / ADP-ribosylation factor-like protein 17 / / / ADP-ribosylation factor-like protein 17(ARL17A17A17A1710 / / / / ARLOCB 1394 / / / LOC100996709,マーカー1092),ADP-ribosylation factor like GTPase 17A / / / ADP-ribosylation factor like GTPase 17B / / / ADP-ribosylation factor-like protein 17 / / / ADP-ribosylation factor-like protein 17(ARL 17A / / / / / / LOC100294341 / / / LOC100996709,マーカー1093),ADP-ribosylation factor like GTPase 17A / / / ADP-ribosylation factor-like protein 17 / / / ADP-ribosylation factor-like protein 17 / / / uncharacterized LOC101929774 / / / uncharacterized LOC105371859 / / / uncharacterized LOC105376844(ARL17A / / / LOC100294341 / / / LOC100996709 / / / LOC101929774 / / / LOC105371859 / / / LOC105376844, Marker 1094), ADP-ribosylation factor like GTPase 4D(ARL4D, Marker 1095), ADP-ribosylation factor like GTPase 5C (ARL5C, marker 1096), ADP-ribosylation factor like GTPase 9 (ARL9, marker 1097), armadillo repeat containing 12 (ARMC12, marker 1098), armadillo repeat containing 2 (ARMC2, marker 1099), armadillo repeat containing 3 (ARMC3, marker 1100), armadillo repeat containing 4 (ARMC4, marker 1101), armadillo repeat containing 8 (ARMC8, marker 1102), armadillo repeat containing 9 (ARMC9, marker 1103), armadillo repeat containing 9 (ARMC9, marker 1104), armadillo repeat containing 9 (ARMC9, marker 1105), armadillo repeat containing, X-linked 4 (ARMCX4, marker 1106), armadillo repeat containing, X-linked 4 (ARMCX4, marker 1107),armadillo repeat containing, X-linked 4 (ARMCX4, marker 1108), armadillo repeat containing, X-linked 4 (ARMCX4, marker 1109), armadillo repeat containing, X-linked 6 (ARMCX6, marker 1110), aryl hydrocarbon receptor nuclear translocator (ARNT, marker 1111), aryl hydrocarbon receptor nuclear translocator (ARNT, marker 1112), ARNTL2 antisense RNA 1 (ARNTL2-AS1, marker 1113), ARPC4-TTLL3 readthrough / / / tubulin tyrosine ligase-like family member 3 (ARPC4-TTLL3 / / / TTLL3, marker 1114), ARPC4-TTLL3 readthrough / / / tubulin tyrosine ligase-like family member 3 (ARPC4-TTLL3 / / / TTLL3, marker 1115), ARPC4-TTLL3 readthrough / / / tubulin tyrosine ligase-like family member 3 (ARPC4-TTLL3 / / / TTLL3, marker 1116), actin-related protein 2 / 3 complex subunit 5 (ARPC5, marker 1117), actin-related protein 2 / 3 complex subunit 5 (ARPC5, marker 1118), actin-related protein 2 / 3 complex inhibitor (ARPIN, marker 1119), actin-related protein 2 / 3 complex inhibitor (ARPIN, marker 1120), cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1121), cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1122),cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1123), cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1124), cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1125), cAMP-regulated phosphoprotein 21kDa (ARPP21, marker 1126), arrestin 3, retinal (X-arrestin) (ARR3, marker 1127), arrestin, beta 1 (ARRB1, marker 1128), arrestin domain containing 2 (ARRDC2, marker 1129), ARRDC3 antisense RNA 1 (ARRDC3-AS1, marker 1130), arylsulfatase A (ARSA, marker 1131), arylsulfatase A (ARSA, marker 1132), arylsulfatase B (ARSB, marker 1133), arylsulfatase B (ARSB, marker 1134), arylsulfatase D (ARSD, marker 1135), arylsulfatase D (ARSD, marker 1136), arylsulfatase D (ARSD, marker 1137), arylsulfatase F (ARSF, marker 1138), arylsulfatase G (ARSG, marker 1139), arylsulfatase family, member K (ARSK, marker 1140), arylsulfatase family, member K (ARSK, marker 1141), ADP-ribosyltransferase 1 (ART1, marker 1142), ADP-ribosyltransferase 1 (ART1, marker 1143), ADP-ribosyltransferase 1 (ART1, marker 1144), ADP-ribosyltransferase 3 (ART3, marker 1145), ADP-ribosyltransferase 4 (Dombrock blood group) (ART4, marker 1146),ADP-ribosyltransferase 4 (Dombrock blood group) (ART4, marker 1147), artemin (ARTN, marker 1148), artemin (ARTN, marker 1149), ARV1 homolog, fatty acid homeostasis modulator (ARV1, marker 1150), armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF, marker 1151), armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF, marker 1152), aristaless related homeobox (ARX, marker 1153), N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1, marker 1154), ASAP1 intronic transcript 1 (ASAP1-IT1, marker 1155), ASAP1 intronic transcript 2 (ASAP1-IT2, marker 1156), ankyrin repeat and SOCS box containing 1 (ASB1, marker 1157), ankyrin repeat and SOCS box containing 10 (ASB10, marker 1158), ankyrin repeat and SOCS box containing 10 (ASB10, marker 1159), ankyrin repeat and SOCS box containing 10 (ASB10, marker 1160), ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase (ASB11, marker 1161), ankyrin repeat and SOCS box containing 12 (ASB12, marker 1162), ankyrin repeat and SOCS box containing 14 (ASB14, marker 1163),Ankyrin repeat and SOCS box containing 14 (ASB14, marker 1164), ankyrin repeat and SOCS box containing 15 (ASB15, marker 1165), ankyrin repeat and SOCS box containing 16 (ASB16, marker 1166), ankyrin repeat and SOCS box containing 17 (ASB17, marker 1167), ankyrin repeat and SOCS box containing 2 (ASB2, marker 1168), ankyrin repeat and SOCS box containing 2 (ASB2, marker 1169), ankyrin repeat and SOCS box containing 3 (ASB3, marker 1170), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1171), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1172), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1173), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1174), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1175), ankyrin repeat and SOCS box containing 4 (ASB4, marker 1176), ankyrin repeat and SOCS box containing 5 (ASB5, marker 1177), achaete-scute family bHLH transcription factor 1 (ASCL1, marker 1178), achaete-scute family bHLH transcription factor 1 (ASCL1, marker 1179), achaete-scute family bHLH transcription factor 1 (ASCL1, marker 1180),achaete-scute family bHLH transcription factor 1 (ASCL1, marker 1181), achaete-scute family bHLH transcription factor 2 (ASCL2, marker 1182), achaete-scute family bHLH transcription factor 2 (ASCL2, marker 1183), achaete-scute family bHLH transcription factor 3 (ASCL3, marker 1184), achaete-scute family bHLH transcription factor 5 (ASCL5, marker 1185), asialoglycoprotein receptor 2 (ASGR2, marker 1186), acid sensing ion channel 2 (ASIC2, marker 1187), acid sensing ion channel family member 4 (ASIC4, marker 1188), acid sensing ion channel family member 5 (ASIC5, marker 1189), agouti signaling protein (ASIP, marker 1190), acetylserotonin O-methyltransferase (ASMT, marker 1191), acetylserotonin O-methyltransferase (ASMT, marker 1192), ASMTL antisense RNA 1 (ASMTL-AS1, marker 1193), ASMTL antisense RNA 1 (ASMTL-AS1, marker 1194), ASMTL antisense RNA 1 (ASMTL-AS1, marker 1195), ASMTL antisense RNA 1 (ASMTL-AS1, marker 1196), asparagine synthetase (glutamine-hydrolyzing) (ASNS, marker 1197), aspartoacylase (ASPA, marker 1198), aspartoacylase (ASPA, marker 1199),aspartate dehydrogenase domain containing (ASPDH, marker 1200), asparaginase (ASPG, marker 1201), asparaginase (ASPG, marker 1202), aspartate beta-hydroxylase (ASPH, marker 1203), asparta, te beta-hydroxylase (ASPH, marker 1204), asporin (ASPN, marker 1205), asporin (ASPN, marker 1206), aspartic peptidase, retroviral-like 1 (ASPRV1, marker 1207), astrotactin 1 (ASTN1, marker 1208), astrotactin 2 (ASTN2, marker 1209), additional sex combs like transcriptional regulator 1 (ASXL1, marker 1210), additional sex combs like transcriptional regulator 3 (ASXL3, marker 1211), additional sex combs like transcriptional regulator 3 (ASXL3, marker 1212), ankyrin repeat, SAM and basic leucine zipper domain containing 1 (ASZ1, marker 1213), ATPase family, AAA domain containing 2B (ATAD2B, marker 1214), ATPase family, AAA domain containing 3B (ATAD3B, marker 1215), ATPase family, AAA domain containing 3C (ATAD3C, marker 1216), arginyltransferase 1 (ATE1, marker 1217), arginyltransferase 1 (ATE1, marker 1218), activating transcription factor 2 (ATF2, marker 1219), activating transcription factor 5 (ATF5, marker 1220), activating transcription factor 5 (ATF5, marker 1221), activating transcription factor 7 (ATF7, marker 1222), activating transcription factor 7 (ATF7, marker 1223), autophagy-related 10 (ATG10,marker 1224), autophagy-related 10 (ATG10, marker 1225), autophagy-related 10 (ATG10, marker 1226), autophagy-related 16-like 1 (ATG16L1, marker 1227), autophagy-related 16-like 2 (ATG16L2, marker 1228), autophagy-related 2B (ATG2B, marker 1229), autophagy-related 3 (ATG3, marker 1230), autophagy-related 7 (ATG7, marker 1231), autophagy-related 9B (ATG9B, marker 1232), autophagy-related 9B (ATG9B, marker 1233), ATH1, acid trehalase-like 1 (yeast) (ATHL1, marker 1234), atlastin GTPase 2 (ATL2, marker 1235), atlastin GTPase 3 (ATL3, marker 1236), ATM serine / threonine kinase (ATM, marker 1237), ATM serine / threonine kinase (ATM, marker 1238), ATM serine / threonine kinase (ATM, marker 1239), ATM interactor (ATMIN, marker 1240), atrophin 1 (ATN1, marker 1241), atrophin 1 (ATN1, marker 1242), atrophin 1 (ATN1, marker 1243), atonal bHLH transcription factor 1 (ATOH1, marker 1244), atonal bHLH transcription factor 7 (ATOH7, marker 1245), atonal bHLH transcription factor 7 (ATOH7, marker 1246), atonal bHLH transcription factor 8 (ATOH8, marker 1247), atonal bHLH transcription factor 8 (ATOH8, marker 1248), ATPase, class V, type 10A(ATP10A,Marker 1249), ATPase, class V, type 10A (ATP10A, marker 1250), ATPase, class V, type 10A (ATP10A, marker 1251), ATPase, class V, type 10B (ATP10B, marker 1252), ATPase, class V, type 10B (ATP10B, marker 1253), ATPase, class VI, type 11A (ATP11A, marker 1254), ATPase, class VI, type 11A (ATP11A, marker 1255), ATP11A antisense RNA 1 (ATP11A-AS1, marker 1256), ATP11A antisense RNA 1 (ATP11A-AS1, marker 1257), ATP11A antisense RNA 1 (ATP11A-AS1, marker 1258), ATPase, class VI, type 11B (ATP11B, marker 1259), ATPase, class VI, type 11B (ATP11B, marker 1260), ATPase, class VI, type 11B (ATP11B, marker 1261), ATPase, class VI, type 11B (ATP11B, marker 1262), ATPase, H+ / K+ transporting, nongastric, alpha polypeptide (ATP12A, marker 1263), ATPase type 13A4 (ATP13A4, marker 1264), ATPase type 13A4 (ATP13A4, marker 1265), ATPase type 13A4 (ATP13A4, marker 1266), ATPase type 13A4 (ATP13A4, marker 1267), ATP13A4 antisense RNA 1 (ATP13A4-AS1, marker 1268), ATPase type 13A5 (ATP13A5, marker 1269), ATPase type 13A5 (ATP13A5, marker 1270), ATP1A1 antisense RNA 1 (ATP1A1-AS1, marker 1271), ATP1A1 antisense RNA 1 (ATP1A1-AS1, marker 1272),ATPase, Na+ / K+ transporting, alpha 3 polypeptide (ATP1A3, marker 1273), ATPase, Na+ / K+ transporting, alpha 4 polypeptide (ATP1A4, marker 1274), ATPase, Na+ / K+ transporting, alpha 4 polypeptide (ATP1A4, marker 1275), ATPase, Na+ / K+ transporting, alpha 4 polypeptide (ATP1A4, marker 1276), ATPase, Na+ / K+ transporting, beta 3 polypeptide (ATP1B3, marker 1277), ATPase, Na+ / K+ transporting, beta 4 polypeptide (ATP1B4, marker 1278), ATPase, Na+ / K+ transporting, beta 4 polypeptide (ATP1B4, marker 1279), ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 (ATP2A1, marker 1280), ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 (ATP2A1, marker 1281), ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (ATP2A2, marker 1282), ATPase, Ca++ transporting, ubiquitous (ATP2A3, marker 1283), ATPase, Ca++ transporting, ubiquitous (ATP2A3, marker 1284), ATPase, Ca++ transporting, ubiquitous (ATP2A3, marker 1285), ATPase, Ca++ transporting, ubiquitous (ATP2A3, marker 1286), ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2, marker 1287), ATPase, Ca++ transporting,Plasma membrane 2 (ATP2B2, marker 1288), ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2, marker 1289), ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2, marker 1290), ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2, marker 1291), ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2, marker 1292), ATPase, Ca++ transporting, plasma membrane 3 (ATP2B3, marker 1293), ATPase, Ca++ transporting, plasma membrane 3 (ATP2B3, marker 1294), ATPase, Ca++ transporting, plasma membrane 3 (ATP2B3, marker 1295), ATPase, Ca++ transporting, plasma membrane 3 (ATP2B3, marker 1296), ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4, marker 1297), ATPase, Ca++ transporting, type 2C, member 2 (ATP2C2, marker 1298), ATPase, Ca++ transporting, type 2C, member 2 (ATP2C2, marker 1299), ATPase, Ca++ transporting, type 2C, member 2 (ATP2C2, marker 1300), ATPase, H+ / K+ exchanging, alpha polypeptide (ATP4A, marker 1301), ATPase, H+ / K+ exchanging, beta polypeptide (ATP4B, marker 1302), ATPase, H+ / K+ exchanging, beta polypeptide (ATP4B, marker 1303), ATPase, H+ / K+ exchanging,beta polypeptide (ATP4B, marker 1304), ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle (ATP5A1, marker 1305), ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit (ATP5E, marker 1306), ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1 (ATP5F1, marker 1307), ATP synthase, H+ transporting, mitochondrial Fo complex subunit C2 (subunit 9) (ATP5G2, marker 1308), ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2 (ATP5J2, marker 1309), ATP5J2-PTCD1 readthrough / / / pentatricopeptide repeat domain 1 (ATP5J2-PTCD1 / / / PTCD1, marker 1310), ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (ATP5O, marker 1311), ATP synthase, H+ transporting, mitochondrial Fo complex subunit s (factor B) (ATP5S, marker 1312), ATP synthase, H+ transporting, mitochondrial Fo complex subunit s (factor B) (ATP5S, marker 1313), ATP5S-like (ATP5SL, marker 1314), ATPase, H+ transporting, lysosomal accessory protein 1-like (ATP6AP1L, marker 1315), ATPase, H+ transporting,Lysosomal accessory protein 1-like (ATP6AP1L, marker 1316), ATPase, H+ transporting, lysosomal V0 subunit a2 (ATP6V0A2, marker 1317), ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 (ATP6V0D2, marker 1318), ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 (ATP6V0D2, marker 1319), ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 (ATP6V0D2, marker 1320), ATP6V0E2 antisense RNA 1 (ATP6V0E2-AS1, marker 1321), ATPase, H+ transporting, lysosomal 56 / 58kDa, V1 subunit B1 (ATP6V1B1, marker 1322), ATPase, H+ transporting, lysosomal 56 / 58 kDa, V1 subunit B1 (ATP6V1B1, marker 1323), ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C2 (ATP6V1C2, marker 1324), ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C2 (ATP6V1C2, marker 1325), ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G3 (ATP6V1G3, marker 1326), ATPase, H+ transporting, lysosomal 50 / 57 kDa, V1 subunit H (ATP6V1H, marker 1327), ATPase, Cu++ transporting, alpha polypeptide (ATP7A, marker 1328), ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1(ATP8A1,ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 (ATP8A1, marker 1330), ATPase, aminophospholipid transporter, class I, type 8A, member 2 (ATP8A2, marker 1331), ATPase, aminophospholipid transporter, class I, type 8B, member 3 (ATP8B3, marker 1332), ATPase, aminophospholipid transporter, class I, type 8B, member 3 (ATP8B3, marker 1333), ATPase, aminophospholipid transporter, class I, type 8B, member 3 (ATP8B3, marker 1334), ATPase, class I, type 8B, member 4 (ATP8B4, marker 1335), ATPase, class I, type 8B, member 5, pseudogene (ATP8B5P, marker 1336), ATPase, class I, type 8B, member 5, pseudogene (ATP8B5P, marker 1337), ATPase, class II, type 9A (ATP9A, marker 1338), ATPase, class II, type 9B (ATP9B, marker 1339), ATPase, class II, type 9B (ATP9B, marker 1340), ATPase, class II, type 9B (ATP9B, marker 1341), ATPase, class II, type 9B (ATP9B, marker 1342), ATP synthase mitochondrial F1 complex assembly factor 2 (ATPAF2, marker 1343), ATR serine / threonine kinase (ATR, marker 1344), attractin-like 1 (ATRNL1, marker 1345), attractin-like 1 (ATRNL1,marker 1346), ataxin 1 (ATXN1, marker 1347), ataxin 1 (ATXN1, marker 1348), ataxin 2-like (ATXN2L, marker 1349), ataxin 3 (ATXN3, marker 1350), ataxin 3 (ATXN3, marker 1351), ataxin 3 (ATXN3, marker 1352), ataxin 3-like (ATXN3L, marker 1353), ataxin 7-like 1 (ATXN7L1, marker 1354), ataxin 7-like 2 (ATXN7L2, marker 1355), ATXN8 opposite strand (non-protein coding) (ATXN8OS, marker 1356), autism susceptibility candidate 2 (AUTS2, marker 1357), autism susceptibility candidate 2 (AUTS2, marker 1358), advillin (AVIL, marker 1359), advillin (AVIL, marker 1360), advillin (AVIL, marker 1361), advillin (AVIL, marker 1362), AVL9 homolog (S. cerevisiase) (AVL9, marker 1363), AVL9 homolog (S. cerevisiase) (AVL9, marker 1364), AVL9 homolog (S. cerevisiase) (AVL9, marker 1365), arginine vasopressin (AVP, marker 1366), arginine vasopressin receptor 1A (AVPR1A, marker 1367), arginine vasopressin receptor 1A (AVPR1A, marker 1368), arginine vasopressin receptor 1A (AVPR1A, marker 1369), arginine vasopressin receptor 1A (AVPR1A, marker 1370), arginine vasopressin receptor 1A (AVPR1A, marker 1371), arginine vasopressin receptor 1B (AVPR1B, marker 1372),Arginine vasopressin receptor 2 (AVPR2, marker 1373), arginine vasopressin receptor 2 (AVPR2, marker 1374), acyl-CoA wax alcohol acyltransferase 1 (AWAT1, marker 1375), axonemal dynein light chain domain containing 1 (AXDND1, marker 1376), axonemal dynein light chain domain containing 1 (AXDND1, marker 1377), alpha-2-glycoprotein 1, zinc-binding (AZGP1, marker 1378), alpha-2-glycoprotein 1, zinc-binding / / / alpha-2-glycoprotein 1, zinc-binding pseudogene 1 (AZGP1 / / / AZGP1P1, marker 1379), alpha-2-glycoprotein 1, zinc-binding pseudogene 1 (AZGP1P1, marker 1380), 5-azacytidine induced 2 (AZI2, marker 1381), azurocidin 1 (AZU1, marker 138, 2), beta-2-microglobulin (B2M, marker 1383), beta-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2, marker 1384), beta-1,3-N-acetylgalactosaminyltransferase 2(B3GALNT2, marker 1385),beta-1,3-N-acetylgalactosaminyltransferase 2(B3GALNT2,marker 1386),UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 1(B3GALT1,marker 1387),UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 2(B3GALT2, marker 1388),UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 2 (B3GALT2, marker 1389), UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 4 (B3GALT4, marker 1390), UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 5 (B3GALT5, marker 1391), beta-1,3-glucuronyltransferase 2 (B3GAT2, marker 1392), beta-1,3-glucuronyltransferase 2 (B3GAT2, marker 1393), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2, marker 1394), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3, marker 1395), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 (B3GNT5, marker 1396), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (B3GNT6, marker 1397),UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (B3GNT6, marker 1398), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 (B3GNT7, marker 1399), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 (B3GNT7, marker 1400), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 (B3GNT8, marker 1401), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 (B3GNTL1, marker 1402), UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 (B3GNTL1, marker 1403), beta-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1, marker 1404), beta-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1, marker 1405), beta-1,4-N-acetyl-galactosaminyl transferase 2 (B4GALNT2, marker 1406), beta-1,4-N-acetyl-galactosaminyl transferase 3 (B4GALNT3, marker 1407), beta-1,4-N-acetyl-galactosaminyl transferase 3 (B4GALNT3, marker 1408), beta-1,4-N-acetyl-galactosaminyl transferase 4(B4GALNT4, marker 1409),beta-1,4-N-acetyl-galactosaminyl transferase 4(B4GALNT4, marker 1410),UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,polypeptide 1 (B4GALT1, marker 1411), UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 (B4GALT1, marker 1412), UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 (B4GALT1, marker 1413), UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 3 (B4GALT3, marker 1414), UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 (B4GALT6, marker 1415), B9 protein domain 1 (B9D1, marker 1416), BAALC antisense RNA 2 (BAALC-AS2, marker 1417), BAALC antisense RNA 2 (BAALC-AS2, marker 1418), bile acid-CoA:amino acid N-acyltransferase (BAAT, marker 1419), beta-site APP-cleaving enzyme 2 (BACE2, marker 1420), BTB and CNC homology 1, basic leucine zipper transcription factor 1 (BACH1, marker 1421), BTB and CNC homology 1, basic leucine zipper transcription factor 1(BACH1, marker 1422),BTB and CNC homology 1, basic leucine zipper transcription factor 1 / / / GRIK1 antisense RNA 2(BACH1 / / / GRIK1-AS2, marker 1423),BTB and CNC homology 1, basic leucine zipper transcription factor 1 / / / GRIK1 antisense RNA 2(BACH1 / / / GRIK1-AS2,Marker 1424), BTB and CNC homology 1, basic leucine zipper transcription factor 1 / / / GRIK1 antisense RNA 2 / / / long intergenic non-protein coding RNA 189 (BACH1 / / / GRIK1-AS2 / / / LINC00189, marker 1425), BCL2-associated agonist of cell death (BAD, marker 1426), BCL2-associated athanogene 2 (BAG2, marker 1427), BCL2-associated athanogene 6 (BAG6, marker 1428), B melanoma antigen (BAGE, marker 1429), B melanoma antigen (BAGE, marker 1430), B melanoma antigen (BAGE, marker 1431), B melanoma antigen (BAGE, marker 1432), BAH domain and coiled-coil containing 1 (BAHCC1, marker 1433), BAH domain and coiled-coil containing 1 (BAHCC1, marker 1434), BAH domain and coiled-coil containing 1 (BAHCC1, marker 1435), BAI1-associated protein 2 (BAIAP2, marker 1436), BAI1-associated protein 2 (BAIAP2, marker 1437), BAIAP2 antisense RNA 1 (head to head) (BAIAP2-AS1, marker 1438), BAI1-associated protein 2-like 2 (BAIAP2L2, marker 1439), BAI1-associated protein 2-like 2 (BAIAP2L2, marker 1440), BAI1-associated protein 3 (BAIAP3, marker 1441), BAI1-associated protein 3 (BAIAP3, marker 1442),barrier to autointegration factor 2 (BANF2, marker 1443), B-cell scaffold protein with ankyrin repeats 1 (BANK1, marker 1444), BarH-like homeobox 1 (BARHL1, marker 1445), BARX homeobox 1 (BARX1, marker 1446), BARX homeobox 2 (BARX2, marker 1447), brain abundant, membrane attached signal protein 1 (BASP1, marker 1448), basic leucine zipper transcription factor, ATF-like (BATF, marker 1449), basic leucine zipper transcription factor, ATF-like 2 (BATF2, marker 1450), bromodomain adjacent to zinc finger domain 1B (BAZ1B, marker 1451), bromodomain adjacent to zinc finger domain 1B (BAZ1B, marker 1452), bromodomain adjacent to zinc finger domain 2A (BAZ2A, marker 1453), bromodomain adjacent to zinc finger domain 2A (BAZ2A, marker 1454), BBSome interacting protein 1 (BBIP1, marker 1455), BBSome interacting protein 1 (BBIP1, marker 1456), BBSome interacting protein 1 (BBIP1, marker 1457), basal body orientation factor 1 (BBOF1, marker 1458), basal body orientation factor 1 (BBOF1, marker 1459), butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 (BBOX1,marker 1460), BBOX1 antisense RNA 1 (BBOX1-AS1, marker 1461), Bardet-Biedl syndrome 1 (BBS1, marker 1462), Bardet-Biedl syndrome 9 (BBS9, marker 1463), Bardet-Biedl syndrome 9 (BBS9, marker 1464), bobby sox homolog (Drosophila) (BBX, marker 1465), basal cell adhesion molecule (Lutheran blood group) (BCAM, marker 1466), brevican (BCAN, marker 1467), brevican (BCAN, marker 1468), B-cell receptor-associated protein 29 (BCAP29, marker 1469), B-cell receptor-associated protein 29 (BCAP29, marker 1470), B-cell receptor-associated protein 29 (BCAP29, marker 1471), breast cancer anti-estrogen resistance 4 (non-protein coding) (BCAR4, marker 1472), breast carcinoma amplified sequence 1 (BCAS1, marker 1473), breast carcinoma amplified sequence 4 (BCAS4, marker 1474), breast carcinoma amplified sequence 4 (BCAS4, marker 1475), branched chain amino-acid transaminase 2, mitochondrial (BCAT2, marker 1476), BCDIN3D antisense RNA 1 (BCDIN3D-AS1, marker 1477), BCDIN3D antisense RNA 1 (BCDIN3D-AS1, marker 1478), B-cell CLL / lymphoma 10 (BCL10, marker 1479), B-cell CLL / lymphoma 11B (zinc finger protein) (BCL11B, marker 1480),B-cell CLL / lymphoma 2 (BCL2, marker 1481), B-cell CLL / lymphoma 2 (BCL2, marker 1482), B-cell CLL / lymphoma 2 (BCL2, marker 1483), BCL2-related protein A1 (BCL2A1, marker 1484), BCL2-like 10 (apoptosis facilitator) (BCL2L10, marker 1485), BCL2-like 10 (apoptosis facilitator) (BCL2L10, marker 1486), BCL2-like 11 (apoptosis facilitator) (BCL2L11, marker 1487), BCL2-like 13 (apoptosis facilitator) (BCL2L13, marker 1488), BCL2-like 14 (apoptosis facilitator) (BCL2L14, marker 1489), BCL2-like 14 (apoptosis facilitator) (BCL2L14, marker 1490), BCL2-like 14 (apoptosis facilitator) (BCL2L14, marker 1491), BCL2-like 14 (apoptosis facilitator) (BCL2L14, marker 1492), BCL2-like 14 (apoptosis facilitator) (BCL2L14, marker 1493), BCL2-like 15 (BCL2L15, marker 1494), BCL2-like 15 (BCL2L15, marker 1495), BCL2-like 15 (BCL2L15, marker 1496), B-cell CLL / lymphoma 3 (BCL3, marker 1497), B-cell CLL / lymphoma 3 (BCL3, marker 1498), B-cell CLL / lymphoma 6 (BCL6, marker 1499), B-cell CLL / lymphoma 6, member B (BCL6B, marker 1500), B-cell CLL / lymphoma 6, member B (BCL6B, marker 1501), B-cell CLL / lymphoma 6, member B (BCL6B, marker 1502),beta-carotene oxygenase 1 (BCO1, marker 1503), beta-carotene oxygenase 2 (BCO2, marker 1504), BCL6 corepressor-like 1 (BCORL1, marker 1505), BCL6 corepressor pseudogene 1 (BCORP1, marker 1506), breakpoint cluster region pseudogene 3 (BCRP3, marker 1507), breakpoint cluster region pseudogene 3 (BCRP3, marker 1508), 3-hydroxybutyrate dehydrogenase, type 1 (BDH1, marker 1509), 3-hydroxybutyrate dehydrogenase, type 1 / / / uncharacterized LOC100129516 (BDH1 / / / LOC100129516, marker 1510), 3-hydroxybutyrate dehydrogenase, type 2 (BDH2, marker 1511), bradykinin receptor B1 (BDKRB1, marker 1512), bradykinin receptor B2 (BDKRB2, marker 1513), BDNF antisense RNA (BDNF-AS, marker 1514), BDNF antisense RNA (BDNF-AS, marker 1515), B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB (BDP1, marker 1516), brain expressed, associated with NEDD4, 1 (BEAN1, marker 1517), beclin 1, autophagy related (BECN1, marker 1518), brain-enriched guanylate kinase-associated (BEGAIN, marker 1519), BEN domain containing 2 (BEND2, marker 1520), BEN domain containing 4 (BEND4, marker 1521),BEN domain containing 5 (BEND5, marker 1522), BEN domain containing 6 (BEND6, marker 1523), BEN domain containing 7 (BEND7, marker 1524), BEN domain containing 7 (BEND7, marker 1525), bestrophin 1 (BEST1, marker 1526), ​​bestrophin 1 (BEST1, marker 1527), bestrophin 1 (BEST1, marker 1528), bestrophin 2 (BEST2, marker 1529), bestrophin 3 (BEST3, marker 1530), bestrophin 3 (BEST3, marker 1531), bestrophin 3 (BEST3, marker 1532), bestrophin 4 (BEST4, marker 1533), Bet1 golgi vesicular membrane trafficking protein-like (BET1L, marker 1534), beaded filament structural protein 2, phakinin (BFSP2, marker 1535), BFSP2 antisense RNA 1 (BFSP2-AS1, marker 1536), BFSP2 antisense RNA 1 (BFSP2-AS1, marker 1537), beta globin locus transcript 3 (non-protein coding) (BGLT3, marker 1538), biglycan (BGN, marker 1539), basic helix-loop-helix family, member a15 (BHLHA15, marker 1540), basic helix-loop-helix family, member e22 (BHLHE22, marker 1541), basic helix-loop-helix family, member e22 (BHLHE22, marker 1542), basic helix-loop-helix family, member e23 (BHLHE23, marker 1543), basic helix-loop-helix family, member e41 (BHLHE41, marker 1544),basic helix-loop-helix family, member e41 (BHLHE41, marker 1545), basic helix-loop-helix family, member e41 (BHLHE41, marker 1546), basic helix-loop-helix family, member e41 (BHLHE41, marker 1547), betaine-homocysteine ​​S-methyltransferase 2 (BHMT2, marker 1548), betaine-homocysteine ​​S-methyltransferase 2 (BHMT2, marker 1549), betaine-homocysteine ​​S-methyltransferase 2 (BHMT2, marker 1550), BicC family RNA binding protein 1 (BICC1, marker 1551), bicaudal D homolog 2 (Drosophila) (BICD2, marker 1552), bridging integrator 2 (BIN2, marker 1553), BIN3 intronic transcript 1 (BIN3-IT1, marker 1554), baculoviral IAP repeat containing 3 (BIRC3, marker 1555), bac, IAP repeat containing uloviral IAP repeat 3 (BIRC3, marker 1556), baculoviral IAP repeat containing 7 (BIRC7, marker 1557), BST2 interferon-stimulated positive regulator (non-protein coding) (BISPR, marker 1558), basic, immunoglobulin-like variable motif containing (BIVM, marker 1559), basic, immunoglobulin-like variable motif containing (BIVM, marker 1560), basic, immunoglobulin-like variable motif containing (BIVM, marker 1561), bladder cancer associated protein / / / uncharacterized LOC105372607 / / / uncharacterized LOC105376973 (BLCAP / / / LOC105372607 / / / LOC105376973, marker 1562), BH3-like motif containing, cell death inducer (BLID, marker 1563), BLK proto-oncogene, Src family tyrosine kinase (BLK, marker 1564), BLK proto-oncogene, Src family tyrosine kinase (BLK, marker 1565), B-cell linker (BLNK, marker 1566), BLOC1S1-RDH5 readthrough / / / retinol dehydrogenase 5 (11-cis / 9-cis) (BLOC1S1-RDH5 / / / RDH5, marker 1567), biogenesis of lysosomal organelles complex-1, subunit 3 (BLOC1S3, marker 1568), biliverdin reductase A (BLVRA, marker 1569), biliverdin reductase A (BLVRA,marker 1570), basic leucine zipper nuclear factor 1 (BLZF1, marker 1571), basic leucine zipper nuclear factor 1 (BLZF1, marker 1572), bone morphogenetic protein 1 (BMP1, marker 1573), bone morphogenetic protein 1 (BMP1, marker 1574), bone morphogenetic protein 1 (BMP1, marker 1575), bone morphogenetic protein 1 (BMP1, marker 1576), bone morphogenetic protein 10 (BMP10, marker 1577), bone morphogenetic protein 15 (BMP15, marker 1578), BMP2 inducible kinase (BMP2K, marker 1579), BMP2 inducible kinase (BMP2K, marker 1580), bone morphogenetic protein 3 (BMP3, marker 1581), bone morphogenetic protein 6 (BMP6, marker 1582), bone morphogenetic protein 6 (BMP6, marker 1583), bone morphogenetic protein 7 (BMP7, marker 1584), bone morphogenetic protein 8a (BMP8A, marker 1585), bone morphogenetic protein 8a (BMP8A, marker 1586), bone morphogenetic protein 8a (BMP8A, marker 1587), bone morphogenetic protein 8b (BMP8B, marker 1588), bone morphogenetic protein 8b (BMP8B, marker 1589), bone morphogenetic protein 8b (BMP8B, marker 1590), BMP binding endothelial regulator (BMPER, marker 1591),bone morphogenetic protein receptor type IB(BMPR1B,ーカー1592),BMS1 ribosome biogenesis factor pseudogene 17 / / / BMS1 ribosome biogenesis factor pseudogene 18(BMS1P17 / / / BMS1P18,マー1593),BMS1 ribosome biogenesis factor pseudogene 20 / / / immunoglobulin lambda constant 2 (Kern-Oz- marker) / / / immunoglobulin lambda constant 3 (Kern-Oz+ marker) / / / immunoglobulin lambda joining 2 / / / immunoglobulin lambda joining 3 / / / immunoglobulin lambda-like polypeptide 5 / / / immunoglobulin lambda variable 1-44 / / / immunoglobulin lambda variable 3-19 / / / immunoglobulin lambda variable 3-25(BMS1P20 / / / IGLC2 / / / IGLC3 / / / IGLJ2 ​​ / / / IGLJ3 / / / IGLL5 / / / IGLV1-44 / / / IGLV3-19 / / / IGLV3-25,マカー1594),BMS1 ribosome biogenesis factor pseudogene 21 / / / mannose-binding lectin (protein A)1, pseudogene(BMS1P21 / / / MBL1P,マカー1595),BMS1 ribosome biogenesis factor pseudogene 5(BMS1P5,plot1596),BMX non-receptor tyrosine kinase(BMX,plot1597),basonuclin 2(BNC2,plot1598),BCL2 / adenovirus E1B 19kD interacting protein like (BNIPL, marker 1599), BCL2 / adenovirus E1B 19kD interacting protein like (BNIPL, marker 1600), bioorientation of chromosomes in cell division 1-like 1 (BOD1L1, marker 1601), bioorientation of chromosomes in cell division 1-like 2 (BOD1L2, marker 1602), bolA family member 2 (BOLA2, marker 1603), BOLA3 antisense RNA 1 (head to head) (BOLA3-AS1, marker 1604), BOLA3 antisense RNA 1 (head to head) (BOLA3-AS1, marker 1605), boule homolog, RNA binding protein (BOLL, marker 1606), BLOC-1 related complex subunit 6 (BORCS6, marker 1607), BLOC-1 related complex subunit 6 (BORCS6, marker 1608), blepharophimosis, epicanthus inversus and ptosis, candidate 1 (non-protein coding) (BPESC1, marker 1609), bactericidal / permeability-increasing protein (BPI, marker 1610), bactericidal / permeability-increasing protein / / / uncharacterized LOC149684 (BPI / / / LOC149684, marker 1611), bactericidal / permeability-increasing protein / / / uncharacterized LOC149684 (BPI / / / LOC149684, marker 1612), BPI fold containing family A, member 1 (BPIFA1, marker 1613),BPI fold containing family A, member 2 (BPIFA2, marker 1614), BPI fold containing family A, member 3 (BPIFA3, marker 1615), BPI fold containing family A, member 4, pseudogene (BPIFA4P, marker 1616), BPI fold containing family B, member 1 (BPIFB1, marker 1617), BPI fold containing family B, member 2 (BPIFB2, marker 1618), BPI fold containing family B, member 4 (BPIFB4, marker 1619), BPI fold containing family B, member 6 (BPIFB6, marker 1620), BPI fold containing family C (BPIFC, marker 1621), 3'(2'), 5'-bisphosphate nucleotidase 1 (BPNT1, marker 1622), basic charge, Y-linked, 2 (BPY2, marker 1623), bromodomain containing 3 (BRD3, marker 1624), bromodomain containing 4 (BRD4, marker 1625), bromodomain containing 4 (BRD4, marker 1626), bromodomain containing 7 pseudogene 3 (BRD7P3, marker 1627), bromodomain containing 7 pseudogene 3 (BRD7P3, marker 1628), bromodomain containing 8 (BRD8, marker 1629), bromodomain containing 8 (BRD8, marker 1630), bromodomain, testis-specific (BRDT, marker 1631), BRE antisense RNA 1 (BRE-AS1, marker 1632), breast cancer estrogen-induced apoptosis 2 (BREA2, marker 1633),BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit (BRF1, marker 1634), BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit (BRF1, marker 1635), brain protein I3 / / / uncharacterized LOC644975 (BRI3 / / / FLJ30064, marker 1636), bone morphogenetic protein / retinoic acid inducible neural-specific 1 (BRINP1, marker 1637), bone morphogenetic protein / retinoic acid inducible neural-specific 2 (BRINP2, marker 1638), bone morphogenetic protein / retinoic acid inducible neural-specific 3 (BRINP3, marker 1639), bromodomain and PHD finger containing 3 (BRPF3, marker 1640), bombesin-like receptor 3 (BRS3, marker 1641), bombesin-like receptor 3 (BRS3, marker 1642), BR serine / threonine kinase 1 (BRSK1, marker 1643), BR serine / threonine kinase 2 (BRSK2, marker 1644), BR serine / threonine kinase 2 (BRSK2, marker 1645), bromodomain and WD repeat domain containing 1 (BRWD1, marker 1646), BRWD1 intronic transcript 2 (non-protein coding) (BRWD1-IT2, marker 1647), BSD domain containing 1 (BSDC1, marker 1648), bassoon presynaptic cytomatrix protein (BSN,Marker 1649), BSN antisense RNA 2 (head to head) (BSN-AS2, marker 1650), barttin CLCNK-type chloride channel accessory beta subunit (BSND, marker 1651), barttin CLCNK-type chloride channel accessory beta subunit (BSND, marker 1652), barttin CLCNK-type chloride channel accessory beta subunit (BSND, marker 1653), B-box and SPRY domain containing (BSPRY, marker 1654), BTB (POZ) domain containing 16 (BTBD16, marker 1655), BTB (POZ) domain containing 17 (BTBD17, marker 1656), BTB (POZ) domain containing 18 (BTBD18, marker 1657), BTB (POZ) domain containing 19 (BTBD19, marker 1658), BTB (POZ) domain containing 19 (BTBD19, marker 1659), BTB (POZ) domain containing 7 (BTBD7, marker 1660), BTB (POZ) domain containing 8 (BTBD8, marker 1661), BTB (POZ) domain containing 9 (BTBD9, marker 1662), BTB (POZ) domain containing 9 (BTBD9, marker 1663), BTB (POZ) domain containing 9 (BTBD9, marker 1664), betacellulin (BTC, marker 1665), betacellulin (BTC, marker 1666), biotinidase (BTD, marker 1667), basic transcription factor 3 (BTF3, marker 1668), basic transcription factor 3-like 4 (BTF3L4, marker 1669),basic transcription factor 3-like 4 (BTF3L4, marker 1670), basic transcription factor 3 pseudogene 11 (BTF3P11, marker 1671), B-cell translocation gene 1, anti-proliferative (BTG1, marker 1672), BTG family, member 3 (BTG3, marker 1673), B-cell translocation gene 4 (BTG4, marker 1674), B-cell translocation gene 4 (BTG4, marker 1675), B-cell translocation gene 4 / / / POU class 2 associating factor 1 (BTG4 / / / POU2AF1, marker 1676), Bruton agammaglobulinemia tyrosine kinase (BTK, marker 1677), B and T lymphocyte associated (BTLA, marker 1678), butyrophilin, subfamily 1, member A1 (BTN1A1, marker 1679), butyrophilin, subfamily 2, member A1 (BTN2A1, marker 1680), butyrophilin, subfamily 2, member A2 (BTN2A2, marker 1681), butyrophilin, subfamily 2, member A2 (BTN2A2, marker 1682), butyrophilin, subfamily 2, member A3, pseudogene (BTN2A3P, marker 1683), butyrophilin, subfamily 3, member A1 (BTN3A1, marker 1684), butyrophilin, subfamily 3, member A2 (BTN3A2, marker 1685), butyrophilin, subfamily 3, member A3 (BTN3A3, marker 1686), butyrophilin, subfamily 3, member A3 (BTN3A3, marker 1687),butyrophilin-like 2 (BTNL2, marker 1688), butyrophilin-like 3 (BTNL3, marker 1689), butyrophilin-like 8 (BTNL8, marker 1690), butyrophilin-like 9 (BTNL9, marker 1691), butyrophilin-like 9 (BTNL9, marker 1692), butyrophilin-like 9 (BTNL9, marker 1693), butyrophilin-like 9 (BTNL9, marker 1694), butyrophilin-like 9 (BTNL9, marker 1695), beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC, marker 1696), beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC, marker 1697), BUB1 mitotic checkpoint serine / threonine kinase (BUB1, marker 1698), BUB1 mitotic checkpoint serine / threonine kinase (BUB1, marker 1699), BUB1 mitotic checkpoint serine / threonine kinase (BUB1, marker 1700), BUB3 mitotic checkpoint protein (BUB3, marker 1701), BUB3 mitotic checkpoint protein (BUB3, marker 1702), BUD31 homolog (BUD31, marker 1703), blood vessel epicardial substance (BVES, marker 1704), BVES antisense RNA 1 (BVES-AS1, marker 1705), BZRAP1 antisense RNA 1 (BZRAP1-AS1, marker 1706), BZRAP1 antisense RNA 1 (BZRAP1-AS1, marker 1707), chromosome 10 open reading frame 10 (C10orf10, marker 1708),chromosome 10 open reading frame 10 (C10orf10, marker 1709), chromosome 10 open reading frame 107 (C10orf107, marker 1710), chromosome 10 open reading frame 11 (C10orf11, marker 1711), chromosome 10 open reading frame 113 (C10orf113, marker 1712), chromosome 10 open reading frame 12 (C10orf12, marker 1713), chromosome 10 open reading frame 126 (C10orf126, marker 1714), chromosome 10 open reading frame 128 (C10orf128, marker 1715), chromosome 10 open reading frame 128 (C10orf128, marker 1716), chromosome 10 open reading frame 25 (C10orf25, marker 1717), chromosome 10 open reading frame 53 (C10orf53, marker 1718), chromosome 10 open reading frame 53 (C10orf53, marker 1719), chromosome 10 open reading frame 54 (C10orf54, marker 1720), chromosome 10 open reading frame 54 (C10orf54, marker 1721), ,chromosome 10 open reading frame 55(C10orf55, marker 1722),chromosome 10 open reading frame 62(C10orf62, marker 1723),chromosome 10 open reading frame 67(C10orf67, marker 1724),chromosome 10 open reading frame 67(C10orf67, marker 1725),chromosome 10 open reading frame 67(C10orf67, marker 1726),chromosome 10 open reading frame 71(C10orf71, marker 1727),C10orf71 antisense RNA 1(C10orf71-AS1, marker 1728),chromosome 10 open reading frame 90(C10orf90, marker 1729),chromosome 10 open reading frame 90(C10orf90, marker 1730),chromosome 10 open reading frame 90 (C10orf90, marker 1731), chromosome 10 open reading frame 91 (C10orf91, marker 1732), chromosome 10 open reading frame 95 (C10orf95, marker 1733), chromosome 10 open reading frame 99 (C10orf99, marker 1734), chromosome 10 open reading frame 99 (C10orf99, marker 1735), chromosome 11 open reading frame 1 (C11orf1, marker 1736), chromosome 11 open reading frame 16 (C11orf16, marker 1737), chromosome 11 open reading frame 21 (C11orf21, marker 1738), chromosome 11 open reading frame 21 (C11orf21, marker 1739),chromosome 11 open reading frame 40 (C11orf40, marker 1740), chromosome 11 open reading frame 42 (C11orf42, marker 1741), chromosome 11 open reading frame 44 (C11orf44, marker 1742), chromosome 11 open reading frame 45 (C11orf45, marker 1743), chromosome 11 open reading frame 49 (C11orf49, marker 1744), chromosome 11 open reading frame 53 (C11orf53, marker 1745), chromosome 11 open reading frame 54 (C11orf54, marker 1746), chromosome 11 open reading frame 57 (C11orf57, marker 1747), chromosome 11 open reading frame 57 (C11orf57, marker 1748), chromosome 11 open reading frame 58 (C11orf58, marker 1749), chromosome 11 open reading frame 58 (C11orf58, marker 1750), chromosome 11 open reading frame 63 (C11orf63, marker 1751), chromosome 11 open reading frame 63 (C11orf63, marker 1752), chromosome 11 open reading frame 65 (C11orf65, marker 1753), chromosome 11 open reading frame 70 (C11orf70, marker 1754), chromosome 11 open reading frame 70 (C11orf70, marker 1755), chromosome 11 open reading frame 72 (C11orf72, marker 1756), chromosome 11 open reading frame 85 (C11orf85, marker 1757),chromosome 11 open reading frame 86 (C11orf86, marker 1758), chromosome 11 open reading frame 87 (C11orf87, marker 1759), chromosome 11 open reading frame 87 (C11orf87, marker 1760), chromosome 11 open reading frame 87 (C11orf87, marker 1761), chromosome 11 open reading frame 88 (C11orf88, marker 1762), chromosome 11 open reading frame 94 (C11orf94, marker 1763), chromosome 11 open reading frame 95 (C11orf95, marker 1764), chromosome 11 open reading frame 97 (C11orf97, marker 1765), chromosome 12 open reading frame 40 (C12orf40, marker 1766), chromosome 12 open reading frame 40 (C12orf40, marker 1767), chromosome 12 open reading frame 42 (C12orf42, marker 1768), chromosome 12 open reading frame 42 (C12orf42, marker 1769), chromosome 12 open reading frame 49 (C12orf49, marker 1770), chromosome 12 open reading frame 49 (C12orf49, marker 1771), chromosome 12 open reading frame 50 (C12orf50, marker 1772), chromosome 12 open reading frame 54 (C12orf54, marker 1773), chromosome 12 open reading frame 54 (C12orf54, marker 1774), chromosome 12 open reading frame 54 (C12orf54, marker 1775),chromosome 12 open reading frame 60 (C12orf60, marker 1776), chromosome 12 open reading frame 65 (C12orf65, marker 1777), chromosome 12 open reading frame 66 (C12orf66, marker 1778), chromosome 12 open reading frame 74 (C12orf74, marker 1779), chromosome 12 open reading frame 76 (C12orf76, marker 1780), chromosome 12 open reading frame 77 (C12orf77, marker 1781), chromosome 12 open reading frame 80 (C12orf80, marker 1782), chromosome 12 open reading frame 80 (C12orf80, marker 1783), chromosome 14 open reading frame 1 (C14orf1, marker 1784), chromosome 14 open reading frame 105 (C14orf105, marker 1785), chromosome 14 open reading frame 105 (C14orf105, marker 1786), chromosome 14 open reading frame 105 (C14orf105, marker 1787), chromosome 14 open reading frame 159 (C14orf159, marker 1788), chromosome 14 open reading frame 178 (C14orf178, marker 1789), chromosome 14 open reading frame 180 (C14orf180, marker 1790), chromosome 14 open reading frame 180 (C14orf180, marker 1791), chromosome 14 open reading frame 39 (C14orf39, marker 1792), chromosome 14 open reading frame 80 (C14orf80,chromosome 14 open reading frame 93 (C14orf93, marker 1794), chromosome 15 open reading frame 32 (C15orf32, marker 1795), chromosome 15 open reading frame 39 (C15orf39, marker 1796), chromosome 15 open reading frame 40 (C15orf40, marker 1797), chromosome 15 open reading frame 41 (C15orf41, marker 1798), chromosome 15 open reading frame 43 (C15orf43, marker 1799), chromosome 15 open reading frame 48 (C15orf48, marker 1800), chromosome 15 open reading frame 52 (C15orf52, marker 1801), chromosome 15 open reading frame 54 (C15orf54, marker 1802), chromosome 15 open reading frame 56 (C15orf56, marker 1803), chromosome 15 open reading frame 57 (C15orf57, marker 1804), chromosome 15 open reading frame 57 (C15orf57, marker 1805), chromosome 15 open reading frame 59 (C15orf59, marker 1806), chromosome 15 open reading frame 62 (C15orf62, marker 1807), chromosome 15 open reading frame 62 (C15orf62, marker 1808), chromosome 15 open reading frame 65 (C15orf65, marker 1809), chromosome 16 open reading frame 13 (C16orf13, marker 1810), chromosome 16 open reading frame 13 (C16orf13, marker 1811),chromosome 16 open reading frame 45 (C16orf45, marker 1812), chromosome 16 open reading frame 46 (C16orf46, marker 1813), chromosome 16 open reading frame 52 (C16orf52, marker 1814), chromosome 16 open reading frame 54 / / / transmembrane protein C16orf54 (C16orf54 / / / LOC105369277, marker 1815), chromosome 16 open reading frame 62 (C16orf62, marker 1816), chromosome 16 open reading frame 70 (C16orf70, marker 1817), chromosome 16 open reading frame 70 (C16orf70, marker 1818), chromosome 16 open reading frame 71 (C16orf71, marker 1819), chromosome 16 open reading frame 78 (C16orf78, marker 1820), chromosome 16 open reading frame 82 (C16orf82, marker 1821), chromosome 16 open reading frame 87 (C16orf87, marker 1822), chromosome 16 open reading frame 92 (C16orf92, marker 1823), chromosome 16 open reading frame 95 (C16orf95, marker 1824), chromosome 17 open reading frame 105 (C17orf105, marker 1825), chromosome 17 open reading frame 47 (C17orf47, marker 1826), chromosome 17 open reading frame 50 (C17orf50, marker 1827), chromosome 17 open reading frame 51 (C17orf51, marker 1828),chromosome 17 open reading frame 51 (C17orf51, marker 1829), chromosome 17 open reading frame 51 (C17orf51, marker 1830), chromosome 17 open reading frame 51 (C17orf51, marker 1831), chromosome 17 open reading frame 53 (C17orf53, marker 1832), chromosome 17 open reading frame 64 (C17orf64, marker 1833), chromosome 17 open reading frame 67 (C17orf67, marker 1834), chromosome 17 open reading frame 74 (C17orf74, marker 1835), chromosome 17 open reading frame 77 (C17orf77, marker 1836), chromosome 17 open reading frame 78 (C17orf78, marker 1837), chromosome 17 open reading frame 89 (C17orf89, marker 1838), chromosome 17 open reading frame 89 (C17orf89, marker 1839), chromosome 17 open reading frame 98 (C17orf98, marker 1840), chromosome 17 open reading frame 99 (C17orf99, marker 1841), chromosome 18 open reading frame 12 (C18orf12, marker 1842), chromosome 18 open reading frame 15 (C18orf15, marker 1843), chromosome 18 open reading frame 21 (C18orf21, marker 1844), chromosome 18 open reading frame 25 (C18orf25, marker 1845), chromosome 18 open reading frame 25 (C18orf25, marker 1846),chromosome 18 open reading frame 25 (C18orf25, marker 1847), chromosome 18 open reading frame 42 (C18orf42, marker 1848), chromosome 18 open reading frame 54 (C18orf54, marker 1849), uncharacterized LOC497259 / / / uncharacterized LOC102724470 (C18orf61 / / / LOC102724470, marker 1850), chromosome 18 open reading frame 8 (C18orf8, marker 1851), chromosome 18 open reading frame 8 (C18orf8, marker 1852), chromosome 19 open reading frame 12 (C19orf12, marker 1853), chromosome 19 open reading frame 18 (C19orf18, marker 1854), chromosome 19 open reading frame 25 (C19orf25, marker 1855), chromosome 19 open reading frame 43 (C19orf43, marker 1856), chromosome 19 open reading frame 44 (C19orf44, marker 1857), chromosome 19 open reading frame 45 (C19orf45, marker 1858), chromosome 19 open reading frame 45 (C19orf45, marker 1859), chromosome 19 open reading frame 47 (C19orf47, marker 1860), chromosome 19 open reading frame 47 (C19orf47, marker 1861), chromosome 19 open reading frame 57 (C19orf57, marker 1862), chromosome 19 open reading frame 73 (C19orf73, marker 1863),Chromosome 19 open reading frame 81 (C19orf81, marker 1864), chromosome 19 open reading frame 84 (C19orf84, marker 1865), C1GALT1 specific chaperone 1 (C1GALT1C1, marker 1866), C1GALT1-specific chaperone 1 like (C1GALT1C1L, marker 1867), complement component 1, q subcomponent, A chain (C1QA, marker 1868), complement component 1, q subcomponent, B chain (C1QB, marker 1869), complement component 1, q subcomponent, C chain (C1QC, marker 1870), complement component 1, q subcomponent-like 1 (C1QL1, marker 1871), complement component 1, q subcomponent-like 1 (C1QL1, marker 1872), C1q and tumor necrosis factor related protein 1 (C1QTNF1, marker 1873), C1QTNF1 antisense RNA 1 (C1QTNF1-AS1, marker 1874), C1q and tumor necrosis factor related protein 2 (C1QTNF2, marker 1875), C1q and tumor necrosis factor related protein 3 (C1QTNF3, marker 1876), C1q and tumor necrosis factor related protein 3 (C1QTNF3, marker 1877), C1q and tumor necrosis factor related protein 4 (C1QTNF4, marker 1878),C1q and tumor necrosis factor related protein 5 / / / membrane frizzled-related protein (C1QTNF5 / / / MFRP, marker 1879), C1q and tumor necrosis factor related protein 6 (C1QTNF6, marker 1880), C1q and tumor necrosis factor related protein 6 (C1QTNF6, marker 1881), C1q and tumor necrosis factor related protein 7 (C1QTNF7, marker 1882), C1q and tumor necrosis factor related protein 7 (C1QTNF7, marker 1883), C1q and tumor necrosis factor related protein 9 (C1QTNF9, marker 1884), C1RL antisense RNA 1 (C1RL-AS1, marker 1885), C1RL antisense RNA 1 (C1RL-AS1, marker 1886), complement component 1, s subcomponent (C1S, marker 1887), chromosome 1 open reading frame 100 (C1orf100, marker 1888), chromosome 1 open reading frame 101 (C1orf101, marker 1889), chromosome 1 open reading frame 101 (C1orf101, marker 1890), chromosome 1 open, reading frame 105 (C1orf105, marker 1891), chromosome 1 open reading frame 111 (C1orf111, marker 1892), chromosome 1 open reading frame 115 (C1orf115, marker 1893), chromosome 1 open reading frame 116 (C1orf116, marker 1894), chromosome 1 open reading frame 116 (C1orf116, marker 1895), chromosome 1 open reading frame 127 (C1orf127, marker 1896), chromosome 1 open reading frame 132 (C1orf132, marker 1897), chromosome 1 open reading frame 145 (C1orf145, marker 1898), chromosome 1 open reading frame 145 (C1orf145, marker 1899), chromosome 1 open reading frame 158 (C1orf158, marker 1900), chromosome 1 open reading frame 162 (C1orf162, marker 1901), chromosome 1 open reading frame 168 (C1orf168, marker 1902), chromosome 1 open reading frame 168 (C1orf168, marker 1903), chromosome 1 open reading frame 186 (C1orf186, marker 1904), chromosome 1 open reading frame 186 (C1orf186, marker 1905), chromosome 1 open reading frame 186 / / / uncharacterized LOC100505650 (C1orf186 / / / LOC100505650, marker 1906), chromosome 1 open reading frame 194 (C1orf194, marker 1907),chromosome 1 open reading frame 204 (C1orf204, marker 1908), chromosome 1 open reading frame 21 (C1orf21, marker 1909), chromosome 1 open reading frame 21 (C1orf21, marker 1910), chromosome 1 open reading frame 220 (C1orf220, marker 1911), chromosome 1 open reading frame 228 (C1orf228, marker 1912), chromosome 1 open reading frame 228 (C1orf228, marker 1913), chromosome 1 open reading frame 228 (C1orf228, marker 1914), chromosome 1 open reading frame 228 (C1orf228, marker 1915), chromosome 1 open reading frame 228 (C1orf228, marker 1916), chromosome 1 open reading frame 234 (C1orf234, marker 1917), chromosome 1 open reading frame 27 (C1orf27, marker 1918), chromosome 1 open reading frame 53 (C1orf53, marker 1919), chromosome 1 open reading frame 56 (C1orf56, marker 1920), chromosome 1 open reading frame 56 (C1orf56, marker 1921), chromosome 1 open reading frame 61 (C1orf61, marker 1922), chromosome 1 open reading frame 61 (C1orf61, marker 1923), chromosome 1 open reading frame 61 (C1orf61, marker 1924), chromosome 1 open reading frame 64 (C1orf64, marker 1925),chromosome 1 open reading frame 68 (C1orf68, marker 1926), chromosome 1 open reading frame 68 (C1orf68, marker 1927), chromosome 1 open reading frame 87 (C1orf87, marker 1928), chromosome 1 open reading frame 95 (C1orf95, marker 1929), chromosome 1 open reading frame 95 (C1orf95, marker 1930), complement component 2 (C2, marker 1931), complement component 2 (C2, marker 1932), chromosome 20 open reading frame 141 (C20orf141, marker 1933), chromosome 20 open reading frame 144 (C20orf144, marker 1934), C20orf166 antisense RNA 1 (C20orf166-AS1, marker 1935), C20orf166 antisense RNA 1 (C20orf166-AS1, marker 1936), chromosome 20 open reading frame 173 (C20orf173, marker 1937), chromosome 20 open reading frame 181 (C20orf181, marker 1938), chromosome 20 open reading frame 187 (C20orf187, marker 1939), chromosome 20 open reading frame 195 (C20orf195, marker 1940), chromosome 20 open reading frame 196 (C20orf196, marker 1941), chromosome 20 open reading frame 197 (C20orf197, marker 1942), chromosome 20 open reading frame 202 (C20orf202, marker 1943), chromosome 20 open reading frame 202 (C20orf202,marker 1944), chromosome 20 open reading frame 203 (C20orf203, marker 1945), chromosome 20 open reading frame 203 (C20orf203, marker 1946), chromosome 20 open reading frame 57 / / / dual specificity phosphatase 15 (C20orf57 / / / DUSP15, marker 1947), chromosome 20 open reading frame 78 (C20orf78, marker 1948), chromosome 20 open reading frame 85 (C20orf85, marker 1949), chromosome 20 open reading frame 96 (C20orf96, marker 1950), C21ORF116 (marker 1951), chromosome 21 open reading frame 2 (C21orf2, marker 1952), chromosome 21 open reading frame 2 (C21orf2, marker 1953), chromosome 21 open reading frame 2 (C21orf2, marker 1954), chromosome 21 open reading frame 2 (C21orf2, marker 1955), chromosome 21 open reading frame 2 (C21orf2, marker 1956), chromosome 21 open reading frame 58 (C21orf58, marker 1957), chromosome 21 open reading frame 58 (C21orf58, marker 1958), chromosome 21 open reading frame 58 (C21orf58, marker 1959), chromosome 21 open reading frame 59 (C21orf59, marker 1960), chromosome 21 open reading frame 62 (C21orf62, marker 1961), chromosome 21 open reading frame 62 (C21orf62,marker 1962), C21orf62 antisense RNA 1 (C21orf62-AS1, marker 1963), C21orf62 antisense RNA 1 (C21orf62-AS1, marker 1964), C21orf91 overlapping transcript 1 (C21orf91-OT1, marker 1965), C21orf91 overlapping transcript 1 (C21orf91-OT1, marker 1966), chromosome 22 open reading frame 15 (C22orf15, marker 1967), chromosome 22 open reading frame 15 (C22orf15, marker 1968), chromosome 22 open reading frame 23 (C22orf23, marker 1969), chromosome 22 open reading frame 24 (C22orf24, marker 1970), chromosome 22 open reading frame 31 (C22orf31, marker 1971), chromosome 22 open reading frame 34 (C22orf34, marker 1972), chromosome 22 open reading frame 34 (C22orf34, marker 1973), chromosome 22 open reading frame 42 (C22orf42, marker 1974), chromosome 22 open reading frame 42 (C22orf42, marker 1975), chromosome 22 open reading frame 46 (C22orf46, marker 1976), C2CD2-like (C2CD2L, marker 1977), C2CD2-like (C2CD2L, marker 1978), C2 calcium-dependent domain containing 3 (C2CD3, marker 1979), C2 calcium-dependent domain containing 4A (C2CD4A, marker 1980), C2 calcium-dependent domain containing 4B (C2CD4B, marker 1981),C2 calcium-dependent domain containing 4B (C2CD4B, marker 1982), chromosome 2 open reading frame 15 (C2orf15, marker 1983), chromosome 2 open reading frame 27A (C2orf27A, marker 1984), chromosome 2 open reading frame 50 (C2orf50, marker 1985), chromosome 2 open reading frame 54 (C2orf54, marker 1986), chromosome 2 open reading frame 57 (C2orf57, marker 1987), chromosome 2 open reading frame 61 (C2orf61, marker 1988), chromosome 2 open reading frame 70 (C2orf70, marker 1989), chromosome 2 open reading frame 71 (C2orf71, marker 1990), chromosome 2 open reading frame 72 (C2orf72, marker 1991), chromosome 2 open reading frame 73 (C2orf73, marker 1992), chromosome 2 open reading frame 80 (C2orf80, marker 1993), chromosome 2 open reading frame 82 (C2orf82, marker 1994), chromosome 2 open reading frame 82 (C2orf82, marker 1995), chromosome 2 open reading frame 83 (C2orf83, marker 1996), chromosome 2 open reading frame 88 (C2orf88, marker 1997), chromosome 2 open reading frame 88 (C2orf88, marker 1998), complement component 3 (C3, marker 1999), complement component 3a receptor 1 (C3AR1, marker 2000),Complement component 3 precursor pseudogene (C3P1, marker 2001), chromosome 3 open reading frame 14 (C3orf14, marker 2002), chromosome 3 open reading frame 20 (C3orf20, marker 2003), chromosome 3 open reading frame 22 (C3orf22, marker 2004), chromosome 3 open reading frame 30 (C3orf30, marker 2005), chromosome 3 open reading frame 33 (C3orf33, marker 2006), chromosome 3 open reading frame 35 (C3orf35, marker 2007), chromosome 3 open reading frame 36 (C3orf36, marker 2008), chromosome 3 open reading frame 49 (C3orf49, marker 2009), chromosome 3 open reading frame 52 (C3orf52, marker 2010), chromosome 3 open reading frame 56 (C3orf56, marker 2011), chromosome 3 open reading frame 58 (C3orf58, marker 2012), chromosome 3 open reading frame 58 (C3orf58, marker 2013), chromosome 3 open reading frame 62 (C3orf62, marker 2014), chromosome 3 open reading frame 62 (C3orf62, marker 2015), chromosome 3 open reading frame 67 (C3orf67, marker 2016), chromosome 3 open reading frame 70 (C3orf70, marker 2017), chromosome 3 open reading frame 79 (C3orf79, marker 2018),chromosome 3 open reading frame 80(C3orf80, marker 2019), complement component 4A (Rodgers blood group) / / / complement component 4B (Chido blood group) / / / complement component 4B (Chido blood group), copy 2(C4A / / / C4B / / / C4B_2, marker 2020), complement component 4A (Rodgers blood group) / / / complement component 4B (Chido blood group) / / / complement component 4B (Chido blood group), copy 2(C4A / / / C4B / / / C4B_2, marker 2021), complement component 4A (Rodgers blood group) / / / complement component 4B (Chido blood group) / / / complement component 4B (Chido blood group), copy 2(C4A / / / C4B / / / C4B_2, marker 2022), complement component 4 binding protein, alpha (C4BPA, marker 2023), complement component 4 binding protein, beta (C4BPB, marker 2024), chromosome 4 open reading frame 17 (C4orf17, marker 2025), chromosome 4 open reading frame 19 (C4orf19, marker 2026), chromosome 4 open reading frame 22 (C4orf22, marker 2027), chromosome 4 open reading frame 26 (C4orf26, marker 2028), chromosome 4 open reading frame 27 (C4orf27, marker 2029),chromosome 4 open reading frame 33 (C4orf33, marker 2030), chromosome 4 open reading frame 33 (C4orf33, marker 2031), chromosome 4 open reading frame 36 (C4orf36, marker 2032), chromosome 4 open reading frame 45 (C4orf45, marker 2033), chromosome 4 open reading frame 47 (C4orf47, marker 2034), chromosome 4 open reading frame 47 (C4orf47, marker 2035), complement component 5a receptor 1 (C5AR1, marker 2036), complement component 5a receptor 2 (C5AR2, marker 2037), chromosome 5 open reading frame 17 (C5orf17, marker 2038), chromosome 5 open reading frame 22 (C5orf22, marker 2039), chromosome 5 open reading frame 28 (C5orf28, marker 2040), chromosome 5 open reading frame 42 (C5orf42, marker 2041), chromosome 5 open reading frame 46 (C5orf46, marker 2042), chromosome 5 open reading frame 47 (C5orf47, marker 2043), chromosome 5 open reading frame 47 (C5orf47, marker 2044), chromosome 5 open reading frame 49 (C5orf49, marker 2045), chromosome 5 open reading frame 51 (C5orf51, marker 2046), chromosome 5 open reading frame 56 (C5orf56, marker 2047), chromosome 5 open reading frame 56 (C5orf56,marker 2048), chromosome 5 open reading frame 56 (C5orf56, marker 2049), chromosome 5 open reading frame 56 (C5orf56, marker 2050), chromosome 5 open reading frame 58 (C5orf58, marker 2051), chromosome 5 open reading frame 58 (C5orf58, marker 2052), chromosome 5 open reading frame 58 (C5orf58, marker 2053), chromosome 5 open reading frame 63 (C5orf63, marker 2054), chromosome 5 open reading frame 63 (C5orf63, marker 2055), chromosome 5 open reading frame 63 (C5orf63, marker 2056), chromosome 5 open reading frame 63 (C5orf63, marker 2057), chromosome 5 open reading frame 64 (C5orf64, marker 2058), C5orf66 antisense RNA 1 (C5orf66-AS1, marker 2059), complement component 6 (C6, marker 2060), chromosome 6 open reading frame 10 (C6orf10, marker 2061), chromosome 6 o, open reading frame 118 (C6orf118, marker 2062), chromosome 6 open reading frame 118 (C6orf118, marker 2063), chromosome 6 open reading frame 15 (C6orf15, marker 2064), chromosome 6 open reading frame 163 (C6orf163, marker 2065), chromosome 6 open reading frame 163 (C6orf163, marker 2066), chromosome 6 open reading frame 183 / / / transmembrane protein FLJ37396 (C6orf183 / / / LOC100996634, marker 2067), chromosome 6 open reading frame 201 (C6orf201, marker 2068), chromosome 6 open reading frame 223 (C6orf223, marker 2069), chromosome 6 open reading frame 25 (C6orf25, marker 2070), chromosome 6 open reading frame 52 (C6orf52, marker 2071), chromosome 6 open reading frame 52 (C6orf52, marker 2072), chromosome 6 open reading frame 52 (C6orf52, marker 2073), chromosome 6 open reading frame 58 (C6orf58, marker 2074), chromosome 6 open reading frame 58 (C6orf58, marker 2075), chromosome 6 open reading frame 89 (C6orf89, marker 2076), chromosome 6 open reading frame 99 (C6orf99, marker 2077), complement component 7 (C7, marker 2078), complement component 7 (C7, marker 2079),chromosome 7 open reading frame 26 (C7orf26, marker 2080), chromosome 7 open reading frame 33 (C7orf33, marker 2081), chromosome 7 open reading frame 34 (C7orf34, marker 2082), chromosome 7 open reading frame 34 (C7orf34, marker 2083), chromosome 7 open reading frame 49 (C7orf49, marker 2084), chromosome 7 open reading frame 50 (C7orf50, marker 2085), chromosome 7 open reading frame 50 (C7orf50, marker 2086), chromosome 7 open reading frame 61 (C7orf61, marker 2087), chromosome 7 open reading frame 62 (C7orf62, marker 2088), chromosome 7 open reading frame 69 (C7orf69, marker 2089), chromosome 7 open Reading frame 71 (C7orf71, marker 2090), chromosome 7 open reading frame 73 / / / uncharacterized LOC105375521 / / / solute carrier family 13 (sodium / sulfate symporter), member 4 (C7orf73 / / / LOC105375521 / / / SLC13A4, marker 2091), chromosome 7 open reading frame 77 (C7orf77, marker 2092), complement component 8, alpha polypeptide (C8A, marker 2093), complement component 8, beta polypeptide (C8B, marker 2094), complement component 8, gamma polypeptide (C8G, marker 2095),chromosome 8 open reading frame 17 (C8orf17, marker 2096), chromosome 8 open reading frame 22 (C8orf22, marker 2097), chromosome 8 open reading frame 31 (C8orf31, marker 2098), chromosome 8 open reading frame 34 (C8orf34, marker 2099), chromosome 8 open reading frame 34 (C8orf34, marker 2100), C8orf34 antisense RNA 1 (C8orf34-AS1, marker 2101), chromosome 8 open reading frame 44 (C8orf44, marker 2102), chromosome 8 open reading frame 46 (C8orf46, marker 2103), chromosome 8 open reading frame 46 (C8orf46, marker 2104), chromosome 8 open reading frame 46 (C8orf46, marker 2105), chromosome 8 open reading frame 49 (C8orf49, marker 2106), chromosome 8 open reading frame 58 (C8orf58, marker 2107), chromosome 8 open reading frame 74 (C8orf74, marker 2108), chromosome 8 open reading frame 74 (C8orf74, marker 2109), complement component 9 (C9, marker 2110), chromosome 9 open reading frame 131 (C9orf131, marker 2111), C9orf135 antisense RNA 1 (head to head) (C9orf135-AS1, marker 2112), chromosome 9 open reading frame 152 (C9orf152, marker 2113), chromosome 9 open reading frame 16 (C9orf16, marker 2114),chromosome 9 open reading frame 163 (C9orf163, marker 2115), chromosome 9 open reading frame 172 (C9orf172, marker 2116), C9orf173 antisense RNA 1 (C9orf173-AS1, marker 2117), C9orf173 antisense RNA 1 / / / family with sequence similarity 166, member A (C9orf173-AS1 / / / FAM166A, marker 2118), chromosome 9 open reading frame 24 (C9orf24, marker 2119), chromosome 9 open reading frame 3 (C9orf3, marker 2120), chromosome 9 open reading frame 3 (C9orf3, marker 2121), chromosome 9 open reading frame 3 (C9orf3, marker 2122), C9orf41 antisense RNA 1 (C9orf41-AS1, marker 2123), chromosome 9 open reading frame 43 (C9orf43, marker 2124), chromosome 9 open reading frame 47 (C9orf47, marker 2125), chromosome 9 open reading frame 47 (C9orf47, marker 2126), chromosome 9 open reading frame 50 (C9orf50, marker 2127), chromosome 9 open reading frame 57 (C9orf57, marker 2128), chromosome 9 open reading frame 62 (C9orf62, marker 2129), chromosome 9 open reading frame 66 (C9orf66, marker 2130), chromosome 9 open reading frame 66 (C9orf66, marker 2131), chromosome 9 open reading frame 72 (C9orf72, marker 2132),chromosome 9 open reading frame 84 (C9orf84, marker 2133), chromosome 9 open reading frame 84 (C9orf84, marker 2134), chromosome 9 open reading frame 85 (C9orf85, marker 2135), chromosome 9 open reading frame 9 (C9orf9, marker 2136), chromosome 9 open reading frame 9 (C9orf9, marker 2137), carbonic anhydrase I (CA1, marker 2138), carbonic anhydrase I (CA1, marker 2139), carbonic anhydrase X (CA10, marker 2140), carbonic anhydrase X (CA10, marker 2141), carbonic anhydrase XII (CA12, marker 2142), carbonic anhydrase XII (CA12, marker 2143), carbonic anhydrase XII (CA12, marker 2144), carbonic anhydrase XII (CA12, marker 2145), carbonic anhydrase XIII (CA13, marker 2146), carbonic anhydrase III (CA3, marker 2147), carbonic anhydrase VA, mitochondrial (CA5A, marker 2148), carbonic anhydrase VB, mitochondrial (CA5B, marker 2149), carbonic anhydrase VI (CA6, marker 2150), carbonic anhydrase VI (CA6, marker 2151), carbonic anhydrase VII (CA7, marker 2152), carbonic anhydrase VIII (CA8, marker 2153), carbonic anhydrase VIII (CA8, marker 2154), carbonic anhydrase IX (CA9, marker 2155), calcium binding protein 39-like (CAB39L,Marker 2156), Cdk5 and Abl enzyme substrate 1 (CABLES1, marker 2157), calcium binding protein 1 (CABP1, marker 2158), calcium binding protein 1 (CABP1, marker 2159), calcium binding protein 1 (CABP1, marker 2160), calcium binding protein 2 (CABP2, marker 2161), calcium binding protein 4 (CABP4, marker 2162), calcium binding protein 4 (CABP4, marker 2163), calcium binding protein 4 (CABP4, marker 2164), calcium binding protein 5 (CABP5, marker 2165), calcium binding protein 7 (CABP7, marker 2166), calcium binding protein 7 (CABP7, marker 2167), calcium-binding protein, spermatid-specific 1 (CABS1, marker 2168), cache domain containing 1 (CACHD1, marker 2169), calcium channel, voltage-dependent, P / Q type, alpha 1A subunit (CACNA1A, marker 2170), calcium channel, voltage-dependent, P / Q type, alpha 1A subunit (CACNA1A, marker 2171), calcium channel, voltage-dependent, P / Q type, alpha 1A subunit (CACNA1A, marker 2172), calcium channel, voltage-dependent, P / Q type, alpha 1A subunit (CACNA1A, marker 2173), calcium channel, voltage-dependent, N type, alpha 1B subunit (CACNA1B, marker 2174),Calcium channel, voltage-dependent, N type, alpha 1B subunit (CACNA1B, marker 2175), calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C, marker 2176), calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C, marker 2177), calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C, marker 2178), calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C, marker 2179), calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D, marker 2180), calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D, marker 2181), calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D, marker 2182), calcium channel, voltage-dependent, L type, alpha 1D subunit (CACNA1D, marker 2183), calcium channel, voltage-dependent, R type, alpha 1E subunit (CACNA1E, marker 2184), calcium channel, voltage-dependent, R type, alpha 1E subunit (CACNA1E, marker 2185), calcium channel, voltage-dependent, R type, alpha 1E subunit (CACNA1E, marker 2186), calcium channel, voltage-dependent, R type,alpha 1E subunit (CACNA1E, marker 2187), calcium channel, voltage-dependent, R type; alpha 1E subunit (CACNA1E, marker 2188), calcium channel, voltage-dependent, R type; alpha 1E subunit (CACNA1E, marker 2189), calcium channel, voltage-dependent, L type; alpha 1F subunit (CACNA1F, marker 2190), calcium channel, voltage-dependent, T type; alpha 1G subunit (CACNA1G, marker 2191), calcium channel, voltage-dependent, T type; alpha 1G subunit (CACNA1G, marker 2192), calcium channel, voltage-dependent, T type; alpha 1G subunit (CACNA1G, marker 2193), calcium channel, voltage-dependent, T type; subunit (CACNA1G, marker 2194), calcium channel, voltage-dependent, T type, alpha 1G subunit (CACNA1G, marker 2195), CACNA1G antisense RNA 1 (CACNA1G-AS1, marker 2196), calcium channel, voltage-dependent, T type, alpha 1H subunit (CACNA1H, marker 2197), calcium channel, voltage-dependent, T type, alpha 1H subunit (CACNA1H, marker 2198), calcium channel, voltage-dependent, T type, alpha 1I subunit (CACNA1I, marker 2199), calcium channel, voltage-dependent, T type,alpha 1I subunit (CACNA1I, marker 2200), calcium channel, voltage-dependent, T type; alpha 1I subunit (CACNA1I, marker 2201), calcium channel, voltage-dependent, L type; alpha 1S subunit (CACNA1S, marker 2202), calcium channel, voltage-dependent, alpha 2 / delta subunit 1 (CACNA2D1, marker 2203), calcium channel, voltage-dependent, alpha 2 / delta subunit 4 (CACNA2D4, marker 2204), calcium channel, voltage-dependent, alpha 2 / delta subunit 4 (CACNA2D4, marker 2205), calcium channel, voltage-dependent, beta 1 subunit (CACNB1, marker 2206), calcium channel, voltage-dependent, beta 1 subunit (CACNB1, marker 2207), calcium channel, Voltage-dependent, beta 1 subunit (CACNB1, marker 2208), calcium channel, voltage-dependent, beta 2 subunit (CACNB2, marker 2209), calcium channel, voltage-dependent, beta 2 subunit (CACNB2, marker 2210), calcium channel, voltage-dependent, beta 2 subunit (CACNB2, marker 2211), calcium channel, voltage-dependent, beta 2 subunit (CACNB2, marker 2212), calcium channel, voltage-dependent, beta 4 subunit (CACNB4, marker 2213), calcium channel,voltage-dependent, beta 4 subunit (CACNB4, marker 2214), calcium channel, voltage-dependent, gamma subunit 1 (CACNG1, marker 2215), calcium channel, voltage-dependent, gamma subunit 2 (CACNG2, marker 2216), calcium channel, voltage-dependent, gamma subunit 2 (CACNG2, marker 2217), calcium channel, voltage-dependent, gamma subunit 3 (CACNG3, marker 2218), calcium channel, voltage-dependent, gamma subunit 4 (CACNG4, marker 2219), calcium channel, voltage-dependent, gamma subunit 4 (CACNG4, marker 2220), calcium channel, voltage-dependent, gamma subunit 5 (CACNG5, marker 2221), calcium channel, voltage-dependent, gamma subunit 5 (CACNG5, marker 2222), calcium channel, voltage-dependent, gamma subunit 6 (CACNG6, marker 2223), calcium cha, Nerve, voltage-dependent, gamma subunit 7 (CACNG7, marker 2224), calcium channel, voltage-dependent, gamma subunit 8 (CACNG8, marker 2225), calcium channel, voltage-dependent, gamma subunit 8 (CACNG8, marker 2226), calcium channel, voltage-dependent, gamma subunit 8 (CACNG8, marker 2227), cactin, spliceosome C complex subunit (CACTIN, marker 2228), cactin, spliceosome C complex subunit (CACTIN, marker 2229), CDK2-associated, cullin domain 1 (CACUL1, marker 2230), CDK2-associated, cullin domain 1 (CACUL1, marker 2231), CDK2-associated, cullin domain 1 (CACUL1, marker 2232), calcyclin binding protein (CACYBP, marker 2233), carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD, marker 2234), cell adhesion molecule 1 (CADM1, marker 2235), cell adhesion molecule 1 (CADM1, marker 2236), cell adhesion molecule 2 (CADM2, marker 2237), cell adhesion molecule 2 (CADM2, marker 2238), cell adhesion molecule 2 (CADM2, marker 2239), cell adhesion molecule 2 (CADM2, marker 2240), CADM2 antisense RNA 1 (CADM2-AS1, marker 2241), cell adhesion molecule 3 (CADM3, marker 2242),Cell adhesion molecule 3 (CADM3, marker 2243), cell adhesion molecule 3 (CADM3, marker 2244), CADM3 antisense RNA 1 (CADM3-AS1, marker 2245), cell adhesion molecule 4 (CADM4, marker 2246), cell adhesion molecule 4 (CADM4, marker 2247), Ca++-dependent secretion activator (CADPS, marker 2248), Ca++-dependent secretion activator (CADPS, marker 2249), Ca++-dependent secretion activator (CADPS, marker 2250), cancer antigen 1 (CAGE1, marker 2251), colon adenocarcinoma hypermethylated (non-protein coding) (CAHM, marker 2252), calcitonin-related polypeptide alpha (CALCA, marker 2253), calcitonin-related polypeptide alpha (CALCA, marker 2254), calcitonin-related polypeptide alpha (CALCA, marker 2255), calcium binding and coiled-coil domain 2 (CALCOCO2, marker 2256), calcium binding and coiled-coil domain 2 (CALCOCO2, marker 2257), calcium binding and coiled-coil domain 2 (CALCOCO2, marker 2258), calcitonin receptor (CALCR, marker 2259), calcitonin receptor (CALCR, marker 2260), calcitonin receptor-like receptor (CALCRL, marker 2261), calcitonin receptor-like receptor (CALCRL, marker 2262),calcitonin receptor-like receptor (CALCRL, marker 2263), caldesmon 1 (CALD1, marker 2264), calcium homeostasis modulator 1 (CALHM1, marker 2265), calcium homeostasis modulator 3 (CALHM3, marker 2266), calmodulin 1 (phosphorylase kinase, delta) / / / calmodulin 2 (phosphorylase kinase, delta) (CALM1 / / / CALM2, marker 2267), calmodulin-like 3 (CALML3, marker 2268), calmodulin-like 3 (CALML3, marker 2269), calmodulin-like 4 (CALML4, marker 2270), calmodulin-like 4 (CALML4, marker 2271), calmodulin-like 5 (CALML5, marker 2272), calmodulin-like 6 (CALML6, marker 2273), calneuron 1 (CALN1, marker 2274), calneuron 1 (CALN1, marker 2275), calreticulin 3 (CALR3, marker 2276), calcyon neuron-specific vesicular protein (CALY, marker 2277), calcyon neuron-specific vesicular protein (CALY, marker 2278), calcium / calmodulin-dependent protein kinase I (CAMK1, marker 2279), calcium / calmodulin-dependent protein kinase ID (CAMK1D, marker 2280), calcium / calmodulin-dependent protein kinase IG (CAMK1G, marker 2281), calcium / calmodulin-dependent protein kinase IG (CAMK1G, marker 2282),Calcium / calmodulin-dependent protein kinase II alpha (CAMK2A, marker 2283), calcium / calmodulin-dependent protein kinase II alpha (CAMK2A, marker 2284), calcium / calmodulin-dependent protein kinase II beta (CAMK2B, marker 2285), calcium / calmodulin-dependent protein kinase II beta (CAMK2B, marker 2286), calcium / calmodulin-dependent protein kinase II beta (CAMK2B, marker 2287), calcium / calmodulin-dependent protein kinase II beta (CAMK2B, marker 2288), calcium / calmodulin-dependent protein kinase II delta (CAMK2D, marker 2289), calcium / calmodulin-dependent protein kinase II gamma (CAMK2G, marker 2290), calcium / calmodulin-dependent protein kinase II gamma (CAMK2G, marker 2291), calcium / calmodulin-dependent protein kinase II inhibitor 2 (CAMK2N2, marker 2292), calcium / calmodulin-dependent protein kinase IV (CAMK4, marker 2293), calcium / calmodulin-dependent protein kinase kinase 1, alpha (CAMKK1, marker 2294), calcium / calmodulin-dependent protein kinase kinase 2, beta (CAMKK2, marker 2295), calmodulin-lysine N-methyltransferase (CAMKMT, marker 2296),Cathelicidin antimicrobial peptide (CAMP, marker 2297), calmodulin-regulated spectrin-associated protein 1 (CAMSAP1, marker 2298), calmodulin-regulated spectrin-associated protein 1 (CAMSAP1, marker 2299), calmodulin-regulated spectrin-associated protein 1 (CAMSAP1, marker 2300), calmodulin binding transcription activator 1 (CAMTA1, marker 2301), cullin-associated and neddylation-dissociated 1 (CAND1, marker 2302), uncharacterized LOC100130460 (CAND1.11, marker 2303), cullin-associated and neddylation-dissociated 2 (putative) (CAND2, marker 2304), calnexin (CANX, marker 2305), calpain 10 (CAPN10, marker 2306), CAPN10 antisense RNA 1 (head to head)(CAPN10-AS1, marker 2307), calpain 11(CAPN11, marker 2308), calpain 13(CAPN13, marker 2309), calpain 13(CAPN13, marker 2310), calpain 14(CAPN14, marker 2311), calpain 15(CAPN15, marker 2312), calpain 2, (m / II) large subunit(CAPN2, marker 2313), calpain 3(CAPN3, marker 2314), calpain 3(CAPN3, marker 2315), calpain 3(CAPN3, marker 2316), calpain 6(CAPN6, marker 2317), calpain 8(CAPN8, marker 2318), calpain 9(CAPN9, marker 2319), calpain 9(CAPN9, marker 2320), calpain,small subunit 2 (CAPNS2, marker 2321), cell cycle associated protein 1 (CAPRIN1, marker 2322), caprin family member 2 (CAPRIN2, marker 2323), calcyphosine (CAPS, marker 2324), calcyphosine (CAPS, marker 2325), calcyphosine (CAPS, marker 2326), calcyphosine 2 (CAPS2, marker 2327), calcyphosine 2 (CAPS2, marker 2328), calcyphosine-like (CAPSL, marker 2329), capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1, marker 2330), capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2, marker 2331), capping protein (actin filament) muscle Z-line, alpha 3 (CAPZA3, marker 2332), capping protein (actin filament) muscle Z-line, beta (CAPZB, marker 2333), caspase recruitment domain family, member 10 (CARD10, marker 2334), caspase recruitment domain family, member 10 (CARD10, marker 2335), caspase recruitment domain family, member 11 (CARD11, marker 2336), caspase recruitment domain family, member 14 (CARD14, marker 2337), caspase recruitment domain family, member 14 (CARD14, marker 2338), caspase recruitment domain family, member 14 (CARD14, marker 2339), caspase recruitment domain family,Member 14 (CARD14, marker 2340), caspase recruitment domain family, member 14 (CARD14, marker 2341), caspase recruitment domain family, member 14 (CARD14, marker 2342), caspase recruitment domain family, member 16 (CARD16, marker 2343), caspase recruitment domain family, member 16 (CARD16, marker 2344), caspase recruitment domain family, member 16 / / / caspase 1 (CARD16 / / / CASP1, marker 2345), caspase recruitment domain family, member 18 (CARD18, marker 2346), caspase recruitment domain family, member 19 (CARD19, marker 2347), caspase recruitment domain family, member 6 (CARD6, marker 2348), caspase recruitment domain family, member 8 (CARD8, marker 2349), CARD8 antisense RNA 1 (CARD8-AS1, marker 2350), CARD8 antisense RNA 1 (CARD8-AS1, marker 2351), caspase recruitment domain family, member 9 (CARD9, marker 2352), calcium responsive transcription factor (CARF, marker 2353), calcium responsive transcription factor (CARF, marker 2354), calcium regulated heat stable protein 1 (CARHSP1, marker 2355), calcium regulated heat stable protein 1 (CARHSP1, marker 2356),cardiac mesoderm enhancer-associated non-coding RNA (CARMN, marker 2357), cardiac mesoderm enhancer-associated non-coding RNA (CARMN, marker 2358), carnosine synthase 1 (CARNS1, marker 2359), cysteinyl-tRNA synthetase (CARS, marker 2360), CARS antisense RNA 1 (CARS-AS1, marker 2361), cysteinyl-tRNA synthetase 2, mitochondrial (putative) (CARS2, marker 2362), cysteinyl-tRNA synthetase 2, mitochondrial (putative) (CARS2, marker 2363), CART prepropeptide (CARTPT, marker 2364), cancer susceptibility candidate 1 (CASC1, marker 2365), cancer susceptibility candidate 11 (non-protein coding) (CASC11, marker 2366), cancer susceptibility candidate 15 (non-protein coding)(CASC15, marker 2367),cancer susceptibility candidate 15 (non-protein coding)(CASC15, marker 2368),cancer susceptibility candidate 15 (non-protein coding)(CASC15, marker 2369),cancer susceptibility candidate 16 (non-protein coding)(CASC16, marker 2370),cancer susceptibility candidate 17 (non-protein coding)(CASC17, marker 2371), cancer susceptibility candidate 18 (non-protein coding)(CASC18, marker 2372),cancer susceptibility candidate 2 (non-protein coding)(CASC2, marker 2373),cancer susceptibility candidate 2 (non-protein coding)(CASC2, marker 2374),cancer susceptibility candidate 2 (non-protein coding)(CASC2, marker 2375),cancer susceptibility candidate 2 (non-protein coding)(CASC2, marker 2376),cancer susceptibility candidate 2 (non-protein coding)(CASC2, marker 2377), cancer susceptibility candidate 22 (non-protein coding)(CASC22, marker 2378), cancer susceptibility candidate 23 (non-protein coding)(CASC23, marker 2379), cancer susceptibility candidate 4(CASC4, marker 2380), cancer susceptibility candidate 4 (CASC4, marker 2381), cancer susceptibility candidate 5 (CASC5, marker 2382), cancer susceptibility candidate 6 (non-protein coding) (CASC6, marker 2383), CAS1 domain containing 1 (CASD1, marker 2384), CAS1 domain containing 1 (CASD1, marker 2385), calcium / calmodulin-dependent serine protein kinase (MAGUK family) (CASK, marker 2386), CASK interacting protein 1 (CASKIN1, marker 2387), CASK interacting protein 1 (CASKIN1, marker 2388),CASK interacting protein 1 (CASKIN1, marker 2389), caspase 1 (CASP1, marker 2390), caspase 1 (CASP1, marker 2391), caspase 1 (CASP1, marker 2392), caspase 1 (CASP1, marker 2393), caspase 1 (CASP1, marker 2394), caspase 10 (CASP10, marker 2395), caspase 10 (CASP10, marker 2396), caspase 10 (CASP10, marker 2397), caspase 10 (CASP10, marker 2398), caspase 12 (gene / pseudogene) (CASP12, marker 2399), caspase 14 (CASP14, marker 2400), caspase 16, pseudogene (CASP16P, marker 2401), caspase 4 (CASP4, marker 2402), caspase 4 (CASP4, marker 2403), caspase 5 (CASP5, marker 2404), caspase 8, apoptosis-related cysteine ​​peptidase (CASP8, marker 2405), caspase 9 (CASP9, marker 2406), calsequestrin 1 (fast-twitch, skeletal muscle) (CASQ1, marker 2407), calsequestrin 2 (cardiac muscle) (, CASQ2, marker 2408), calcium-sensing receptor (CASR, marker 2409), calcium-sensing receptor (CASR, marker 2410), calcium-sensing receptor (CASR, marker 2411), calcium-sensing receptor (CASR, marker 2412), calcium-sensing receptor (CASR, marker 2413), Cas scaffolding protein family member 4 (CASS4, marker 2414), Cas scaffolding protein family member 4 (CASS4, marker 2415), calpastatin (CAST, marker 2416), calpastatin (CAST, marker 2417), castor zinc finger 1 (CASZ1, marker 2418), castor zinc finger 1 (CASZ1, marker 2419), castor zinc finger 1 (CASZ1, marker 2420), castor zinc finger 1 (CASZ1, marker 2421), catalase (CAT, marker 2422), CATIP antisense RNA 1 (CATIP-AS1, marker 2423), cation channel, sperm associated 2 (CATSPER2, marker 2424), cation channel, sperm associated 2 (CATSPER2, marker 2425), cation channel, sperm associated 2 / / / cation channel, sperm associated 2 pseudogene 1 (CATSPER2 / / / CATSPER2P1, marker 2426), cation channel, sperm associated 3 (CATSPER3, marker 2427), catsper channel auxiliary subunit beta (CATSPERB, marker 2428), catsper channel auxiliary subunit beta (CATSPERB, marker 2429),Catsper channel auxiliary subunit delta (CATSPERD, marker 2430), catsper channel auxiliary subunit gamma (CATSPERG, marker 2431), catsper channel auxiliary subunit gamma (CATSPERG, marker 2432), catsper channel auxiliary subunit gamma (CATSPERG, marker 2433), uncharacterized LOC100506513 (CATX-1, marker 2434), uncharacterized LOC100506513 (CATX-1, marker 2435), caveolin 2 (CAV2, marker 2436), caveolin 3 (CAV3, marker 2437), calcium channel, voltage-dependent, beta subunit associated regulatory protein (CBARP, marker 2438), calcium channel, voltage-dependent, beta subunit associated regulatory protein (CBARP, marker 2439), calcium channel, voltage-dependent, beta subunit associated regulatory protein protein (CBARP, marker 2440), core-binding factor, runt domain, alpha subunit 2; translocated to, 2 (CBFA2T2, marker 2441), core-binding factor, runt domain, alpha subunit 2; translocated to, 2 (CBFA2T2, marker 2442), core-binding factor, runt domain, alpha subunit 2; translocated to, 3 (CBFA2T3, marker 2443), Cbl proto-oncogene B, E3 ubiquitin protein ligase (CBLB, marker 2444),Cbl proto-oncogene C, E3 ubiquitin protein ligase (CBLC, marker 2445), Cbl proto-oncogene C, E3 ubiquitin protein ligase (CBLC, marker 2446), cerebellin 1 precursor (CBLN1, marker 2447), cerebellin 2 precursor (CBLN2, marker 2448), cerebellin 3 precursor (CBLN3, marker 2449), cerebellin 4 precursor (CBLN4, marker 2450), cerebellin 4 precursor (CBLN4, marker 2451), CBR3 antisense RNA 1 (CBR3-AS1, marker 2452), chromobox homolog 2 (CBX2, marker 2453), chromobox homolog 2 (CBX2, marker 2454), chromobox homolog 3 pseudogene 2 (CBX3P2, marker 2455), chromobox homolog 4 (CBX4, marker 2456), chromobox homolog 5 (CBX5, marker 2457), chromobox homolog 8 (CBX8, marker 2458), chibby homolog 1 (Drosophila) (CBY1, marker 2459), chibby homolog 3 (Drosophila) (CBY3, marker 2460), coiled-coil and C2 domain containing 1A (CC2D1A, marker 2461), coiled-coil and C2 domain containing 1A (CC2D1A, marker 2462), coiled-coil and C2 domain containing 1B (CC2D1B, marker 2463), coiled-coil and C2 domain containing 2A (CC2D2A, marker 2464), coiled-coil and C2 domain containing 2A (CC2D2A, marker 2465),coiled-coil and C2 domain containing 2B (CC2D2B, marker 2466), coiled-coil and C2 domain containing 2B / / / ENTPD1 antisense RNA 1 / / / uncharacterized LOC105378440 (CC2D2B / / / ENTPD1-AS1 / / / LOC105378440, marker 2467), cell cycle and apoptosis regulator 2 (CCAR2, marker 2468), collagen and calcium binding EGF domains 1 (CCBE1, marker 2469), collagen and calcium binding EGF domains 1 (CCBE1, marker 2470), collagen and calcium binding EGF domains 1 (CCBE1, marker 2471), cysteine ​​conjugate-beta lyase, cytoplasmic (CCBL1, marker 2472), coiled-coil domain containing 102B (CCDC102B, marker 2473), coiled-coil domain containing 103 / / / family with sequence similarity 187, member A (CCDC103 / / / FAM187A, marker 2474), coiled-coil domain containing 105 (CCDC105, marker 2475), coiled-coil domain containing 110 (CCDC110, marker 2476), coiled-coil domain containing 114 (CCDC114, marker 2477), coiled-coil domain containing 116 (CCDC116, marker 2478), coiled-coil domain containing 120 (CCDC120, marker 2479), coiled-coil domain containing 120 (CCDC120, marker 2480),coiled-coil domain containing 121 (CCDC121, marker 2481), coiled-coil domain containing 122 (CCDC122, marker 2482), coiled-coil domain containing 122 (CCDC122, marker 2483), coiled-coil domain containing 125 (CCDC125, marker 2484), coiled-coil domain containing 129 (CCDC129, marker 2485), coiled-coil domain containing 129 (CCDC129, marker 2486), coiled-coil domain containing 13 (CCDC13, marker 2487), coiled-coil domain containing 13 (CCDC13, marker 2488), CCDC13 antisense RNA 1 (CCDC13-AS1, marker 2489), coiled-coil domain containing 136 (CCDC136, marker 2490), coiled-coil domain containing 136 (CCDC136, marker 2491), coiled-coil domain containing 14 (CCDC14, marker 2492), coiled-coil domain containing 14 (CCDC14, marker 2493), coiled-coil domain containing 140 (CCDC140, marker 2494), coiled-coil domain containing 141 (CCDC141, marker 2495), coiled-coil domain containing 142 (CCDC142, marker 2496), coiled-coil domain containing 144A (CCDC144A, marker 2497), coiled-coil domain containing 144B (pseudogene) (CCDC144B, marker 2498), coiled-coil domain containing 144B (pseudogene)(CCDC144B,marker 2499), coiled-coil domain containing 144C, pseudogene (CCDC144CP, marker 2500), CCDC144NL antisense RNA 1 / / / uncharacterized LOC105369205 / / / uncharacterized LOC339260 (CCDC144NL-AS1 / / / LOC105369205 / / / LOC339260, marker 2501), coiled-coil domain containing 146 (CCDC146, marker 2502), coiled-coil domain containing 148 (CCDC148, marker 2503), coiled-coil domain containing 148 (CCDC148, marker 2504), CCDC148 antisense RNA 1 (CCDC148-AS1, marker 2505), coiled-coil domain containing 149 (CCDC149, marker 2506), coiled-coil domain containing 149 (CCDC149, marker 2507), coiled-coil domain containing 149 (CCDC149, marker 2508), coiled-coil domain containing 150 (CCDC150, marker 2509), coiled-coil domain containing 153 (CCDC153, marker 2510), coiled-coil domain containing 154 (CCDC154, marker 2511), coiled-coil domain containing 155 (CCDC155, marker 2512), coiled-coil domain containing 157 (CCDC157, marker 2513), coiled-coil domain containing 157 (CCDC157, marker 2514), coiled-coil domain containing 158 (CCDC158, marker 2515), coiled-coil domain containing 158 (CCDC158, marker 2516),Coiled-coil domain containing 159 (CCDC159, marker 2517), coiled-coil domain containing 163, pseudogene (CCDC163P, marker 2518), coiled-coil domain containing 168 (CCDC168, marker 2519), coiled-coil domain containing 168 (CCDC168, marker 2520), coiled-coil domain containing 168 (CCDC168, marker 2521), coiled-coil domain containing 169 (CCDC169, marker 2522), coiled-coil domain containing 17 (CCDC17, marker 2523), coiled-coil domain containing 170 (CCDC170, marker 2524), coiled-coil domain containing 171 (CCDC171, marker 2525), coiled-coil domain containing 171 (CCDC171, marker 2526), ​​coiled-coil domain containing 171 (CCDC171, marker 2527), coiled-coil domain containing 171 (CCDC171, marker 2528), coiled-coil domain containing 171 (CCDC171, marker 2529), coiled-coil domain containing 171 (CCDC171, marker 2530), coiled-coil domain containing 171 (CCDC171, marker 2531), coiled-coil domain containing 173 (CCDC173, marker 2532), coiled-coil domain containing 178 (CCDC178, marker 2533), coiled-coil domain containing 18 (CCDC18, marker 2534),coiled-coil domain containing 180 / / / LOC100499484-C9orf174 readthrough (CCDC180 / / / LOC100499484-C9orf174, marker 2535), coiled-coil domain containing 180 / / / LOC100499484-C9orf174 readthrough (CCDC180 / / / LOC100499484-C9orf174, marker 2536), coiled-coil domain containing 181 (CCDC181, marker 2537), coiled-coil domain containing 181 (CCDC181, marker 2538), coiled-coil domain containing 182 (CCDC182, marker 2539), coiled-coil domain containing 184 (CCDC184, marker 2540), coiled-coil domain containing 185 (CCDC185, marker 2541), coiled-coil domain containing 187 (CCDC187, marker 2542), coiled-coil domain containing 187 (CCDC187, marker 2543), coiled-coil domain containing 189 (CCDC189, marker 2544), coiled-coil domain containing 190 (CCDC190, marker 2545), coiled-coil domain containing 24 (CCDC24, marker 2546), CCDC26 long non-coding RNA (CCDC26, marker 2547), coiled-coil domain containing 27 (CCDC27, marker 2548), coiled-coil domain containing 28B (CCDC28B, marker 2549), coiled-coil domain containing 30 (CCDC30, marker 2550), coiled-coil domain containing 30 (CCDC30, marker 2551),coiled-coil domain containing 30 / / / phosphopantothenoylcysteine ​​synthetase (CCDC30 / / / PPCS, marker 2552), coiled-coil domain containing 33 (CCDC33, marker 2553), coiled-coil domain containing 34 (CCDC34, marker 2554), coiled-coil domain containing 36 (CCDC36, marker 2555), coiled-coil domain containing 36 (CCDC36, marker 2556), coiled-coil domain containing 36 (CCDC36, marker 2557), CCDC37 antisense RNA 1 (head to head) (CCDC37-AS1, marker 2558), CCDC37 antisense RNA 1 (head to head) (CCDC37-AS1, marker 2559), CCDC37 antisense RNA 1 (head to head) (CCDC37-AS1, marker 2560), coiled-coil domain containing 38 (CCDC38, marker 2561), coiled-coil domain containing 39 / / / uncharacterized LOC101928882 (CCDC39 / / / LOC101928882, marker 2562), coiled-coil domain containing 40 (CCDC40, marker 2563), coiled-coil domain containing 40 (CCDC40, marker 2564), coiled-coil domain containing 40 (CCDC40, marker 2565), coiled-coil domain containing 40 (CCDC40, marker 2566), coiled-coil domain containing 40 (CCDC40, marker 2567), coiled-coil domain containing 42 (CCDC42, marker 2568),coiled-coil domain containing 54 (CCDC54, marker 2569), coiled-coil domain containing 57 (CCDC57, marker 2570), coiled-coil domain containing 57 (CCDC57, marker 2571), coiled-coil domain containing 57 (CCDC57, marker 2572), coiled-coil domain containing 57 (CCDC57, marker 2573), coiled-coil domain containing 57 (CCDC57, marker 2574), coiled-coil domain containing 60 (CCDC60, marker 2575), coiled-coil domain containing 61 (CCDC61, marker 2576), coiled-coil domain containing 61 (CCDC61, marker 2577), coiled-coil domain containing 62 (CCDC62, marker 2578), coiled-coil domain containing 63 (CCDC63, marker 2579), coiled-coil domain containing 64 (CCDC64, marker 2580), coiled-coil domain containing 65 (CCDC65, marker 2581), coiled-coil domain containing 65 (CCDC65, marker 2582), coil, ed-coil domain containing 65 (CCDC65, marker 2583), coiled-coil domain containing 66 (CCDC66, marker 2584), coiled-coil domain containing 67 (CCDC67, marker 2585), coiled-coil domain containing 67 (CCDC67, marker 2586), coiled-coil domain containing 67 (CCDC67, marker 2587), coiled-coil domain containing 67 (CCDC67, marker 2588), coiled-coil domain containing 69 (CCDC69, marker 2589), coiled-coil domain containing 7 (CCDC7, marker 2590), coiled-coil domain containing 7 (CCDC7, marker 2591), coiled-coil domain containing 7 (CCDC7, marker 2592), coiled-coil domain containing 70 (CCDC70, marker 2593), coiled-coil domain containing 71 (CCDC71, marker 2594), coiled-coil domain containing 71-like (CCDC71L, marker 2595), coiled-coil domain containing 71-like (CCDC71L, marker 2596), coiled-coil domain containing 74B (CCDC74B, marker 2597), coiled-coil domain containing 78 (CCDC78, marker 2598), coiled-coil domain containing 79 (CCDC79, marker 2599), coiled-coil domain containing 80 (CCDC80, marker 2600),coiled-coil domain containing 80 / / / long intergenic non-protein coding RNA 1279 (CCDC80 / / / LINC01279, marker 2601), coiled-coil domain containing 82 (CCDC82, marker 2602), coiled-coil domain containing 82 (CCDC82, marker 2603), coiled-coil domain containing 83 (CCDC83, marker 2604), coiled-coil domain containing 85A (CCDC85A, marker 2605), coiled-coil domain containing 85A (CCDC85A, marker 2606), coiled-coil domain containing 85A (CCDC85A, marker 2607), coiled-coil domain containing 85B (CCDC85B, marker 2608), coiled-coil domain containing 85B (CCDC85B, marker 2609), coiled-coil domain containing 87 (CCDC87, marker 2610), coiled-coil domain containing 88A (CCDC88A, marker 2611), coiled-coil domain containing 88B (CCDC88B, marker 2612), coiled-coil domain containing 88C / / / uncharacterized LOC105370624 (CCDC88C / / / LOC105370624, marker 2613), coiled-coil domain containing 89 (CCDC89, marker 2614), coiled-coil domain containing 90B (CCDC90B, marker 2615), coiled-coil domain containing 91 (CCDC91, marker 2616), coiled-coil domain containing 96 (CCDC96, marker 2617),Coiled-coil domain containing 97 (CCDC97, marker 2618), cervical carcinoma expressed PCNA regulatory lncRNA (CCEPR, marker 2619), coiled-coil glutamate-rich protein 1 (CCER1, marker 2620), calicin (CCIN, marker 2621), cholecystokinin A receptor (CCKAR, marker 2622), cholecystokinin A receptor (CCKAR, marker 2623), cholecystokinin B receptor (CCKBR, marker 2624), chemokine (CC motif) ligand 1 (CCL1, marker 2625), chemokine (CC motif) ligand 11 (CCL11, marker 2626), chemokine (CC motif) ligand 13 (CCL13, marker 2627), chemokine (CC motif) ligand 13 (CCL13, marker 2628), chemokine (CC motif) ligand 14 / / / CCL15-CCL14 readthrough (NMD candidate) (CCL14 / / / CCL15-CCL14, marker 2629), chemokine (CC motif) ligand 15 / / / CCL15-CCL14 readthrough (NMD candidate) (CCL15 / / / CCL15-CCL14, marker 2630), chemokine (CC motif) ligand 16 (CCL16, marker 2631), chemokine (CC motif) ligand 17 (CCL17, marker 2632), chemokine (CC motif) ligand 18 (CCL18, marker 2633), chemokine (CC motif) ligand 18 (CCL18, marker 2634), chemokine (CC motif) ligand 19 (CCL19, marker 2635),chemokine (CC motif) ligand 20 (CCL20, marker 2636), chemokine (CC motif) ligand 21 (CCL21, marker 2637), chemokine (CC motif) ligand 22 (CCL22, marker 2638), chemokine (CC motif) ligand 23 (CCL23, marker 2639), chemokine (CC motif) ligand 23 (CCL23, marker 2640), chemokine (CC motif) ligand 24 (CCL24, marker 2641), chemokine (CC motif) ligand 25 (CCL25, marker 2642), chemokine (CC motif) ligand 27 (CCL27, marker 2643), chemokine (CC motif) ligand 28 (CCL28, marker 2644), chemokine (CC motif) ligand 28 (CCL28, marker 2645), chemokine (CC motif) ligand 28 (CCL28, marker 2646), chemokine (CC motif) ligand 3 / / / chemokine (CC motif) ligand 3-like 1 / / / chemokine (CC motif) ligand 3-like 3 (CCL3 / / / CCL3L1 / / / CCL3L3, marker 2647), chemokine (CC motif) ligand 4 (CCL4, marker 2648), chemokine (CC motif) ligand 5 (CCL5, marker 2649), chemokine (CC motif) ligand 5 (CCL5, marker 2650), chemokine (CC motif) ligand 5 (CCL5, marker 2651), chemokine (CC motif) ligand 7 (CCL7, marker 2652), chemokine (CC motif) ligand 8 (CCL8, marker 2653), cyclin B2 (CCNB2, marker 2654), cyclin B2 (CCNB2,marker 2655), cyclin B3 (CCNB3, marker 2656), cyclin C (CCNC, marker 2657), cyclin D3 (CCND3, marker 2658), cyclin E1 (CCNE1, marker 2659), cyclin G2 (CCNG2, marker 2660), cyclin J (CCNJ, marker 2661), cyclin L1 (CCNL1, marker 2662), cyclin L1 (CCNL1, marker 2663), cyclin O (CCNO, marker 2664), CCNT2 antisense RNA 1 (CCNT2-AS1, marker 2665), cyclin Y (CCNY, marker 2666), cyclin Y-like 2, pseudogene (CCNYL2, marker 2667), centriolar coiled coil protein 110 kDa (CCP110, marker 2668), chemokine (CC motif) receptor 1 (CCR1, marker 2669), chemokine (CC motif) receptor 10 (CCR10, marker 2670), chemokine (CC motif) receptor 2 (CCR2, marker 2671), chemokine (CC motif) receptor 2 (CCR2, marker 2672), chemokine (CC motif) receptor 3 (CCR3, marker 2673), chemokine (CC motif) receptor 4 (CCR4, marker 2674), chemokine (CC motif) receptor 5 (gene / pseudogene) (CCR5, marker 2675), chemokine (CC motif) receptor 6 (CCR6, marker 2676), chemokine (CC motif) receptor 7 (CCR7, marker 2677), chemokine (CC motif) receptor 7 (CCR7, marker 2678), chemokine (CC motif) receptor 8 (CCR8, marker 2679), chemokine (CC motif) receptor 9 (CCR9, marker 2680),chemokine (CC motif) receptor-like 2 (CCRL2, marker 2681), centriole, cilia, and spindle-associated protein (CCSAP, marker 2682), centriole, cilia, and spindle-associated protein (CCSAP, marker 2683), centriole, cilia, and spindle-associated protein (CCSAP, marker 2684), coiled-coil serine-rich protein 1 (CCSER1, marker 2685), coiled-coil serine-rich protein 1 (CCSER1, marker 2686), coiled-coil serine-rich protein 2 (CCSER2, marker 2687), chaperonin containing TCP1, subunit 8 (theta) (CCT8, marker 2688), chaperonin containing TCP1, subunit 8 (theta)-like 2 (CCT8L2, marker 2689), CCZ1 homolog, vacuolar protein trafficking and biogenesis associated (CCZ1, marker 2690), CD101 molecule (CD101, marker 2691), CD101 molecule (CD101, marker 2692), CD109 molecule (CD109, marker 2693), CD14 molecule (CD14, marker 2694), CD160 molecule (CD160, marker 2695), CD163 molecule (CD163, marker 2696), CD163 molecule (CD163, marker 2697), CD163 molecule (CD163, marker 2698), CD163 molecule-like 1 (CD163L1, marker 2699), CD177 molecule (CD177, marker 2700), CD180 molecule (CD180, marker 2701), CD19 molecule (CD19, marker 2702),CD1a molecule (CD1A, marker 2703), CD1b molecule (CD1B, marker 2704), CD1c molecule (CD1C, marker 2705), CD1d molecule (CD1D, marker 2706), CD1e molecule (CD1E, marker 2707), CD1e molecule (CD1E, marker 2708), CD2 molecule (CD2, marker 2709), CD200 receptor 1 (CD200R1, marker 2710), CD200 receptor 1 (CD200R1, marker 2711), CD207 molecule, langerin (CD207, marker 2712), CD209 molecule (CD209, marker 2713), CD209 molecule (CD209, marker 2714), CD209 molecule (CD209, marker 2715), CD22 molecule (CD22, marker 2716), CD22 CD22 molecule (CD22, marker 2717), CD22 molecule (CD22, marker 2718), CD226 molecule (CD226, marker 2719), CD244 molecule, natural killer cell receptor 2B4 (CD244, marker 2720), CD244 molecule, natural killer cell receptor 2B4 (CD244, marker 2721), CD247 molecule (CD247, marker 2722), CD27 molecule (CD27, marker 2723), CD274 molecule (CD274, marker 2724), CD274 molecule (CD274, marker 2725), CD276 molecule (CD276, marker 2726), CD28 molecule (CD28, marker 2727), CD28 molecule (CD28, marker 2728), CD28 molecule (CD28, marker 2729), CD300a molecule (CD300A, marker 2730), CD300a molecule (CD300A, marker 2731), CD300a molecule (CD300A, marker 2732),CD300c molecule (CD300C, marker 2733), CD300 molecule-like family member b (CD300LB, marker 2734), CD300 molecule-like family member b (CD300LB, marker 2735), CD300 molecule-like family member f (CD300LF, marker 2736), CD300 molecule-like family member g (CD300LG, marker 2737), CD300 molecule-like family member g (CD300LG, marker 2738), CD300 molecule-like family member g (CD300LG, marker 2739), CD300 molecule-like family member g (CD300LG, marker 2740), CD33 molecule (CD33, marker 2741), CD34 molecule (CD34, marker 2742), CD36 molecule (thrombospondin receptor) (CD36, marker 2743), CD36 molecule (thrombospondin receptor) receptor) (CD36, marker 2744), CD36 molecule (thrombospondin receptor) (CD36, marker 2745), CD36 molecule (thrombospondin receptor) (CD36, marker 2746), CD36 molecule (thrombospondin receptor) (CD36, marker 2747), CD37 molecule (CD37, marker 2748), CD37 molecule (CD37, marker 2749), CD38 molecule (CD38, marker 2750), CD3d molecule, delta (CD3-TCR complex) (CD3D, marker 2751), CD3e molecule, epsilon (CD3-TCR complex) (CD3E, marker 2752), CD3g molecule, gamma (CD3-TCR complex) (CD3G, marker 2753),CD4 molecule (CD4, marker 2754), CD4 molecule (CD4, marker 2755), CD40 molecule, TNF receptor superfamily member 5 (CD40, marker 2756), CD40 molecule, TNF receptor superfamily member 5 (CD40, marker 2757), CD40 ligand (CD40LG, marker 2758), CD44 molecule (Indian blood group) (CD44, marker 2759), CD44 molecule (Indian blood group) (CD44, marker 2760), CD44 molecule (Indian blood group) (CD44, marker 2761), CD44 molecule (Indian blood group) (CD44, marker 2762), CD44 molecule (Indian blood group) (CD44, marker 2763), CD44 molecule (Indian blood group) (CD44, marker 2764), CD48 molecule (CD48, marker 2765), CD48 molecule (CD48, marker 2766), CD5 molecule (CD5, marker 2767), CD5 molecule (CD5, marker 2768), CD52 molecule (CD52, marker 2769), CD53 molecule (CD53, marker 2770), CD53 molecule (CD53, marker 2771), CD53 molecule (CD53, marker 2772), CD58 molecule (CD58, marker 2773), CD58 molecule (CD58, marker 2774), CD59 molecule, complement regulatory protein (CD59, marker 2775), CD5 molecule-like (CD5L, marker 2776), CD6 molecule (CD6, marker 2777), CD6 molecule (CD6, marker 2778), CD6 molecule (CD6, marker 2779), CD6 molecule (CD6, marker 2780),CD6 molecule (CD6, marker 2781), CD6 molecule (CD6, marker 2782), CD6 molecule (CD6, marker 2783), CD68 molecule (CD68, marker 2784), CD69 molecule (CD69, marker 2785), CD7 molecule (CD7, marker 2786), CD7 molecule (CD7, marker 2787), CD72 molecule (CD72, marker 2788), CD74 molecule, major histocompatibility complex, class II invariant chain (CD74, marker 2789), CD74 molecule, major histocompatibility complex, class II invariant chain (CD74, marker 2790), CD79a molecule, immunoglobulin-associated alpha (CD79A, marker 2791), CD79b molecule, immunoglobulin-associated beta (CD79B, marker 2792), CD79b molecule, immunoglobulin-associated beta (, CD79B, marker 2793), CD79b molecule, immunoglobulin-associated beta (CD79B, marker 2794), CD80 molecule (CD80, marker 2795), CD80 molecule (CD80, marker 2796), CD80 molecule (CD80, marker 2797), CD81 antisense RNA 1 (CD81-AS1, marker 2798), CD82 molecule (CD82, marker 2799), CD84 molecule (CD84, marker 2800), CD84 molecule (CD84, marker 2801), CD84 molecule (CD84, marker 2802), CD84 molecule (CD84, marker 2803), CD84 molecule (CD84, marker 2804), CD84 molecule (CD84, marker 2805), CD84 molecule (CD84, marker 2806), CD84 molecule (CD84, marker 2807), CD86 CD86 molecule (CD86, marker 2808), CD86 molecule (CD86, marker 2809), CD86 molecule (CD86, marker 2810), CD8a molecule (CD8A, marker 2811), CD8b molecule (CD8B, marker 2812), CD8b molecule (CD8B, marker 2813), CD8b molecule (CD8B, marker 2814), CD8b molecule (CD8B, marker 2815), CD9 molecule (CD9, marker 2816), CD9 molecule (CD9, marker 2817), CD93 molecule (CD93, marker 2818), CD93 molecule (CD93, marker 2819), CD96 molecule (CD96, marker 2820), CD96 molecule (CD96, marker 2821), CD99 molecule-like 2 (CD99L2, marker 2822), cytidine deaminase (CDA, marker 2823), cytidine and dCMP deaminase domain containing 1(CDADC1,marker 2824), codanin 1 (CDAN1, marker 2825), cell division cycle 14A (CDC14A, marker 2826), cell division cycle 14A (CDC14A, marker 2827), cell division cycle 14A (CDC14A, marker 2828), cell division cycle 14A (CDC14A, marker 2829), cell division cycle 14A (CDC14A, marker 2830), cell division cycle 14B (CDC14B, marker 2831), cell division cycle 14B (CDC14B, marker 2832), cell division cycle 14B (CDC14B, marker 2833), cell division cycle 14B (CDC14B, marker 2834), cell division cycle 14C (CDC14C, marker 2835), cell division cycle 20B (CDC20B, marker 2836), cell division cycle 20B (CDC20B, marker 2837), cell division cycle 20B (CDC20B, marker 2838), cell division cycle 20B (CDC20B, marker 2839), cell division cycle 20B (CDC20B, marker 2840), cell division cycle 25C (CDC25C, marker 2841), cell division cycle 34 (CDC34, marker 2842), cell division cycle 37 pseudogene 1 (CDC37P1, marker 2843), cell division cycle 42 (CDC42, marker 2844), cell division cycle 42 (CDC42, marker 2845), CDC42 intronic transcript 1 (CDC42-IT1, marker 2846), CDC42 binding protein kinase alpha (DMPK-like) (CDC42BPA, marker 2847),CDC42 binding protein kinase alpha (DMPK-like) (CDC42BPA, marker 2848), CDC42 binding protein kinase beta (DMPK-like) (CDC42BPB, marker 2849), CDC42 binding protein kinase gamma (DMPK-like) (CDC42BPG, marker 2850), CDC42 binding protein kinase gamma (DMPK-like) (CDC42BPG, marker 2851), CDC42 effector protein (Rho GTPase binding) 2 (CDC42EP2, marker 2852), CDC42 effector protein (Rho GTPase binding) 4 (CDC42EP4, marker 2853), CDC42 small effector 1 (CDC42SE1, marker 2854), CUB domain-containing protein 1 (CDCP1, marker 2855), cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11, marker 2856), cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11, marker 2857), cadherin 12, type 2 (N-cadherin 2) (CDH12, marker 2858), cadherin 15, type 1, M-cadherin (myotubule) (CDH15, marker 2859), cadherin 15, type 1, M-cadherin (myotubule) (CDH15, marker 2860), cadherin 16, KSP-cadherin (CDH16, marker 2861), cadherin 17, LI cadherin (liver-intestine) (CDH17, marker 2862), cadherin 18, type 2 (CDH18, marker 2863), cadherin 19, type 2 (CDH19, marker 2864), cadherin 19, type 2 (CDH19, marker 2865), cadherin 19,type 2 (CDH19, marker 2866), cadherin 20, type 2 (CDH20, marker 2867), cadherin 22, type 2 (CDH22, marker 2868), cadherin-related 23 (CDH23, marker 2869), cadherin-related 23 (CDH23, marker 2870), cadherin-related 23 (CDH23, marker 2871), cadherin-related 23 (CDH23, marker 2872), cadherin 24, type 2 (CDH24, marker 2873), cadherin 26 (CDH26, marker 2874), cadherin 26 (CDH26, marker 2875), cadherin 26 (CDH26, marker 2876), cadherin 4, type 1, R-cadherin (retinal) (CDH4, marker 2877), cadherin 4, type 1, R-cadherin (retinal) (CDH4, marker 2878), cadherin 5, type 2 (vascular endothelium) (CDH5, marker 2879), cadherin 6, type 2, K-cadherin (fetal kidney) (CDH6, marker 2880), cadherin 7, type 2 (CDH7, marker 2881), cadherin 7, type 2 (CDH7, marker 2882), cadherin 8, type 2 (CDH8, marker 2883), cadherin 8, type 2 (CDH8, marker 2884), cadherin 8, type 2 (CDH8, marker 2885), cadherin 9, type 2 (T1-cadherin) (CDH9, marker 2886), cadherin-related family members 1 (CDHR1, marker 2887), cadherin-related family member 1 (CDHR1, marker 2888), cadherin-related family member 3 (CDHR3, marker 2889), cadherin-related family member 3 (CDHR3,marker 2890), cadherin-related family member 5 (CDHR5, marker 2891), cadherin-related family member 5 (CDHR5, marker 2892), cadherin-related family member 5 (CDHR5, marker 2893), CDIPT antisense RNA 1 (head to head) (CDIPT-AS1, marker 2894), cyclin-dependent kinase 12 (CDK12, marker 2895), cyclin-dependent kinase 12 (CDK12, marker 2896), cyclin-dependent kinase 13 (CDK13, marker 2897), cyclin-dependent kinase 13 (CDK13, marker 2898), cyclin-dependent kinase 14 (CDK14, marker 2899), cyclin-dependent kinase 15 (CDK15, marker 2900), cyclin-dependent kinase 15 (CDK15, marker 2901), cyclin-dependent kinase 15 (CDK15, marker 2902), cyclin-dependent kinase 18 (CDK18, marker 2903), cyclin-dependent kinase 19 (CDK19, marker 2904), cyclin-dependent kinase 2 (CDK2, marker 2905), cyclin-dependent kinase 3 / / / TEN1-CDK3 readthrough (NMD candidate) (CDK3 / / / TEN1-CDK3, marker 2906), cyclin-dependent kinase 5, regulatory subunit 1 (p35) (CDK5R1, marker 2907), cyclin-dependent kinase 5, regulatory subunit 2 (p39) (CDK5R2, marker 2908), CDK5 regulatory subunit associated protein 2 (CDK5RAP2, marker 2909),cyclin-dependent kinase 6 (CDK6, marker 2910), cyclin-dependent kinase 9 (CDK9, marker 2911), CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1, marker 2912), CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1, marker 2913), cyclin-dependent kinase-like 1 (CDC2-related kinase) (CDKL1, marker 2914), cyclin-dependent kinase-like 1 (CDC2-related kinase) (CDKL1, marker 2915), cyclin-dependent kinase-like 1 (CDC2-related kinase) (CDKL1, marker 2916), cyclin-dependent kinase-like 2 (CDC2-related kinase) (CDKL2, marker 2917), cyclin-dependent kinase-like 2 (CDC2-related kinase) (CDKL2, marker 2918), cyclin-dependent kinase-like 3 (CDKL3, marker 2919), cyclin-dependent kinase-like 5 (CDKL5, marker 2920), cyclin-dependent kinase-like 5 (CDKL5, marker 2921), cyclin-dependent kinase inhibitor 2A (CDKN2A, marker 2922), cyclin-dependent kinase inhibitor 2A (CDKN2A, marker 2923), CDKN2A antisense RNA 1 (head to head) (CDKN2A-AS1, marker 2924), cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B, marker 2925), CDKN2B antisense RNA 1 (CDKN2B-AS1, marker 2926),Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (CDKN2C, marker 2927), cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (CDKN2C, marker 2928), cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) (CDKN2D, marker 2929), cerebral dopamine neurotrophic factor (CDNF, marker 2930), cysteine ​​dioxygenase type 1 / / / uncharacterized LOC105379131 (CDO1 / / / LOC105379131, marker 2931), cell adhesion associated, oncogene regulated (CDON, marker 2932), cell adhesion associated, oncogene regulated (CDON, marker 2933), cerebellar degeneration related protein 1 (CDR1, marker 2934), CMT1A duplicated region transcript 1 (CDRT1, marker 2935), CMT1A duplicated region transcript 1 (CDRT1, marker 2936), CMT1A duplicated region transcript 1 (CDRT1, marker 2937), CMT1A duplicated region transcript 15 (CDRT15, ​​marker 2938), CMT1A duplicated region transcript 15-like 2 (CDRT15L2, marker 2939), CDP-diacylglycerol synthase 1 (CDS1, marker 2940), CDP-diacylglycerol synthase 2 (CDS2, marker 2941), corneodesmosin (CDSN, marker 2942), corneodesmosin (CDSN, marker 2943),caudal type homeobox 1(CDX1,マーカー2944),caudal type homeobox 2(CDX2,マーカー2945),caudal type homeobox 2(CDX2,マーカー2946),chromodomain protein, Y-linked, 1(CDY1,マーカー2947),chromodomain protein, Y-linked, 1 / / / chromodomain protein, Y-linked, 1B / / / chromodomain protein, Y-linked, 2A / / / chromodomain protein, Y-linked, 2B(CDY1 / / / CDY1B / / / CDY2A / / / CDY2B,マーカー2948),carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)(CEACAM1,マーカー2949),carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)(CEACAM1,マーカー2950),carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)(CEACAM1,マーカー2951),carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)(CEACAM1,マーカー2952),carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)(CEACAM1,マーカー2953),carcinoembryonic antigen-related cell adhesion molecule 21(CEACAM21,マーカー2954),carcinoembryonic antigen-related cell adhesion molecule 3(CEACAM3,マーカー2955),carcinoembryonic antigen-related cell adhesion molecule 3(CEACAM3,マーカー2956),carcinoembryonic antigen-related cell adhesion molecule 3(CEACAM3,マーカー2957),carcinoembryonic antigen-related cell adhesion molecule 4(CEACAM4,マーカー2958),carcinoembryonic antigen-related cell adhesion molecule 5(CEACAM5,マーカー2959),carcinoembryonic antigen-related cell adhesion molecule 5(CEACAM5,マーカー2960),carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)(CEACAM6,マーカー2961),carcinoembryonic antigen-related cell adhesion molecule 7(CEACAM7,マーカー2962),carcinoembryonic antigen-related cell adhesion molecule 7(CEACAM7,マーカー2963),carcinoembryonic antigen-related cell adhesion molecule 7(CEACAM7,マーカー2964),carcinoembryonic antigen-related cell adhesion molecule 8(CEACAM8,マーカー2965),CCAAT / enhancer binding protein (C / EBP), delta(CEBPD,マーカー2966),CCAAT / enhancer binding protein (C / EBP), epsilon(CEBPE,マーカー2967),cat eye syndrome chromosome region,candidate 3 (non-protein coding) (CECR3, marker 2968), CECR5 antisense RNA 1 (CECR5-AS1, marker 2969), cat eye syndrome chromosome region, candidate 7 (non-protein coding) (CECR7, marker 2970), cat eye syndrome chromosome region, candidate 9 (non-protein coding) (CECR9, marker 2971), cat eye syndrome chromosome region, candidate 9 (non-protein coding) (CECR9, marker 2972), carboxyl ester lipase (CEL, marker 2973), carboxyl ester lipase (CEL, marker 2974), chymotrypsin-like elastase family, member 1 (CELA1, marker 2975), chymotrypsin-like elastase family, member 2A / / / chymotrypsin-like elastase family, member 2B (CELA2A / / / CELA2B, marker 2976), chymotrypsin-like, elastase family, member 2A / / / chymotrypsin-like elastase family, member 2B (CELA2A / / / CELA2B, marker 2977), chymotrypsin-like elastase family, member 2B (CELA2B, marker 2978), chymotrypsin-like elastase family, member 3A (CELA3A, marker 2979), chymotrypsin-like elastase family, member 3A (CELA3A, marker 2980), chymotrypsin-like elastase family, member 3B (CELA3B, marker 2981), CUGBP, Elav-like family member 1 (CELF1, marker 2982), CUGBP, Elav-like family member 2 (CELF2, marker 2983), CUGBP, Elav-like family member 2 (CELF2, marker 2984), CUGBP, Elav-like family member 2 (CELF2, marker 2985), CELF2 antisense RNA 1 (CELF2-AS1, marker 2986), CUGBP, Elav-like family member 3 (CELF3, marker 2987), CUGBP, Elav-like family member 3 (CELF3, marker 2988), CUGBP, Elav-like family member 4 (CELF4, marker 2989), CUGBP, Elav-like family member 4 (CELF4, marker 2990), CUGBP, Elav-like family member 4 (CELF4, marker 2991), CUGBP, Elav-like family member 4 (CELF4, marker 2992), CUGBP, Elav-like family member 4 (CELF4, marker 2993), CUGBP, Elav-like family member 6 (CELF6, marker 2994),Carboxyl ester lipase pseudogene (CELP, marker 2995), cadherin, EGF LAG seven-pass G-type receptor 1 (CELSR1, marker 2996), cadherin, EGF LAG seven-pass G-type receptor 1 (CELSR1, marker 2997), cell migration inducing protein, hyaluronan binding (CEMIP, marker 2998), cell migration inducing protein, hyaluronan binding (CEMIP, marker 2999), cementum protein 1 (CEMP1, marker 3000), centromere protein F (CENPF, marker 3001), centromere protein I (CENPI, marker 3002), centromere protein I (CENPI, marker 3003), centromere protein N (CENPN, marker 3004), centromere protein T (CENPT, marker 3005), centromere protein V (CENPV, marker 3006), centrosomal protein 104kDa (CEP104, marker 3007), centrosomal protein 112kDa (CEP112, marker 3008), centrosomal protein 112kDa (CEP112, marker 3009), centrosomal protein 126kDa (CEP126, marker 3010), centrosomal protein 126kDa (CEP126, marker 3011), centrosomal protein 126kDa (CEP126, marker 3012), centrosomal protein 135kDa (CEP135, marker 3013), centrosomal protein 152kDa (CEP152, marker 3014), centrosomal protein 152kDa (CEP152, marker 3015), centrosomal protein 164kDa (CEP164,CEP250, marker 3016), centrosomal protein 250kDa (CEP250, marker 3017), centrosomal protein 290kDa (CEP290, marker 3018), centrosomal protein 295kDa (CEP295, marker 3019), centrosomal protein 295kDa (CEP295, marker 3020), centrosomal protein 41kDa (CEP41, marker 3021), centrosomal protein 41kDa (CEP41, marker 3022), centrosomal protein 41kDa (CEP41, marker 3023), centrosomal protein 41kDa (CEP41, marker 3024), centrosomal protein 44kDa (CEP44, marker 3025), centrosomal protein 57kDa-like 1 (CEP57L1, marker 3026), centrosomal protein 57kDa-like 1 (CEP57L1, marker 3027), centrosomal protein 57kDa-like 1 (CEP57L1, marker 3028), centrosomal protein 63kDa (CEP63, marker 3029), centrosomal protein 68kDa (CEP68, marker 3030), centrosomal protein 70kDa (CEP70, marker 3031), centrosomal protein 72kDa (CEP72, marker 3032), CEP83 antisense RNA 1 (head to head) (CEP83-AS1, marker 3033), centrosomal protein 85kDa-like (CEP85L, marker 3034), centrosomal protein 89 kDa (CEP89, marker 3035), centrosomal protein 95 kDa (CEP95, marker 3036), centrosomal protein 95 kDa (CEP95, marker 3037), choline / ethanolamine phosphotransferase 1 (CEPT1,Marker 3038), cerebral endothelial cell adhesion molecule (CERCAM, Marker 3039), cerebral endothelial cell adhesion molecule (CERCAM, Marker 3040), ceramide synthase 3 (CERS3, Marker 3041), ceramide synthase 3 (CERS3, Marker 3042), ceramide synthase 5 (CERS5, Marker 3043), ceramide synthase 6 (CERS6, Marker 3044), carboxylesterase 1 pseudogene 1 (CES1 / / / CES1P1, Marker 3045), carboxylesterase 1 pseudogene 1 (CES1P1, Marker 3046), carboxylesterase 3 (CES3, Marker 3047), carboxylesterase 4A (CES4A, Marker 3048), carboxylesterase 5A (CES5A, Marker 3049), centrin 1 (CETN1, marker 3050), cholesterol ester transfer protein, plasma (CETP, marker 3051), cilia and flagella associated protein 100 (CFAP100, marker 3052), cilia and flagella associated protein 100 (CFAP100, marker 3053), cilia and flagella associated protein 126 (CFAP126, marker 3054), cilia and flagella associated protein 157 (CFAP157, marker 3055), cilia and flagella associated protein 157 (CFAP157, marker 3056), cilia and flagella associated protein 157 (CFAP157, marker 3057),cilia and flagella associated protein 161(CFAP161, marker 3058),cilia and flagella associated protein 206(CFAP206, marker 3059),cilia and flagella associated protein 221(CFAP221, marker 3060),cilia and flagella associated protein 221(CFAP221, marker 3061),cilia and flagella associated protein 221 (CFAP221, marker 3062), cilia and flagella associated protein 221 (CFAP221, marker 3063), cilia and flagella associated protein 43 (CFAP43, marker 3064), cilia and flagella associated protein 43 (CFAP43, marker 3065), cilia and flagella associated protein 43 (CFAP43, marker 3066), cilia and flagella associated protein 43(CFAP43, marker 3067), cilia and flagella associated protein 44 (CFAP44, marker 3068), cilia and flagella associated protein 44 (CFAP44, marker 3069), cilia and flagella associated protein 45 (CFAP45, marker 3070), cilia and flagella associated protein 46 (CFAP46, marker 3071), cilia and flagella associated protein 46 (CFAP46, marker 3072), cilia and flagella associated protein 47 (CFAP47, marker 3073), cilia and flagella associated protein 47 (CFAP47, marker 3074),cilia and flagella associated protein 47 (CFAP47, 3075), cilia and flagella associated protein 52 (CFAP52, 3076), cilia and flagella associated protein 52 (CFAP52, 3077), cilia and flagella associated protein Protein 53 (CFAP53, 3078), Cilia and Flagella Associated Protein 53 (CFAP53, 3079), Cilia and Flagella Associated Protein 54 (CFAP54, 3080), Cilia and Flagella Associated Protein [ PMC free article ] [ PubMed ] [ Cross Ref ] 57(CFAP57,Can 3081), Cilia and Flagella Associated Protein 58 (CFAP58,Can 3082), Cilia and Flagella Associated Protein 58 (CFAP58,Can 3083), Cilia and Flagella Associated Protein [ PMC free article ] [ PubMed ] [ Cross Ref ] 61( CFAP61, No. 3084), Cilia and Flagella Associated Protein [ PMC free article ] [ PubMed ] 65( CFAP65, Q3087), Cilia and Flagella Associated Protein 65 (CFAP65, Q3088), Cilia and Flagella Associated Protein 65 (CFAP65, Q3089), Cilia and Flagella Associated Protein 69 (CFAP69, scale 3090), cilia and flagella associated protein 70 (CFAP70, scale 3091),cilia and flagella associated protein 70(CFAP70, marker 3092),cilia and flagella associated protein 73(CFAP73, marker 3093),cilia and flagella associated protein 74(CFAP74, marker 3094),cilia and flagella associated protein 74(CFAP74, marker 3095),cilia and flagella associated protein 74(CFAP74, marker 3096),cilia and flagella associated protein 74(CFAP74, marker 3097),cilia and flagella associated protein 97(CFAP97, marker 3098),cilia and flagella associated protein 97(CFAP97, marker 3099),cilia and flagella associated protein 99(CFAP99, marker 3100),complement factor B(CFB, marker 3101),complement factor B(CFB, marker 3102), cripto, FRL-1, cryptic family 1 (CFC1, marker 3103), crypto, FRL-1, cryptic family 1 (CFC1, marker 3104), crypto, FRL-1, cryptic family 1 / / / crypto, FRL-1, cryptic family 1B (CFC1 ​​ / / / CFC1B, marker 3105), crypto, FRL-1, cryptic family 1B (CFC1B, marker 3106), complement factor D (adipsin) (CFD, marker 3107), complement factor H (CFH, marker 3108), complement factor H / / / complement factor H-related 1 (CFH / / / CFHR1, marker 3109),complement factor H-related 2 (CFHR2, marker 3110), complement factor H-related 3 (CFHR3, marker 3111), complement factor H-related 3 (CFHR3, marker 3112), complement factor H-related 4 (CFHR4, marker 3113), complement factor H-related 5 (CFHR5, marker 3114), complement factor I (CFI, marker 3115), complement factor I (CFI, marker 3116), cofilin 1 (non-muscle) (CFL1, marker 3117), cofilin 1 (non-muscle) / / / uncharacterized LOC101927853 (CFL1 / / / LOC101927853, marker 3118), CASP8 and FADD-like apoptosis regulator (CFLAR, marker 3119), CASP8 and FADD-like apoptosis regulator CFLAR antisense RNA 1 (CFLAR-AS1, marker 3123), complement factor properdin (CFP, marker 3124), cystic fibrosis transmembrane conductance regulator (CFTR, marker 3125), cystic fibrosis transmembrane conductance regulator (CFTR, marker 3126), cystic fibrosis transmembrane conductance regulator (CFTR, marker 3127), cystic fibrosis transmembrane conductance regulator (CFTR, marker 3128),Glycoprotein hormones, alpha polypeptide (CGA, marker 3129), glycoprotein hormones, alpha polypeptide (CGA, marker 3130), chorionic gonadotropin, beta polypeptide / / / chorionic gonadotropin, beta polypeptide 5 / / / chorionic gonadotropin, beta polypeptide 7 (CGB / / / CGB5 / / / CGB7, marker 3131), cell growth regulator with EF-hand domain 1 (CGREF1, marker 3132), neuropeptide Y receptor type 4-like / / / neuropeptide Y receptor type 4 / / / neuropeptide Y receptor Y4 (CH17-360D5.1 / / / LOC105379861 / / / NPY4R, marker 3133), uncharacterized LOC102724558 / / / uncharacterized LOC101927468 / / / LOC101927468, marker 3134), putative uncharacterized protein C21orf125 / / / long intergenic non-protein coding RNA 319 (CH507-42P11.6 / / / LINC00319, marker 3135), uncharacterized LOC105372831 / / / uncharacterized LOC105377139 (CH507-9B2.8 / / / LOC105377139, marker 3136), chondroadherin (CHAD, marker 3137), chondroadherin-like (CHADL, marker 3138), chromatin assembly factor 1, subunit A (p150) (CHAF1A, marker 3139), choline O-acetyltransferase (CHAT, marker 3140),coiled-coil-helix-coiled-coil-helix domain containing 3 (CHCHD3, marker 3141), coiled-coil-helix-coiled-coil-helix domain containing 5 (CHCHD5, marker 3142), coiled-coil-helix-coiled-coil-helix domain containing 5 (CHCHD5, marker 3143), chromodomain helicase DNA binding protein 2 (CHD2, marker 3144), chromodomain helicase DNA binding protein 3 (CHD3, marker 3145), chromodomain helicase DNA binding protein 5 (CHD5, marker 3146), chromodomain helicase DNA binding protein 5 (CHD5, marker 3147), chromodomain helicase DNA binding protein 6 (CHD6, marker 3148), chromodomain helicase DNA binding protein 7 (CHD7, marker 3149), chromodomain helicase DNA binding protein 9 (CHD9, marker 3150), choline dehydrogenase (CHDH, , marker 3151), choline dehydrogenase (CHDH, marker 3152), choline dehydrogenase (CHDH, marker 3153), choline dehydrogenase (CHDH, marker 3154), choline dehydrogenase (CHDH, marker 3155), checkpoint kinase 1 (CHEK1, marker 3156), calcium homeostasis endoplasmic reticulum protein (CHERP, marker 3157), checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase / / / uncharacterized LOC100128843 (CHFR / / / LOC100128843, marker 3158), chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1, marker 3159), chitinase 3-like 2 (CHI3L2, marker 3160), chitinase, acidic (CHIA, marker 3161), chitinase, acidic pseudogene 2 (CHIAP2, marker 3162), cysteine-rich hydrophobic domain 1 (CHIC1, marker 3163), cysteine-rich hydrophobic domain 1 (CHIC1, marker 3164), chitinase 1 (chitotriosidase) (CHIT1, marker 3165), CHKB antisense RNA 1 (head to head) (CHKB-AS1, marker 3166), cell adhesion molecule L1-like (CHL1, marker 3167), cell adhesion molecule L1-like (CHL1, marker 3168), CHL1 antisense RNA 1 (CHL1-AS1, marker 3169), choroideremia-like (Rab escort protein 2) (CHML, marker 3170),choroideremia-like (Rab escort protein 2) (CHML, marker 3171), choroideremia-like (Rab escort protein 2) (CHML, marker 3172), chimerin 2 (CHN2, marker 3173), chimerin 2 / / / uncharacterized LOC101928168 (CHN2 / / / LOC101928168, marker 3174), cysteine ​​and histidine-rich domain containing 1 (CHORDC1, marker 3175), calcineurin-like EF-hand protein 2 (CHP2, marker 3176), choline phosphotransferase 1 (CHPT1, marker 3177), chordin (CHRD, marker 3178), chordin (CHRD, marker 3179), chordin-like 2 (CHRDL2, marker 3180), cholinergic receptor, muscarinic 1 (CHRM1, marker 3181), cholinergic receptor, muscarinic 2 (CHRM2, marker 3182), cholinergic receptor, muscarinic 3 (CHRM3, marker 3183), cholinergic receptor, muscarinic 3 (CHRM3, marker 3184), cholinergic receptor, muscarinic 3 (CHRM3, marker 3185), cholinergic receptor, muscarinic 3 (CHRM3, marker 3186), CHRM3 antisense RNA 2 (CHRM3-AS2, marker 3187), cholinergic receptor, muscarinic 4 (CHRM4, marker 3188), cholinergic receptor, muscarinic 5 (CHRM5, marker 3189), cholinergic receptor, nicotinic alpha 1 (CHRNA1, marker 3190), cholinergic receptor,nicotinic alpha 1(CHRNA1,マーカー3191),cholinergic receptor, nicotinic alpha 10(CHRNA10,マーカー3192),cholinergic receptor, nicotinic alpha 10(CHRNA10,マーカー3193),cholinergic receptor, nicotinic alpha 10(CHRNA10,マーカー3194),cholinergic receptor, nicotinic alpha 2(CHRNA2,マーカー3195),cholinergic receptor, nicotinic alpha 3(CHRNA3,マーカー3196),cholinergic receptor, nicotinic alpha 3(CHRNA3,マーカー3197),cholinergic receptor, nicotinic alpha 4(CHRNA4,マーカー3198),cholinergic receptor, nicotinic alpha 4 / / / uncharacterized LOC102723788(CHRNA4 / / / LOC102723788,マーカー3199),cholinergic receptor, nicotinic alpha 4 / / / uncharacterized LOC102723788(CHRNA4 / / / LOC102723788,マーカー3200),cholinergic receptor, nicotinic alpha 4 / / / uncharacterized LOC102723788(CHRNA4 / / / LOC102723788,マーカー3201),cholinergic receptor, nicotinic alpha 6(CHRNA6,マーカー3202),cholinergic receptor, nicotinic beta 2(CHRNB2,マーカー3203),cholinergic receptor, nicotinic beta 3(CHRNB3,マーカー3204),cholinergic receptor, nicotinic beta 3(CHRNB3,マーカー3205),Cholinergic receptor, nicotinic beta 4 (CHRNB4, marker 3206), cholinergic receptor, nicotinic delta (CHRND, marker 3207), cholinergic receptor, nicotinic epsilon (CHRNE, marker 3208), cholinergic receptor, nicotinic epsilon (CHRNE, marker 3209), cholinergic receptor, nicotinic gamma (CHRNG, marker 3210), carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (CHST1, marker 3211), carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (CHST1, marker 3212), carbohydrate (chondroitin 4) sulfotransferase 13 (CHST13, marker 3213), carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 (CHST15, marker 3214), carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 (CHST15, marker 3215), carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 (CHST2, marker 3216), carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3, marker 3217), chondroitin sulfate synthase 3 (CHSY3, marker 3218), churchill domain containing 1 (CHURC1, marker 3219), cytokine-induced apoptosis inhibitor 1 (CIAPIN1, marker 3220), calcium and integrin binding family member 3 (CIB3,marker 3221), calcium and integrin binding family member 3 (CIB3, marker 3222), calcium and integrin binding family member 4 (CIB4, marker 3223), cell death-inducing DFFA-like effector a (CIDEA, marker 3224), cell death-inducing DFFA-like effector c (CIDEC, marker 3225), cell death-inducing DFFA-like effector c pseudogene (CIDECP, marker 3226), class II, major histocompatibility complex, transactivator (CIITA, marker 3227), class II, major histocompatibility complex, transactivator (CIITA, marker 3228), class II, major histocompatibility complex, transactivator (CIITA, marker 3229), cartilage intermediate layer protein, nucleotide pyrophosphohydrolase (CILP, marker 3230), cartilage intermediate layer protein 2 (CILP2, marker 3231), cyclin-dependent kinase 2 interacting protein (CINP, marker 3232), CIRBP antisense RNA 1 (CIRBP-AS1, marker 3233), CIRBP antisense RNA 1 (CIRBP-AS1, marker 3234), CDGSH iron sulfur domain 2 (CISD2, marker 3235), CDGSH iron sulfur domain 3 (CISD3, marker 3236), cytokine inducible SH2-containing protein (CISH, marker 3237),Citron rho-interacting serine / threonine kinase (CIT, marker 3238), Cbp / p300-interacting transactivator, with Glu / Asp-rich carboxy-terminal domain, 1 (CITED1, marker 3239), Cbp / p300-interacting transactivator, with Glu / Asp-rich carboxy-terminal domain, 2 (CITED2, marker 3240), CDKN1A-interacting zinc finger protein 1 (CIZ1, marker 3241), cytoskeleton-associated protein 2 (CKAP2, marker 3242), cytoskeleton-associated protein 2 (CKAP2, marker 3243), cytoskeleton-associated protein 4 (CKAP4, marker 3244), creatine kinase, muscle (CKM, marker 3245), creatine kinase, mitochondrial 2 (sarcomeric) (CKMT2, marker 3246), cytoplasmic linker associated protein 2 (CLASP2, marker 3247), Charcot-Leyden crystal galectin (CLC, marker 3248), chloride channel accessory 1 (CLCA1, marker 3249), chloride channel accessory 2 (CLCA2, marker 3250), chloride channel accessory 2 (CLCA2, marker 3251), chloride channel accessory 2 (CLCA2, marker 3252), chloride channel accessory 2 (CLCA2, marker 3253), chloride channel accessory 3, pseudogene (CLCA3P, marker 3254), chloride channel accessory 4 (CLCA4, marker 3255),chloride channel, voltage-sensitive 1(CLCN1, marker 3256),chloride channel, voltage-sensitive 4(CLCN4, marker 3257),chloride channel, voltage-sensitive 4(CLCN4, marker 3258),chloride channel, voltage-sensitive 5(CLCN5, marker 3259),chloride channel, voltage-sensitive 7(CLCN7, marker 3260),chloride channel, voltage-sensitive Ka / / / chloride channel, voltage-sensitive Kb(CLCNKA / / / CLCNKB, marker 3261),chloride channel, voltage-sensitive Kb(CLCNKB, marker 3262),chloride channel, voltage-sensitive Kb(CLCNKB, marker 3263),chloride channel, voltage-sensitive Kb(CLCNKB, marker 3264),claudin 1(CLDN1, marker 3265),claudin 10 / / / uncharacterized LOC101927308(CLDN10 / / / LOC101927308, marker 3266), CLDN10 antisense RNA 1 (CLDN10-AS1, marker 3267), claudin 11 (CLDN11, marker 3268), claudin 11 / / / uncharacterized LOC105374213 (CLDN11 / / / LOC105374213, marker 3269), claudin 12 (CLDN12, marker 3270), claudin 14 (CLDN14, marker 3271), claudin 15 (CLDN15, marker 3272), claudin 16 (CLDN16, marker 3273), claudin 17 (CLDN17, marker 3274), claudin 18 (CLDN18, marker 3275), claudin 18 (CLDN18, marker 3276),Claudin 18 (CLDN18, marker 3277), claudin 19 (CLDN19, marker 3278), claudin 2 (CLDN2, marker 3279), claudin 20 (CLDN20, marker 3280), claudin 23 (CLDN23, marker 3281), claudin 4 (CLDN4, marker 3282), claudin 5 (CLDN5, marker 3283), claudin 8 (CLDN8, marker 3284), claudin 9 (CLDN9, marker 3285), claudin domain containing 1 (CLDND1, marker 3286), claudin domain containing 1 (CLDND1, marker 3287), claudin domain containing 2 (CLDND2, marker 3288), C-type lectin domain family 10, member A (CLEC10A, marker 3289), C-type lectin domain family 11, member A (CLEC11A, marker 3290), C-type lectin domain family 12, member A (CLEC12A, marker 3291), C-type lectin domain family 12, member A (CLEC12A, marker 3292), C-type lectin domain family 12, member A (CLEC12A, marker 3293), C-type lectin domain family 12, member B (CLEC12B, marker 3294), C-type lectin domain family 12, member B (CLEC12B, marker 3295), C-type lectin domain family 14, member A (CLEC14A, marker 3296), C-type lectin domain family 16, member A (CLEC16A, marker 3297), C-type lectin domain family 18, member A / / / C-type lectin domain family 18,Member C (CLEC18A / / / CLEC18C, marker 3298), C-type lectin domain family 1, member A (CLEC1A, marker 3299), C-type lectin domain family 1, member B (CLEC1B, marker 3300), C-type lectin domain family 2, member B (CLEC2B, marker 3301), C-type lectin domain family 2, member B (CLEC2B, marker 3302), C-type lectin domain family 2, member D (CLEC2D, marker 3303), C-type lectin domain family 2, member D (CLEC2D, marker 3304), C-type lectin domain family 2, member D (CLEC2D, marker 3305), C-type lectin domain family 2, member D (CLEC2D, marker 3306), C-type lectin domain family 2, member L (CLEC2L, marker 3307), C-type lectin domain family 3, member A (CLEC3A, marker 3308), C-type lectin domain family 3, member B / / / exosome component 7 (CLEC3B / / / EXOSC7, marker 3309), C-type lectin domain family 4, member A (CLEC4A, marker 3310), C-type lectin domain family 4, member A (CLEC4A, marker 3311), C-type lectin domain family 4, member C (CLEC4C, marker 3312), C-type lectin domain family 4, member C (CLEC4C, marker 3313), C-type lectin domain family 4, member D (CLEC4D, marker 3314),C-type lectin domain family 4, member D (CLEC4D, marker 3315), C-type lectin domain family 4, member E (CLEC4E, marker 3316), C-type lectin domain family 4, member E (CLEC4E, marker 3317), C-type lectin domain family 4, member F (CLEC4F, marker 3318), C-type lectin domain family 4, member G (CLEC4G, marker 3319), C-type lectin domain family 4, member M (CLEC4M, marker 3320), C-type lectin domain family 4, member M (CLEC4M, marker 3321), C-type lectin domain family 5, member A (CLEC5A, marker 3322), C-type lectin domain family 7, member A (CLEC7A, marker 3323), C-type lectin domain family 7, member A(CLEC7A, marker 3324), C-type lectin domain family 7, member A(CLEC7A, marker 3325), C-type lectin domain family 7, member er A (CLEC7A, marker 3326), C-type lectin domain family 7, member A (CLEC7A, marker 3327), C-type lectin domain family 7, member A (CLEC7A, marker 3328), C-type lectin-like 1 (CLECL1, marker 3329), C-type lectin-like 1 (CLECL1, marker 3330), chloride intracellular channel 1 pseudogene 1 (CLIC1P1, marker 3331), chloride intracellular channel 2 (CLIC2, marker 3332), chloride intracellular channel 3 (CLIC3, marker 3333), chloride intracellular channel 5 (CLIC5, marker 3334), chloride intracellular channel 5 (CLIC5, marker 3335), chloride intracellular channel 5 (CLIC5, marker 3336), chloride intracellular channel 5 (CLIC5, marker 3337), chloride intracellular channel 5 (CLIC5, marker 3338), chloride intracellular channel 6 (CLIC6, marker 3339), clathrin interactor 1 (CLINT1, marker 3340), CAP-GLY domain containing linker protein 1 (CLIP1, marker 3341), CAP-GLY domain containing linker protein 1 (CLIP1, marker 3342), CLIP1 antisense RNA 1 (CLIP1-AS1, marker 3343), CAP-GLY domain containing linker protein 3 (CLIP3, marker 3344), CAP-GLY domain containing linker protein family, member 4 (CLIP4, marker 3345),CDC-like kinase 3 (CLK3, marker 3346), CDC-like kinase 4 (CLK4, marker 3347), CDC-like kinase 4 (CLK4, marker 3348), chronic lymphocytic leukemia up-regulated 1 / / / uncharacterized LOC100507616 (CLLU1 / / / LOC100507616, marker 3349), chronic lymphocytic leukemia up-regulated 1 / / / uncharacterized LOC100507616 (CLLU1 / / / LOC100507616, marker 3350), calmin (calponin-like, transmembrane) (CLMN, marker 3351), calmin (calponin-like, transmembrane) (CLMN, marker 3352), calmin (calponin-like, transmembrane) (CLMN, marker 3353), ceroid-lipofuscinosis, neuronal 6, late infantile, variant (CLN6, marker 3354), ceroid-lipofuscinosis, neuronal 6, late infantile, variant (CLN6, marker 3355), cytokine-dependent hematopoietic cell linker (CLNK, marker 3356), cytokine-dependent hematopoietic cell linker (CLNK, marker 3357), cytokine-dependent hematopoietic cell linker (CLNK, marker 3358), clock circadian regulator (CLOCK, marker 3359), cleavage and polyadenylation factor I subunit 1 (CLP1, marker 3360), ClpB homolog, mitochondrial AAA ATPase chaperonin (CLPB, marker 3361), colipase,pancreatic (CLPS, marker 3362), CLPTM1-like (CLPTM1L, marker 3363), clarin 1 (CLRN1, marker 3364), clarin 1 (CLRN1, marker 3365), clarin 1 (CLRN1, marker 3366), CLRN1 antisense RNA 1 (CLRN1-AS1, marker 3367), clarin 3 (CLRN3, marker 3368), claspin (CLSPN, marker 3369), calsyntenin 2 (CLSTN2, marker 3370), CLSTN2 antisense RNA 1 (CLSTN2-AS1, marker 3371), clathrin, light chain A (CLTA, marker 3372), clathrin, light chain A (CLTA, marker 3373), clathrin, light chain B (CLTB, marker 3374), clathrin, heavy chain (Hc)(CLTC, marker 3375), clathrin, heavy chain (Hc)(CLTC, marker 3376), clusterin(CLU, marker 3377), clusterin(CLU, marker 3378), clusterin associated protein 1(CLUAP1, marker 3379), clustered mitochondrial (cluA / CLU1) homolog pseudogene 3(CLUHP3, marker 3380), clustered mitochondrial (cluA / CLU1) homolog pseudogene 3(CLUHP3, marker 3381), clusterin-like 1 (retinal)(CLUL1, marker 3382), clavesin 1(CLVS1, marker 3383), clavesin 2(CLVS2, marker 3384), citrate lyase beta like(CLYBL, marker 3385), citrate lyase beta like (CLYBL, marker 3386), CLYBL antisense RNA 1 (CLYBL-AS1, marker 3387), CLYBL antisense RNA 2 (CLYBL-AS2,Marker 3388), CLYBL intronic transcript 1 (non-protein coding) (CLYBL-IT1 / / / RP11-134O15.2, Marker 3389), CLYBL intronic transcript 1 (non-protein coding) (CLYBL-IT1 / / / RP11-134O15.2, Marker 3390), chymase 1, mast cell (CMA1, Marker 3391), cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene (CMAHP, Marker 3392), cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene (CMAHP, Marker 3393), cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene (CMAHP, Marker 3394), cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene (CMAHP, Marker 3395), cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS, marker 3396), carboxymethylenebutenolidase homolog (Pseudomonas) (CMBL, marker 3397), Cx(9)-C motif containing 4 / / / mature T-cell proliferation 1 (CMC4 / / / MTCP1, marker 3398), c-Maf inducing protein / / / uncharacterized LOC100129617 (CMIP / / / LOC100129617, marker 3399), chemerin chemokine-like receptor 1 (CMKLR1, marker 3400), chemerin chemokine-like receptor 1 (CMKLR1, marker 3401),chemerin chemokine-like receptor 1 (CMKLR1, marker 3402), cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (CMPK1, marker 3403), CKLF-like MARVEL transmembrane domain containing 1 (CMTM1, marker 3404), CKLF-like MARVEL transmembrane domain containing 1 (CMTM1, marker 3405), CKLF-like MARVEL transmembrane domain containing 2 (CMTM2, marker 3406), CKLF-like MARVEL transmembrane domain containing 3 (CMTM3, marker 3407), CKLF-like MARVEL transmembrane domain containing 6 (CMTM6, marker 3408), cardiomyopathy associated 5 (CMYA5, marker 3409), cyclic nucleotide binding domain containing 1 (CNBD1, marker 3410), cyclic nucleotide binding domain containing 1 (CNBD1, marker 3411), cyclic nucleotide binding domain containing 2 (CNBD2, marker 3412), cyclic nucleotide binding domain containing 2 (CNBD2, marker 3413), cyclic nucleotide binding domain containing 2 (CNBD2, marker 3414), cyclic nucleotide binding domain containing 2 (CNBD2, marker 3415), carnosine dipeptidase 1 (metallopeptidase M20 family) (CNDP1, marker 3416), CNDP dipeptidase 2 (metallopeptidase M20 family) (CNDP2,cyclic nucleotide gated channel alpha 1 (CNGA1, marker 3417), cyclic nucleotide gated channel alpha 3 (CNGA3, marker 3419), cyclic nucleotide gated channel alpha 4 (CNGA4, marker 3420), cyclic nucleotide gated channel beta 1 (CNGB1, marker 3421), cyclic nucleotide gated channel beta 1 (CNGB1, marker 3422), cyclic nucleotide gated channel beta 1 (CNGB1, marker 3423), cyclic nucleotide gated channel beta 3 (CNGB3, marker 3424), cyclic nucleotide gated channel beta 3 (CNGB3, marker 3425), cornichon family AMPA receptor auxiliary protein 2 (CNIH2, marker 3426), cornichon family AMPA receptor auxiliary protein 4 (CNIH4, marker 3427), connector enhancer of kinase suppressor of Ras 2 (CNKSR2, marker 3428), CNKSR family member 3 (CNKSR3, marker 3429), CNKSR family member 3 (CNKSR3, marker 3430), cyclin and CBS domain divalent metal cation transport mediator 1 (CNNM1, marker 3431), cyclin and CBS domain divalent metal cation transport mediator 2 (CNNM2, marker 3432), cyclin and CBS domain divalent metal cation transport mediator 3 (CNNM3, marker 3433),CCR4-NOT transcription complex subunit 2 (CNOT2, marker 3434), CCR4-NOT transcription complex subunit 2 (CNOT2, marker 3435), CCR4-NOT transcription complex subunit 3 (CNOT3, marker 3436), CCR4-NOT transcription complex subunit 4 (CNOT4, marker 3437), CCR4-NOT transcription complex subunit 4 (CNOT4, marker 3438), CCR4-NOT transcription complex subunit 6-like (CNOT6L, marker 3439), CCR4-NOT transcription complex subunit 6-like (CNOT6L, marker 3440), 2',3'-cyclic nucleotide 3' phosphodiesterase (CNP, marker 3441), canopy FGF signaling regulator 1 (CNPY1, marker 3442), canopy FGF signaling regulator 2 (CNPY2, marker 3443), canopy FGF signaling regulator 3 (CNPY3, marker 3444), canopy FGF signaling regulator 4 (CNPY4, marker 3445), cannabinoid receptor 1 (brain) (CNR1, marker 3446), cannabinoid receptor 1 (brain) (CNR1, marker 3447), cannabinoid receptor 1 (brain) (CNR1, marker 3448), cannabinoid receptor 2 (CNR2, marker 3449), cyclin N-terminal domain containing 1 (CNTD1, marker 3450), cyclin N-terminal domain containing 2 (CNTD2, marker 3451),ciliary neurotrophic factor / / / ZFP91-CNTF readthrough (NMD candidate) (CNTF / / / ZFP91-CNTF, marker 3452), ciliary neurotrophic factor receptor (CNTFR, marker 3453), CNTFR antisense RNA 1 (CNTFR-AS1, marker 3454), CNTFR antisense RNA 1 (CNTFR-AS1, marker 3455), contactin 1 (CNTN1, marker 3456), contactin 1 (CNTN1, marker 3457), contactin 1 (CNTN1, marker 3458), contactin 2 (axonal) (CNTN2, marker 3459), contactin 2 (axonal) (CNTN2, marker 3460), contactin 3 (plasmacytoma-associated) (CNTN3, marker 3461), contactin 4 (CNTN4, marker 3462), contactin 5 (CNTN5, marker 3463), contactin 5(CNTN5, marker 3464), contactin 6(CNTN6, marker 3465), contactin associated protein-like 3(CNTNAP3, marker 3466), contactin associated protein-like 3 / / / contactin associated protein-like 3B / / / contactin associated protein-like 3-like(CNTNAP3 / / / CNTNAP3B / / / LOC100289279, marker 3467), contactin associated protein-like 4(CNTNAP4, marker 3468), contactin associated protein-like 4(CNTNAP4, marker 3469), contactin associated protein-like 4(CNTNAP4, marker 3470), contactin associated protein-like 4(CNTNAP4,marker 3471), contactin associated protein-like 5 (CNTNAP5, marker 3472), contactin associated protein-like 5 (CNTNAP5, marker 3473), contactin associated protein-like 5 (CNTNAP5, marker 3474), centrobin, centrosomal BRCA2 interacting protein (CNTROB, marker 3475), centrobin, centrosomal BRCA2 interacting protein (CNTROB, marker 3476), centrobin, centrosomal BRCA2 interacting protein (CNTROB, marker 3477), cytochrome c oxidase assembly factor 1 homolog (COA1, marker 3478), cytochrome c oxidase assembly factor 1 homolog (COA1, marker 3479), cytochrome c oxidase assembly factor 1 homolog (COA1, marker 3480), cytochrome c oxidase assembly factor 3 (COA3, marker 3481), cordon-bleu WH2 repeat protein like 1(COBLL1, marker 3482), cordon-bleu WH2 repeat protein like 1(COBLL1, marker 3483), cordon-bleu WH2 repeat protein like 1(COBLL1, marker 3484), component of oligomeric golgi complex 1(COG1, marker 3485), component of oligomeric golgi complex 2(COG2, marker 3486), component of oligomeric golgi complex 3(COG3, marker 3487), component of oligomeric golgi complex 6(COG6, marker 3488),Collagen, type X, alpha 1 (COL10A1, marker 3489), collagen, type X, alpha 1 (COL10A1, marker 3490), collagen, type XI, alpha 2 (COL11A2, marker 3491), collagen, type XII, alpha 1 (COL12A1, marker 3492), collagen, type XIV, alpha 1 (COL14A1, marker 3493), collagen, type XIV, alpha 1 (COL14A1, marker 3494), collagen, type XV, alpha 1 (COL15A1, marker 3495), collagen, type XVII, alpha 1 (COL17A1, marker 3496), COL18A1 antisense RNA 1 (COL18A1-AS1, marker 3497), collagen, type XIX, alpha 1 (COL19A1, marker 3498), collagen, type I, alpha 1 (COL1A1, marker 3499), collagen, type XX, alpha 1 (COL20A1, marker 3500), collagen, type XX, alpha 1 (COL20A1, marker 3501), collagen, type XXII, alpha 1 (COL22A1, marker 3502), collagen, type XXIV, alpha 1 (COL24, A1, marker 3503), collagen, type XXV, alpha 1 (COL25A1, marker 3504), collagen, type XXV, alpha 1 (COL25A1, marker 3505), collagen, type XXV, alpha 1 (COL25A1, marker 3506), collagen, type XXVI, alpha 1 (COL26A1, marker 3507), collagen, type XXVII, alpha 1 (COL27A1, marker 3508), collagen, type XXVII, alpha 1 (COL27A1, marker 3509), collagen, type XXVIII, alpha 1 (COL28A1, marker 3510), collagen, type XXVIII, alpha 1 (COL28A1, marker 3511), collagen, type III, alpha 1(COL3A1, marker 3512),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3,marker 3513),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3,marker 3514),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3,marker 3515),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3, marker 3516),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3,marker 3517),collagen, type IV, alpha 3 (Goodpasture antigen)(COL4A3,marker 3518),collagen, type IV, alpha 3 (Goodpasture antigen) (COL4A3, marker 3519), collagen, type IV, alpha 4 (COL4A4, marker 3520), collagen, type IV, alpha 4 (COL4A4, marker 3521), collagen,Type IV, alpha 4 (COL4A4, marker 3522), collagen, type V, alpha 3 (COL5A3, marker 3523), collagen, type VI, alpha 1 (COL6A1, marker 3524), collagen, type VI, alpha 1 (COL6A1, marker 3525), collagen, type VI, alpha 1 (COL6A1, marker 3526), ​​collagen, type VI, alpha 1 (COL6A1, marker 3527), collagen, type VI, alpha 5 (COL6A5, marker 3528), collagen, type VI, alpha 5 (COL6A5, marker 3529), collagen, type VI, alpha 6 (COL6A6, marker 3530), collagen, type VI, alpha 6 (COL6A6, marker 3531), collagen, type VIII, alpha 1 (COL8A1, marker 3532), collagen, type VIII, alpha 1 (COL8A1, marker 3533), collagen, type VIII, alpha 2 (COL8A2, marker 3534), collagen, type VIII, alpha 2 (COL8A2, marker 3535), collagen, type IX, alpha 1 (COL9A1, marker 3536), collagen, type IX, alpha 2 (COL9A2, marker 3537), colorectal cancer associated 1 (COLCA1, marker 3538), collectin subfamily member 10 (C-type lectin) (COLEC10, marker 3539), collectin subfamily member 11 (COLEC11, marker 3540), collectin subfamily member 12 (COLEC12, marker 3541), collagen beta(1-O)galactosyltransferase 2 (COLGALT2, marker 3542),COMM domain containing 10 (COMMD10, marker 3543), COMM domain containing 10 (COMMD10, marker 3544), COMM domain containing 4 (COMMD4, marker 3545), COMM domain containing 5 (COMMD5, marker 3546), COMM domain containing 6 (COMMD6, marker 3547), cartilage oligomeric matrix protein (COMP, marker 3548), catechol-O-methyltransferase (COMT, marker 3549), catechol-O-methyltransferase (COMT, marker 3550), catechol-O-methyltransferase (COMT, marker 3551), catechol-O-methyltransferase (COMT, marker 3552), coatomer protein complex subunit alpha (COPA, marker 3553), coatomer protein complex subunit alpha (COPA, marker 3554), coatomer protein complex subunit beta 1 (COPB1, marker 3555), coatomer protein complex subunit beta 2 (beta prime) (COPB2, marker 3556), coatomer protein complex subunit epsilon (COPE, marker 3557), coatomer protein complex subunit gamma 2 (COPG2, marker 3558), COP9 signalosome subunit 4 (COPS4, marker 3559), COP9 signalosome subunit 7B (COPS7B, marker 3560), COP9 signalosome subunit 8 (COPS8, marker 3561), coatomer protein complex subunit zeta 2 (COPZ2, marker 3562),Coatomer protein complex subunit zeta 2 (COPZ2, marker 3563), coenzyme Q10B (COQ10B, marker 3564), coenzyme Q2 4-hydroxybenzoate polyprenyltransferase (COQ2, marker 3565), coenzyme Q9 (COQ9, marker 3566), corin, serine peptidase (CORIN, marker 3567), corin, serine peptidase (CORIN, marker 3568), corin, serine peptidase (CORIN, marker 3569), coronin, actin binding protein, 1B / / / protein tyrosine phosphatase, receptor type, C-associated protein (CORO1B / / / PTPRCAP, marker 3570), coronin 6 (CORO6, marker 3571), coronin 7 (CORO7, marker 3572), cortistatin (CORT, marker 3573), COX10 heme A:farnesyltransferase cytochrome c oxidase assembly factor (COX10, marker 3574), COX10 antisense RNA 1 / / / uncharacterized LOC100506974 (COX10-AS1 / / / LOC100506974, marker 3575), COX14 cytochrome c oxidase assembly factor / / / glycerol-3-phosphate dehydrogenase 1 (COX14 / / / GPD1, marker 3576), COX17 cytochrome c oxidase copper chaperone (COX17, marker 3577), COX18 cytochrome c oxidase assembly factor (COX18, marker 3578), COX19 cytochrome c oxidase assembly factor (COX19, marker 3579),Cytochrome c oxidase subunit IV isoform 1 (COX4I1, marker 3580), cytochrome c oxidase subunit VIa polypeptide 1 (COX6A1, marker 3581), cytochrome c oxidase subunit VIa polypeptide 2 (COX6A2, marker 3582), cytochrome c oxidase subunit VIb polypeptide 2 (testis) (COX6B2, marker 3583), cytochrome c oxidase subunit VIc pseudogene 2 (COX6CP2, marker 3584), cytochrome c oxidase subunit VIIb2 (COX7B2, marker 3585), cytochrome c oxidase subunit VIIIC (COX8C, marker 3586), ceruloplasmin (ferroxidase) (CP, marker 3587), ceruloplasmin (ferroxidase) (CP, marker 3588), ceruloplasmin (ferroxidase) (CP, marker 3589), ceruloplasmin (ferroxidase) (CP, marker 3590), carboxypeptidase A1 (pancreatic) (CPA1, marker 3591), carboxypeptidase A2 (pancreatic) (CPA2, marker 3592), carboxypeptidase A3 (mast cell) (CPA3, marker 3593), carboxypeptidase A5 (CPA5, marker 3594), carboxypeptidase A6 (CPA6, marker 3595), carboxypeptidase A6 (CPA6, marker 3596), carboxypeptidase B1 (tissue) (CPB1, marker 3597), carboxypeptidase B2 (plasma) (CPB2, marker 3598), carboxypeptidase D (CPD, marker 3599), CPEB1 antisense RNA 1 (CPEB1-AS1,CPEB1 antisense RNA 1 (CPEB1-AS1, marker 3601), cytoplasmic polyadenylation element binding protein 2 (CPEB2, marker 3602), cytoplasmic polyadenylation element binding protein 2 (CPEB2, marker 3603), CPEB2 antisense RNA 1 (head to head) (CPEB2-AS1, marker 3604), cytoplasmic polyadenylation element binding protein 3 (CPEB3, marker 3605), cytoplasmic polyadenylation element binding protein 3 (CPEB3, marker 3606), cytoplasmic polyadenylation element binding protein 3 (CPEB3, marker 3607), cytoplasmic polyadenylation element binding protein 3 (CPEB3, marker 3608), cytoplasmic polyadenylation element binding protein 4 (CPEB4, marker 3609), cadherin-like and PC-esterase domain containing 1 (CPED1, marker 3610), cadherin-like and PC-esterase domain containing 1 (CPED1, marker 3611), complexin 1 (CPLX1, marker 3612), complexin 2 (CPLX2, marker 3613), complexin 2 (CPLX2, marker 3614), complexin 3 (CPLX3, marker 3615), complexin 3 (CPLX3, marker 3616), carboxypeptidase M (CPM, marker 3617), carboxypeptidase M (CPM, marker 3618), carboxypeptidase M (CPM, marker 3619), carboxypeptidase M (CPM,marker 3620), carboxypeptidase M (CPM, marker 3621), carboxypeptidase M (CPM, marker 3622), carboxypeptidase N, polypeptide 2 (CPN2, marker 3623), copine IV (CPNE4, marker 3624), copine V (CPNE5, marker 3625), copine V / / / uncharacterized LOC100131043 (CPNE5 / / / LOC100131043, marker 3626), copine VI (neuronal) (CPNE6, marker 3627), copine VI (neuronal) (CPNE6, marker 3628), copine VII (CPNE7, marker 3629), copine VIII (CPNE8, marker 3630), copine VIII (CPNE8, marker 3631), carboxypeptidase O (CPO, marker 3632), carboxypeptidase Q (CPQ, marker 3633), carboxypeptidase Q (CPQ, marker 3634), CPS1 intronic transcript 1 (CPS1-IT1, marker 3635), carnitine palmitoyltransferase 1A (liver) (CPT1A, marker 3636), CPX chromosome region, candidate 1 (CPXCR1, marker 3637), CPX chromosome region, candidate 1 (CPXCR1, marker 3638), carboxypeptidase X (M14 family), member 2 (CPXM2, marker 3639), complement component (3b / 4b) receptor 1 (Knops blood group) (CR1, marker 3640), complement component (3b / 4b) receptor 1 (Knops blood group) (CR1, marker 3641), complement component (3b / 4b) receptor 1 (Knops blood group) (CR1, marker 3642),Complement component (3b / 4b) receptor 1 (Knops blood group) (CR1, marker 3643), complement component (3b / 4b) receptor 1 (Knops blood group) (CR1, marker 3644), complement component (3d / Epstein-Barr virus) receptor 2 (CR2, marker 3645), cellular retinoic acid binding protein 1 (CRABP1, marker 3646), calcium release activated channel regulator 2A (CRACR2A, marker 3647), calcium release activated channel regulator 2A (CRACR2A, marker 3648), calcium release activated channel regulator 2A (CRACR2A, marker 3649), cramped chromatin regulator homolog 1 (CRAMP1, marker 3650), carnitine O-acetyltransferase (CRAT, marker 3651), cervical cancer-associated transcript 37 (CRAT37, marker 3652), crumbs family member 1, photoreceptor morphogenesis associated (CRB1, marker 3653), crumbs family member 1, photoreceptor morphogenesis associated (CRB1, marker 3654), crumbs family member 2 (CRB2, marker 3655), cysteine-rich C-terminal 1 (CRCT1, marker 3656), cAMP-responsive element binding protein 3-like 1 (CREB3L1, marker 3657), cAMP-responsive element binding protein 3-like 2 (CREB3L2, marker 3658),cAMP responsive element binding protein 3-like 3 (CREB3L3, marker 3659), cAMP responsive element binding protein 5 (CREB5, marker 3660), CREB binding protein (CREBBP, marker 3661), CREB3 regulatory factor (CREBRF, marker 3662), CREB / ATF bZIP transcription factor (CREBZF, marker 3663), CREB / ATF bZIP transcription factor (CREBZF, marker 3664), cellular repressor of E1A-stimulated genes 2 (CREG2, marker 3665), cellular repressor of E1A-stimulated genes 2 (CREG2, marker 3666), cAMP responsive element modulator (CREM, marker 3667), corticotropin releasing hormone (CRH, marker 3668), corticotropin releasing hormone (CRH, marker 3669), corticotropin releasing hormone binding protein (CRHBP, marker 3670), corticotropin releasing hormone receptor 1 / / / MGC57346-CRHR1 readthrough (CRHR1 / / / MGC57346-CRHR1, marker 3671), corticotropin releasing hormone receptor 1 / / / MGC57346-CRHR1 readthrough (CRHR1 / / / MGC57346-CRHR1, marker 3672), corticotropin releasing hormone receptor 1 / / / MGC57346-CRHR1 readthrough (CRHR1 / / / MGC57346-CRHR1, marker 3673),CRHR1 intronic transcript 1 / / / ADP-ribosylation factor pseudogene (CRHR1-IT1 / / / MGC57346, marker 3674), CRHR1 intronic transcript 1 / / / ADP-ribosylation factor pseudogene (CRHR1-IT1 / / / MGC57346, marker 3675), corticotropin releasing hormone receptor 2 (CRHR2, marker 3676), corticotropin releasing hormone receptor 2 (CRHR2, marker 3677), cysteine-rich protein 1 (intestinal) (CRIP1, marker 3678), cysteine-rich protein 2 (CRIP2, marker 3679), cysteine-rich secretory protein 1 (CRISP1, marker 3680), cysteine-rich secretory protein 1 (CRISP1, marker 3681), cysteine-rich secretory protein 2 (CRISP2, marker 3682), cysteine-rich secretory protein 3 (CRISP3, marker 3683), cysteine-rich secretory protein LCCL d, omain containing 2 (CRISPLD2, marker 3684), cytokine receptor-like factor 2 (CRLF2, marker 3685), cardiolipin synthase 1 (CRLS1, marker 3686), cornulin (CRNN, marker 3687), ciliary rootlet coiled-coil, rootletin (CROCC, marker 3688), ciliary rootlet coiled-coil, rootletin pseudogene 2 (CROCCP2, marker 3689), ciliary rootlet coiled-coil, rootletin pseudogene 3 (CROCCP3, marker 3690), ciliary rootlet coiled-coil, rootletin pseudogene 3 (CROCCP3, marker 3691), carnitine O-octanoyltransferase (CROT, marker 3692), C-reactive protein, pentraxin-related protein (CRP, marker 3693), C-reactive protein, pentraxin-related protein (CRP, marker 3694), cartilage acidic protein 1 (CRTAC1, marker 3695), cartilage acidic protein 1 (CRTAC1, marker 3696), cytotoxic and regulatory T-cell molecule (CRTAM, marker 3697), CREB regulated transcription coactivator 1 (CRTC1, marker 3698), CREB regulated transcription coactivator 3 (CRTC3, marker 3699), cone-rod homeobox (CRX, marker 3700), cone-rod homeobox (CRX, marker 3701), crystallin alpha A / / / alpha-crystallin A chain (CRYAA / / / LOC102724652, marker 3702), crystallin beta A1 (CRYBA1,marker 3703), crystallin beta A2 (CRYBA2, marker 3704), crystallin beta A4 (CRYBA4, marker 3705), crystallin beta B1 (CRYBB1, marker 3706), crystallin beta B2 (CRYBB2, marker 3707), crystallin beta B2 pseudogene 1 / / / uncharacterized LOC105372965 (CRYBB2P1 / / / LOC105372965, marker 3708), crystallin beta B3 (CRYBB3, marker 3709), crystallin gamma A (CRYGA, marker 3710), crystallin gamma B (CRYGB, marker 3711), crystallin gamma C (CRYGC, marker 3712), crystallin gamma N (CRYGN, marker 3713), crystallin gamma S (CRYGS, marker 3714), crystallin gamma S (CRYGS, marker 3715), crystallin lambda 1 (CRYL1, marker 3716), crystallin zeta like 1 (CRYZL1, marker 3717), cysteine ​​sulfinic acid decarboxylase (CSAD, marker 3718), cysteine ​​sulfinic acid decarboxylase (CSAD, marker 3719), CSAG family, member 3 (CSAG3, marker 3720), colony stimulating factor 1 (macrophage) (CSF1, marker 3721), colony stimulating factor 1 (macrophage) (CSF1, marker 3722), colony stimulating factor 1 (macrophage) (CSF1, marker 3723), colony stimulating factor 1 receptor (CSF1R, marker 3724), colony stimulating factor 2 (granulocyte-macrophage) (CSF2,Colony stimulating factor 2 (granulocyte-macrophage) (CSF2, marker 3726), colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA, marker 3727), colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA, marker 3728), colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA, marker 3729), colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB, marker 3730), colony stimulating factor 3 (CSF3, marker 3731), colony stimulating factor 3 receptor (CSF3R, marker 3732), chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1, marker 3733), chondroitin sulfate N-acetylgalactosaminyltransferase 2 (CSGALNACT2, marker 3734), chorionic somatomammotropin hormone 1 (placental lactogen) (CSH1, marker 3735), chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone 2 / / / chorionic somatomammotropin hormone-like 1(CSH1 / / / CSH2 / / / CSHL1, marker 3736),chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone-like 1(CSH1 / / / CSHL1,マーカー3737),chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone-like 1(CSH1 / / / CSHL1,マーカー3738),chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone-like 1(CSH1 / / / CSHL1,マーカー3739),chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone-like 1 / / / growth hormone 1 / / / growth hormone 2(CSH1 / / / CSHL1 / / / GH1 / / / GH2,マーカー3740),chorionic somatomammotropin hormone 1 (placental lactogen) / / / chorionic somatomammotropin hormone-like 1 / / / growth hormone 1 / / / growth hormone 2(CSH1 / / / CSHL1 / / / GH1 / / / GH2,マーカー3741),chorionic somatomammotropin hormone 2(CSH2,マーカー3742),chorionic somatomammotropin hormone 2(CSH2,マーカー3743),chorionic somatomammotropin hormone 2(CSH2,マーカー3744),chorionic somatomammotropin hormone 2(CSH2,マーカー3745),chorionic somatomammotropin hormone-like 1 (CSHL1, marker 3746), chorionic somatomammotropin hormone-like 1 (CSHL1, marker 3747), chorionic somatomammotropin hormone-like 1 (CSHL1, marker 3748), chorionic somatomammotropin hormone-like 1 (CSHL1, marker 3749), chorionic somatomammotropin hormone-like 1 (CSHL1, marker 3750), CUB and Sushi multiple domains 1 (CSMD1, marker 3751), CUB and Sushi multiple domains 1 (CSMD1, marker 3752), CUB and Sushi multiple domains 1 (CSMD1, marker 3753), CUB and Sushi multiple domains 1 (CSMD1, marker 3754), CUB and Sushi multiple domains 1 (CSMD1, marker 3755), CUB and Sushi multiple domains 2 (CSMD2, marker 3756), CUB and Sushi multiple domains 2 (CSMD2, marker 3757), CSMD2 antisense RNA 1 (CSMD2-AS1, marker 3758), CUB and Sushi multiple domains 3 (CSMD3, marker 3759), casein alpha s1 (CSN1S1, marker 3760), casein alpha s2-like A, pseudogene (CSN1S2AP, marker 3761), casein beta (CSN2, marker 3762), casein kappa (CSN3, marker 3763), casein kinase 1, alpha 1 (CSNK1A1, marker 3764), casein kinase 1, alpha 1 pseudogene 1 (CSNK1A1P1, marker 3765), casein kinase 1,delta (CSNK1D, marker 3766), casein kinase 1, epsilon / / / TPTE and PTEN homologous inositol lipid phosphatase pseudogene / / / LOC400927-CSNK1E readthrough (CSNK1E / / / LOC400927 / / / LOC400927-CSNK1E, marker 3767), casein kinase 1, gamma 1 (CSNK1G1, marker 3768), CSNK1G2 antisense RNA 1 (CSNK1G2-AS1, marker 3769), casein kinase 1, gamma 3 (CSNK1G3, marker 3770), chondroitin sulfate proteoglycan 4 (CSPG4, marker 3771), chondroitin sulfate proteoglycan 4 (CSPG4, marker 3772), chondroitin sulfate proteoglycan 4 pseudogene 1, Y-linked (CSPG4P1Y, marker 3773), chondroitin sulfate proteoglycan 4 pseudogene 5 (CSPG4P5, marker 3774), centrosome and spindle pole associated protein 1 (CSPP1, marker 3775), cysteine-serine-rich nuclear protein 3 (CSRNP3, marker 3776), cysteine-serine-rich nuclear protein 3 (CSRNP3, marker 3777), cysteine-serine-rich nuclear protein 3 (CSRNP3, marker 3778), cysteine-serine-rich nuclear protein 3 (CSRNP3, marker 3779), cysteine ​​and glycine-rich protein 3 (cardiac LIM protein) (CSRP3, marker 3780), cystatin 11 (CST11, marker 3781), cystatin 11 (CST11, marker 3782),Cystatin 13, pseudogene (CST13P, marker 3783), cystatin C (CST3, marker 3784), cystatin C (CST3, marker 3785), cystatin D (CST5, marker 3786), cystatin E / M (CST6, marker 3787), cystatin F (leukocystatin) (CST7, marker 3788), cystatin 8 (cystatin-related epididymal specific) (CST8, marker 3789), cystatin 9 (testatin) (CST9, marker 3790), cystatin 9-like (CST9L, marker 3791), cystatin A (stefin A) (CSTA, marker 3792), cystatin B (stefin B) (CSTB, marker 3793), CSTF3 antisense RNA 1 (head to head) (CSTF3-AS1, marker 3794), cystatin-like 1(CSTL1, marker 3795), cancer / testis antigen family 45, member A1 / / / cancer / testis antigen family 45, member A10 / / / cancer / testis antigen family 45, member A2 / / / cancer / testis antigen family 45, member A3 / / / cancer / testis antigen family 45, member A4 / / / cancer / testis antigen family 45, member A5 / / / cancer / testis antigen family 45, member A6 / / / cancer / testis antigen family 45, member A7 / / / cancer / testis antigen family 45, member A8 / / / cancer / testis antigen family 45,member A9(CT45A1 / / / CT45A10 / / / CT45A2 / / / CT45A3 / / / CT45A4 / / / CT45A5 / / / CT45A6 / / / CT45A7 / / / CT45A8 / / / CT45A9,マーカー3796),cancer / testis antigen family 45, member A1 / / / cancer / testis antigen family 45, member A10 / / / cancer / testis antigen family 45, member A2 / / / cancer / testis antigen family 45, member A3 / / / cancer / testis antigen family 45, member A4 / / / cancer / testis antigen family 45, member A5 / / / cancer / testis antigen family 45, member A6 / / / cancer / testis antigen family 45, member A7 / / / cancer / testis antigen family 45, member A8 / / / cancer / testis antigen family 45, member A9(CT45A1 / / / CT45A10 / / / CT45A2 / / / CT45A3 / / / CT45A4 / / / CT45A5 / / / CT45A6 / / / CT45A7 / / / CT45A8 / / / CT45A9,マーカー3797),cancer / testis antigen family 47, member A1 / / / cancer / testis antigen family 47, member A10 / / / cancer / testis antigen family 47, member A11 / / / cancer / testis antigen family 47, member A12 / / / cancer / testis antigen family 47, member A2 / / / cancer / testis antigen family 47,member A3 / / / cancer / testis antigen family 47, member A4 / / / cancer / testis antigen family 47, member A5 / / / cancer / testis antigen family 47, member A6 / / / cancer / testis antigen family 47, member A7 / / / cancer / testis antigen family 47, member A8 / / / cancer / testis antigen family 47, member A9(CT47A1 / / / CT47A10 / / / CT47A11 / / / CT47A12 / / / CT47A2 / / / CT47A3 / / / CT47A4 / / / CT47A5 / / / CT47A6 / / / CT47A7 / / / CT47A8 / / / CT47A9, marker 3798), cancer / testis antigen 55 (CT55, marker 3799), cancer / testis antigen 62 (CT62, marker 3800), cancer / testis antigen 83 (CT83, marker 3801), cancer / testis antigen 1A / / / cancer / testis antigen 1B (CTAG1A / / / CTAG1B, marker 3802), cancer / testis antigen 1A / / / cancer / testis antigen 1B (CTAG1A / / / CTAG1B, marker 3803), cancer / testis antigen 1A / / / cancer / testis antigen 1B (CTAG1A / / / CTAG1B, marker 3804), cancer / testis antigen 2 (CTAG2, marker 3805), cancer / testis antigen 2 (CTAG2, marker 3806), cutaneous T-cell lymphoma-associated antigen 1 (CTAGE1, marker 3807), CTAGE family, member 11, pseudogene (CTAGE11P, marker 3808),CTAGE family, member 5 (CTAGE5, marker 3809), CTAGE family, member 5 (CTAGE5, marker 3810), uncharacterized LOC101927096 (CTB-113P19.1, marker 3811), uncharacterized LOC101927115 (CTB-12O2.1, marker 3812), uncharacterized LOC101927115 (CTB-12O2.1, marker 3813), uncharacterized LOC105379181 (CTB-49A3.2, marker 3814), C-terminal binding protein 1 / / / uncharacterized LOC101928588 (CTBP1 / / / LOC101928588, marker 3815), CTBP1 antisense RNA (CTBP1-AS, marker 3816), CTBP1 antisense RNA 2 (head to head) (CTBP1-AS2, marker 3817), C-terminal binding protein 2 (CTBP2, marker 3818), CTS telomere maintenance complex component 1 (CTC1, marker 3819), CTS telomere maintenance complex component 1 (CTC1, marker 3820), CCCTC-binding factor (zinc finger protein)-like (CTCFL, marker 3821), uncharacterized LOC101929081 (CTD-2194D22.4, marker 3822), uncharacterized LOC101929176 (CTD-2297D10.2, marker 3823), un, characterized LOC101929472 (CTD-2350J17.1, marker 3824), uncharacterized LOC101928857 (CTD-3080P12.3, marker 3825), cardiotrophin 1 (CTF1, marker 3826), CBP80 / 20-dependent translation initiation factor (CTIF, marker 3827), cytotoxic T-lymphocyte-associated protein 4 (CTLA4, marker 3828), cytotoxic T-lymphocyte-associated protein 4 (CTLA4, marker 3829), cytotoxic T-lymphocyte-associated protein 4 (CTLA4, marker 3830), cytotoxic T-lymphocyte-associated protein 4 (CTLA4, marker 3831), cytotoxic T-lymphocyte-associated protein 4 (CTLA4, marker 3832), catenin (cadherin-associated protein), alpha 3 (CTNNA3, marker 3833), catenin (cadherin-associated protein), alpha 3 (CTNNA3, marker 3834), catenin (cadherin-associated protein), alpha 3 (CTNNA3, marker 3835), catenin (cadherin-associated protein), alpha 3 (CTNNA3, marker 3836), catenin (cadherin-associated protein), delta 2 (CTNND2, marker 3837), cystinosin, lysosomal cystine transporter (CTNS, marker 3838), chymotrypsinogen B1 / / / chymotrypsinogen B2 (CTRB1 / / / CTRB2, marker 3839), chymotrypsinogen B2 (CTRB2, marker 3840),chymotrypsin C (caldecrin) (CTRC, marker 3841), chymotrypsin-like (CTRL, marker 3842), cathepsin F (CTSF, marker 3843), cathepsin G (CTSG, marker 3844), cathepsin L pseudogene 8 (CTSLP8, marker 3845), cathepsin S (CTSS, marker 3846), cathepsin S (CTSS, marker 3847), cathepsin S (CTSS, marker 3848), cathepsin W (CTSW, marker 3849), cathepsin Z (CTSZ, marker 3850), cortactin (CTTN, marker 3851), cytosolic thiouridylase subunit 2 homolog (S. pombe) (CTU2, marker 3852), cytosolic thiouridylase subunit 2 homolog (S. pombe) (CTU2, marker 3853), cytosolic thiouridylase subunit 2 homolog (S. pombe) (CTU2, marker 3854), cortexin 3 (CTXN3, marker 3855), cortexin 3 (CTXN3, marker 3856), cubilin (intrinsic factor-cobalamin receptor) (CUBN, marker 3857), CUE domain containing 1 (CUEDC1, marker 3858), cullin 3 (CUL3, marker 3859), cullin 4A (CUL4A, marker 3860), cullin 5 (CUL5, marker 3861), cullin 7 (CUL7, marker 3862), cullin 9 (CUL9, marker 3863), cullin 9 (CUL9, marker 3864), cut-like homeobox 2 (CUX2, marker 3865), CWF19-like 2, cell cycle control (S. pombe) (CWF19L2, marker 3866), CWF19-like 2, cell cycle control (S. pombe) (CWF19L2, marker 3867),Cell wall biogenesis 43 C-terminal homolog (CWH43, marker 3868), cell wall biogenesis 43 C-terminal homolog (CWH43, marker 3869), chemokine (C-X3-C motif) ligand 1 (CX3CL1, marker 3870), chemokine (C-X3-C motif) ligand 1 (CX3CL1, marker 3871), chemokine (C-X3-C motif) receptor 1 (CX3CR1, marker 3872), chemokine (C-X3-C motif) receptor 1 (CX3CR1, marker 3873), chemokine (CXC motif) ligand 10 (CXCL10, marker 3874), chemokine (CXC motif) ligand 11 (CXCL11, marker 3875), chemokine (CXC motif) ligand 11 (CXCL11, marker 3876), chemokine (CXC motif) ligand 13 (CXCL13, marker 3877), chemokine (CXC motif) ligand 14 (CXCL14, marker 3878), chemokine (CXC motif) ligand 17 (CXCL17, marker 3879), chemokine (CXC motif) ligand 2 (CXCL2, marker 3880), chemokine (CXC motif) ligand 2 (CXCL2, marker 3881), chemokine (CXC motif) ligand 5 (CXCL5, marker 3882), chemokine (CXC motif) ligand 8 (CXCL8, marker 3883), chemokine (CXC motif) ligand 8 (CXCL8, marker 3884), chemokine (CXC motif) ligand 9 (CXCL9, marker 3885), chemokine (CXC motif) receptor 1 (CXCR1, marker 3886),chemokine (CXC motif) receptor 2 (CXCR2, marker 3887), chemokine (CXC motif) receptor 3 (CXCR3, marker 3888), chemokine (CXC motif) receptor 3 (CXCR3, marker 3889), chemokine (CXC motif) receptor 5 (CXCR5, marker 3890), chemokine (CXC motif) receptor 5 (CXCR5, marker 3891), chemokine (CXC motif) receptor 6 (CXCR6, marker 3892), chemokine (CXC motif) receptor 6 (CXCR6, marker 3893), CXXC finger protein 1 pseudogene 1 (CXXC1P1, marker 3894), chromosome X open reading frame 21 (CXorf21, marker 3895), chromosome X open reading frame 36 (CXorf36, marker 3896), chromosome X open reading frame 36(CXorf36, marker 3897),chromosome X open reading frame 36(CXorf36,marker 3898),chromosome X open reading frame 36(CXorf36,marker 3899),chromosome CXorf40B / / / LOC642980, marker 3900), chromosome X open reading frame 51A / / / chromosome X open reading frame 51B(CXorf51A / / / CXorf51B, marker 3901), chromosome X open reading frame 56(CXorf56, marker 3902),Chromosome X Open Reading Frame 57(CXorf57,Dimer3903),Chromosome X Open Reading Frame 58(CXorf58,Dimer3904),Chromosome X Open Reading Frame 65(CXorf65,Dimer3905),Chromosome X Open Reading Frame 67(CXorf67,マーカー3906),immunoglobulin lambda light chain-like / / / immunoglobulin lambda constant 1 (Mcg marker) / / / immunoglobulin lambda constant 2 (Kern-Oz- marker) / / / immunoglobulin lambda constant 3 (Kern-Oz+ marker) / / / immunoglobulin lambda constant 7 / / / immunoglobulin lambda joining 3 / / / immunoglobulin lambda-like polypeptide 5 / / / immunoglobulin lambda variable 1-44 / / / immunoglobulin lambda variable 3-25 / / / immunoglobulin lambda variable 4-3(CYAT1 / / / IGLC1 / / / IGLC2 / / / IGLC3 / / / IGLC7 / / / IGLJ3 / / / IGLL5 / / / IGLV1-44 / / / IGLV3-25 / / / IGLV4-3,Dictionary 3907),immunoglobulin lambda light chain-like / / / immunoglobulin lambda constant 1 (Mcg marker) / / / immunoglobulin lambda constant 2 (Kern-Oz- marker) / / / immunoglobulin lambda constant 3 (Kern-Oz+ marker) / / / immunoglobulin lambda constant 7 / / / immunoglobulin lambda joining 3 / / / immunoglobulin lambda-like polypeptide 5 / / / immunoglobulin lambda variable 1-44 / / / immunoglobulin lambda variable 3-25 / / / immunoglobulin lambda variable 4-3 / / / immunoglobulin lambda variable 7-43(CYAT1 / / / IGLC1 / / / IGLC2 / / / IGLC3 / / / IGLC7 / / / IGLJ3 / / / IGLL5 / / / IGLV1-44 / / / IGLV3-25 / / / IGLV4-3 / / / IGLV7-43,マーカー3908),immunoglobulin lambda light chain-like / / / immunoglobulin lambda constant 1 (Mcg marker) / / / immunoglobulin lambda constant 2 (Kern-Oz- marker) / / / immunoglobulin lambda constant 3 (Kern-Oz+ marker) / / / immunoglobulin lambda joining 3 / / / immunoglobulin lambda variable 1-44 / / / immunoglobulin lambda variable 3-25 / / / immunoglobulin lambda variable 4-3(CYAT1 / / / IGLC1 / / / IGLC2 / / / IGLC3 / / / IGLJ3 / / / IGLV1-44 / / / IGLV3-25 / / / IGLV4-3,マーカー3909),immunoglobulin lambda light chain-like / / / immunoglobulin lambda constant 1 (Mcg marker) / / / immunoglobulin lambda constant 2 (Kern-Oz- marker) / / / immunoglobulin lambda constant 3 (Kern-Oz+ marker) / / / immunoglobulin lambda-like polypeptide 5 / / / immunoglobulin lambda variable 1-44 / / / immunoglobulin lambda variable 3-25 / / / immunoglobulin lambda variable 4-3(CYAT1 / / / IGLC1 / / / IGLC2 / / / IGLC3 / / / IGLL5 / / / IGLV1-44 / / / IGLV3-25 / / / IGLV4-3,マーカー3910),immunoglobulin lambda light chain-like / / / immunoglobulin lambda-like polypeptide 5 / / / immunoglobulin lambda variable 3-1 (CYAT1 / / / IGLL5 / / / IGLV3-1, marker 3911), cytochrome b561 family, member D2 (CYB561D2, marker 3912), cytochrome b5 type A (microsomal) (CYB5A, marker 3913), cytochrome b5 reductase 1 (CYB5R1, marker 3914), cytochrome b5 reductase 4 (CYB5R4, marker 3915), cytochrome b5 reductase-like (CYB5RL, marker 3916), cytochrome b5 reductase-like (CYB5RL, marker 3917), cytochrome b-245, alpha polypeptide (CYBA, marker 3918), cytochrome b-245, beta polypeptide (CYBB, marker 3919), cytochrome b-245 beta polypeptide (CYBB, marker 3920), cytochrome b-245 beta polypeptide (CYBB, marker 3921), cytochrome b-245 beta polypeptide (CYBB, marker 3922), cytoglobin (CYGB, marker 3923), cylicin, basic protein of sperm head cytoskeleton 1 (CYLC1, marker 3924), cylicin, basic protein of sperm head cytoskeleton 1 (CYLC1, marker 3925), cylicin, basic protein of sperm head cytoskeleton 1 (CYLC1, marker 3926), cylicin, basic protein of sperm head cytoskeleton 2 (CYLC2, marker 3927),Cylindromatosis (turban tumor syndrome) (CYLD, marker 3928), cylindromatosis (turban tumor syndrome) (CYLD, marker 3929), cylindromatosis (turban tumor syndrome) (CYLD, marker 3930), chymosin pseudogene (CYMP, marker 3931), cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1, marker 3932), cytochrome P450, family 11, subfamily B, polypeptide 1 (CYP11B1, marker 3933), cytochrome P450, family 11, subfamily B, polypeptide 1 (CYP11B1, marker 3934), cytochrome P450, family 11, subfamily B, polypeptide 2 (CYP11B2, marker 3935), cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1, marker 3936), cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1, marker 3937), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3938), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3939), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3940), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3941), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1,cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3943), cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1, marker 3944), cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2, marker 3945), cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1, marker 3946), CYP1B1 antisense RNA 1 (CYP1B1-AS1, marker 3947), CYP1B1 antisense RNA 1 (CYP1B1-AS1, marker 3948), cytochrome P450, family 21, subfamily A, polypeptide 1 pseudogene / / / cytochrome P450, family 21, subfamily A, polypeptide 2 (CYP21A1P / / / CYP21A2, marker 3949), cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1, marker 3950), cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1, marker 3951), cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1, marker 3952), cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1, marker 3953), cytochrome P450, family 2, subfamily A, polypeptide 13 (CYP2A13, marker 3954), cytochrome P450, family 2, subfamily A, polypeptide 6 (CYP2A6, marker 3955), cytochrome P450,family 2, subfamily A, polypeptide 6(CYP2A6,マーカー3956),cytochrome P450, family 2, subfamily A, polypeptide 6(CYP2A6,マーカー3957),cytochrome P450, family 2, subfamily A, polypeptide 6(CYP2A6,マーカー3958),cytochrome P450, family 2, subfamily A, polypeptide 7(CYP2A7,マーカー3959),cytochrome P450, family 2, subfamily A, polypeptide 7 / / / cytochrome P450, family 2, subfamily A, polypeptide 7 pseudogene 1(CYP2A7 / / / CYP2A7P1,マーカー3960),cytochrome P450, family 2, subfamily A, polypeptide 7 pseudogene 1(CYP2A7P1,マー, marker 3961), cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6, marker 3962), cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6, marker 3963), cytochrome P450, family 2, subfamily B, polypeptide 7, pseudogene (CYP2B7P, marker 3964), cytochrome P450, family 2, subfamily C, polypeptide 18 (CYP2C18, marker 3965), cytochrome P450, family 2, subfamily C, polypeptide 18 (CYP2C18, marker 3966), cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19, marker 3967), cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8, marker 3968), cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8, marker 3969), cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9, marker 3970), cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9, marker 3971), cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9, marker 3972), cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9, marker 3973), cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9, marker 3974), cytochrome P450, family 2, subfamily C,polypeptide 9(CYP2C9,マーカー3975),cytochrome P450, family 2, subfamily C, polypeptide 9(CYP2C9,マーカー3976),cytochrome P450, family 2, subfamily D, polypeptide 6(CYP2D6,マーカー3977),cytochrome P450, family 2, subfamily D, polypeptide 6 / / / cytochrome P450, family 2, subfamily D, polypeptide 7 (gene / pseudogene) / / / cytochrome P450, family 2, subfamily D, polypeptide 6 pseudogene(CYP2D6 / / / CYP2D7 / / / LOC101929829,マーカー3978),cytochrome P450, family 2, subfamily D, polypeptide 7 (gene / pseudogene)(CYP2D7,マーカー3979),cytochrome P450, family 2, subfamily E, polypeptide 1(CYP2E1,マーカー3980),cytochrome P450, family 2, subfamily E, polypeptide 1(CYP2E1,マーカー3981),cytochrome P450, family 2, subfamily E, polypeptide 1(CYP2E1,マーカー3982),cytochrome P450, family 2, subfamily F, polypeptide 1(CYP2F1,マーカー3983),cytochrome P450, family 2, subfamily J, polypeptide 2(CYP2J2,マーカー3984),cytochrome P450, family 2, subfamily R, polypeptide 1(CYP2R1,マーカー3985),cytochrome P450, family 2, subfamily T, polypeptide 1,Pseudogene (CYP2T1P, marker 3986), cytochrome P450, family 2, subfamily U, polypeptide 1 (CYP2U1, marker 3987), cytochrome P450, family 2, subfamily U, polypeptide 1 (CYP2U1, marker 3988), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1, marker 3989), cytochrome P450, family 39, subfamily A, polypeptide 1 (CYP39A1, marker 3990), cytochrome P450, family 39, subfamily A, polypeptide 1 (CYP39A1, marker 3991), cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4, marker 3992), cytochrome P450, family 3, subfamily A, polypeptide 4(CYP3A4, marker 3993),cytochrome P450, family 3, subfamily A, polypeptide 4(CYP3A4, marker 3994),cytochrome P450, family 3, subfamily A, polypeptide 4(CYP3A4, marker 3995),cytochrome P450, family 3, subfamily A, polypeptide 43(CYP3A43, marker 3996),cytochrome P450, family 3, subfamily A, polypeptide 43(CYP3A43, marker 3997),cytochrome P450, family 3, subfamily A, polypeptide 43(CYP3A43, marker 3998),cytochrome P450, family 3, subfamily A, polypeptide 43(CYP3A43, marker 3999), cytochrome P450, family 3,subfamily A, polypeptide 5(CYP3A5,マーカー4000),cytochrome P450, family 3, subfamily A, polypeptide 5(CYP3A5,マーカー4001),cytochrome P450, family 3, subfamily A, polypeptide 5(CYP3A5,マーカー4002),cytochrome P450, family 3, subfamily A, polypeptide 5(CYP3A5,マーカー4003),cytochrome P450, family 3, subfamily A, polypeptide 7(CYP3A7,マーカー4004),cytochrome P450, family 3, subfamily A, polypeptide 7 / / / CYP3A7-CYP3A51P readthrough(CYP3A7 / / / CYP3A7-CYP3A51P,マーカー4005),CYP3A7-CYP3A51P readthrough(CYP3A7-CYP3A51P,マーカー4006),cytochrome P450, family 46, subfamily A, polypeptide 1(CYP46A1,マーカー4007),cytochrome P450, family 4, subfamily A, polypeptide 11(CYP4A11,マーカー4008),cytochrome P450, family 4, subfamily A, polypeptide 11(CYP4A11,マーカー4009),cytochrome P450, family 4, subfamily A, polypeptide 11(CYP4A11,マーカー4010),cytochrome P450, family 4, subfamily A, polypeptide 11 / / / cytochrome P450, family 4, subfamily A, polypeptide 22(CYP4A11 / / / CYP4A22,マーカー4011),cytochrome P450, family 4, subfamily A,polypeptide 11 / / / cytochrome P450, family 4, subfamily A, polypeptide 22(CYP4A11 / / / CYP4A22,マーカー4012),cytochrome P450, family 4, subfamily B, polypeptide 1(CYP4B1,マーカー4013),cytochrome P450, family 4, subfamily B, polypeptide 1(CYP4B1,マーカー4014),cytochrome P450, family 4, subfamily F, polypeptide 11(CYP4F11,マーカー4015),cytochrome P450, family 4, subfamily F, polypeptide 12(CYP4F12,マーカー4016),cytochrome P450, family 4, subfamily F, polypeptide 2(CYP4F2,マーカー4017),cytochrome P450, family 4, subfamily F, polypeptide 2 / / / cytochrome P450, family 4, subfamily F, polypeptide 3(CYP4F2 / / / CYP4F3,マーカー4018),cytochrome P450, family 4, subfamily F, polypeptide 22(CYP4F22,マーカー4019),cytochrome P450, family 4, subfamily F, polypeptide 29, pseudogene(CYP4F29P,マーカー4020),cytochrome P450, family 4, subfamily F, polypeptide 3(CYP4F3,マーカー4021),cytochrome P450, family 4, subfamily F, polypeptide 30, pseudogene(CYP4F30P,マーカー4022),cytochrome P450, family 4, subfamily F, polypeptide 35, pseudogene(CYP4F35P,cytochrome P450, family 4, subfamily F, polypeptide 8 (CYP4F8, marker 4024), cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2, marker 4025), cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2, marker 4026), cytochrome P450, family 4, subfamily V, polypeptide 2 / / / kallikrein B1 (CYP4V2 / / / KLKB1, marker 4027), cytochrome P450, family 4, subfamily V, polypeptide 2 / / / kallikrein B1 (CYP4V2 / / / KLKB1, marker 4028), cytochrome P450, family 4, subfamily Z, polypeptide 1 (CYP4Z1, marker 4029), cytochrome P450, family 4, subfamily Z, polypeptide 2, pseudogene (CYP4Z2P, marker 4030), CYP51A1 antisense RNA 1 (CYP51A1-AS1, marker 4031), cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1, marker 4032), cytochrome P450, family 7, subfamily B, polypeptide 1 (CYP7B1, marker 4033), cytochrome P450, family 8, subfamily B, polypeptide 1 (CYP8B1, marker 4034), cystin 1 (CYS1, marker 4035), cysteinyl leukotriene receptor 1 (CYSLTR1, marker 4036), cysteinyl leukotriene receptor 1 (CYSLTR1, marker 4037),Cysteinyl leukotriene receptor 1 (CYSLTR1, marker 4038), cysteinyl leukotriene receptor 2 (CYSLTR2, marker 4039), cysteine-rich tail protein 1 (CYSRT1, marker 4040), cytohesin 1 (CYTH1, marker 4041), cytohesin 2 (CYTH2, marker 4042), cytohesin 3 (CYTH3, marker 4043), cytohesin 3 (CYTH3, marker 4044), cytohesin 3 (CYTH3, marker 4045), cytohesin 4 (CYTH4, marker 4046), cytohesin 4 (CYTH4, marker 4047), cytohesin 4 (CYTH4, marker 4048), cytohesin 1 interacting protein (CYTIP, marker 4049), D21S2088E (D21S2088E, marker 4050), D21S2088E (D21S2088E, marker 4051), uncharacterized D21S2090E (D21S2090E, marker 4052), disheveled associated activator of morphogenesis 1 (DAAM1, marker 4053), disheveled associated activator of morphogenesis 2 (DAAM2, marker 4054), Dab, reelin signal transducer, homolog 1 (Drosophila) (DAB1, marker 4055), DAB1 antisense RNA 1 (DAB1-AS1, marker 4056), Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) (DAB2, marker 4057), Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)(DAB2, marker 4058),Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)(DAB2,Marker 4059), DAB2 interacting protein (DAB2IP, marker 4060), DAB2 interacting protein (DAB2IP, marker 4061), disheveled-binding antagonist of beta-catenin 2 (DACT2, marker 4062), disheveled-binding antagonist of beta-catenin 3 (DACT3, marker 4063), DACT3 antisense RNA 1 (DACT3-AS1, marker 4064), diacylglycerol lipase, alpha (DAGLA, marker 4065), DAN domain family member 5, BMP antagonist (DAND5, marker 4066), D-amino-acid oxidase (DAO, marker 4067), D-amino acid oxidase activator (DAOA, marker 4068), D-amino acid oxidase activator (DAOA, marker 4069), DAOA antisense RNA 1 (DAOA-AS1, marker 4070), death associated protein 3 (DAP3, marker 4071), death-associated protein kinase 2 (DAPK2, marker 4072), death-associated protein kinase 2 (DAPK2, marker 4073), death-associated protein kinase 3 (DAPK3, marker 4074), death associated protein like 1 (DAPL1, marker 4075), dual adaptor of phosphotyrosine and 3-phosphoinositides (DAPP1, marker 4076), dual adaptor of phosphotyrosine and 3-phosphoinositides (DAPP1, marker 4077), dual adaptor of phosphotyrosine and 3-phosphoinositides (DAPP1, marker 4078),dual adapter of phosphotyrosine and 3-phosphoinositides (DAPP1, dimer 4079), DARS antisense RNA 1 (DARS-AS1, dimer 4080), dynein assembly factor with WDR repeat domains 1 (DAW1, dimer 4081), deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4082),deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4(DAZ1 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4083),deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4(DAZ1 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4084),deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4(DAZ1 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4085),deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4(DAZ1 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4086),deleted in azoospermia 1 / / / deleted in azoospermia 2 / / / deleted in azoospermia 3 / / / deleted in azoospermia 4(DAZ1 / / / DAZ2 / / / DAZ3 / / / DAZ4,マーカー4087),DAZ associated protein 2(DAZAP2,マーカー4088),D4Z4 binding element transcript (non-protein coding) / / / double homeobox 3 / / / double homeobox 4 / / / double homeobox 4 like 1 / / / double homeobox 4 like 10 / / / double homeobox 4 like 11 / / / double homeobox 4 like 12 / / / double homeobox 4 like 13 / / / double homeobox 4 like 14 / / / double homeobox 4 like 15 / / / double homeobox 4 like 2 / / / double homeobox 4 like 20 / / / double homeobox 4 like 21 / / / double homeobox 4 like 22 / / / double homeobox 4 like 23 / / / double homeobox 4 like 24 / / / double homeobox 4 like 25 / / / double homeobox 4 like 3 / / / double homeobox 4 like 4 / / / double homeobox 4 like 5 / / / double homeobox 4 like 6 / / / double homeobox 4 like 7 / / / double homeobox 4 like 8 / / / dou, ble homeobox protein 4-like protein 4(DBET / / / DUX3 / / / DUX4 / / / DUX4L1 / / / DUX4L10 / / / DUX4L11 / / / DUX4L12 / / / DUX4L13 / / / DUX4L14 / / / DUX4L15 / / / DUX4L2 / / / DUX4L20 / / / DUX4L21 / / / DUX4L22 / / / DUX4L23 / / / DUX4L24 / / / DUX4L25 / / / DUX4L3 / / / DUX4L4 / / / DUX4L5 / / / DUX4L6 / / / DUX4L7 / / / DUX4L8 / / / LOC100287823,4089),D4Z4 binding element transcript (non-protein coding) / / / double homeobox 4 / / / double homeobox 4 like 1 / / / double homeobox 4 like 10 / / / double homeobox 4 like 11 / / / double homeobox 4 like 12 / / / double homeobox 4 like 13 / / / double homeobox 4 like 14 / / / double homeobox 4 like 15 / / / double homeobox 4 like 2 / / / double homeobox 4 like 20 / / / double homeobox 4 like 21 / / / double homeobox 4 like 22 / / / double homeobox 4 like 23 / / / double homeobox 4 like 24 / / / double homeobox 4 like 25 / / / double homeobox 4 like 3 / / / double homeobox 4 like 4 / / / double homeobox 4 like 5 / / / double homeobox 4 like 6 / / / double homeobox 4 like 7 / / / double homeobox 4 like 8(DBET / / / DUX4 / / / DUX4L1 / / / DUX4L10 / / / DUX4L11 / / / DUX4L12 / / / DUX4L13 / / / DUX4L14 / / / DUX4L15 / / / DUX4L2 / / / DUX4L20 / / / DUX4L21 / / / DUX4L22 / / / DUX4L23 / / / DUX4L24 / / / DUX4L25 / / / DUX4L3 / / / DUX4L4 / / / DUX4L5 / / / DUX4L6 / / / DUX4L7 / / / DUX4L8,マーカー4090),DBF4 zinc finger B(DBF4B,マーカー4091),DBF4 zinc finger B(DBF4B,マーカー4092),dopamine beta-hydroxylase (dopamine beta-monooxygenase) (DBH, marker 4093), dopamine beta-hydroxylase (dopamine beta-monooxygenase) (DBH, marker 4094), DBH antisense RNA 1 (DBH-AS1, marker 4095), diazepam binding inhibitor-like 5 pseudogene (DBIL5P, marker 4096), diazepam binding inhibitor-like 5 pseudogene 2 (DBIL5P2, marker 4097), D site of albumin promoter (albumin D-box) binding protein (DBP, marker 4098), dihydrolipoamide branched chain transacylase E2 (DBT, marker 4099), DDB1 and CUL4 associated factor 13 (DCAF13, marker 4100), DDB1 and CUL4 associated factor 13 (DCAF13, marker 4101), DDB1 and CUL4 associated factor 15 (DCAF15, marker 4102), DDB1 and CUL4 associated factor 16 (DCAF16, marker 4103), DDB1 and CUL4 associated factor 4 (DCAF4, marker 4104), DDB1 and CUL4 associated factor 4-like 1 (DCAF4L1, marker 4105), DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2, marker 4106), DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2, marker 4107), DDB1 and CUL4 associated factor 5 (DCAF5, marker 4108), DDB1 and CUL4 associated factor 6 (DCAF6, marker 4109),DDB1 and CUL4 associated factor 7 (DCAF7, marker 4110), DDB1 and CUL4 associated factor 7 (DCAF7, marker 4111), DDB1 and CUL4 associated factor 8 (DCAF8, marker 4112), DDB1 and CUL4 associated factor 8 (DCAF8, marker 4113), DDB1 and CUL4 associated factor 8 (DCAF8, marker 4114), DDB1 and CUL4 associated factor 8 (DCAF8, marker 4115), DDB1 and CUL4 associated factor 8 (DCAF8, marker 4116), DDB1 and CUL4 associated factor 8-like 2 / / / uncharacterized locus FLJ32742 (DCAF8L2 / / / FLJ32742, marker 4117), dephospho-CoA kinase domain containing (DCAKD, marker 4118), dendritic cell-associated nuclear protein / / / TRAF-interacting protein with Forkhead-associated domain, family member B (DCANP1 / / / TIFAB, marker 4119), discoidin, CUB and LCCL domain containing 2 (DCBLD2, marker 4120), DCC netrin 1 receptor (DCC, marker 4121), DCC netrin 1 receptor (DCC, marker 4122), dermcidin (DCD, marker 4123), doublecortin domain containing 1 / / / doublecortin domain containing 5 (DCDC1 / / / DCDC5, marker 4124), doublecortin domain containing 2 (DCDC2, marker 4125),doublecortin domain containing 2B (DCDC2B, marker 4126), dachsous cadherin-related 1 (DCHS1, marker 4127), dachsous cadherin-related 2 (DCHS2, marker 4128), dachsous cadherin-related 2 (DCHS2, marker 4129), doublecortin-like kinase 1 (DCLK1, marker 4130), doublecortin-like kinase 1 (DCLK1, marker 4131), doublecortin-like kinase 2 (DCLK2, marker 4132), doublecortin-like kinase 2 (DCLK2, marker 4133), doublecortin-like kinase 2 (DCLK2, marker 4134), doublecortin-like kinase 3 (DCLK3, marker 4135), DNA cross-link repair 1C (DCLRE1C, marker 4136), DNA cross-link repair 1C (DCLRE1C, marker 4137), decorin (DCN, marker 4138), decorin (DCN, marker 4139), decorin (DCN, marker 4140), decorin (DCN, marker 4141), decorin / / / uncharacterized LOC101928584 (DCN / / / LOC101928584, marker 4142), decorin / / / uncharacterized LOC101928584 (DCN / / / LOC101928584, marker 4143), DC-STAMP domain containing 1 (DCST1, marker 4144), DC-STAMP domain containing 2 (DCST2, marker 4145), dendrocyte expressed seven transmembrane protein (DCSTAMP, marker 4146), dopachrome tautomerase (DCT, marker 4147), dopachrome tautomerase (DCT, marker 4148),dopachrome tautomerase (DCT, marker 4149), dopachrome tautomerase (DCT, marker 4150), dynactin 1 (DCTN1, marker 4151), DCTN1 antisense RNA 1 (DCTN1-AS1, marker 4152), dynactin 2 (p50) (DCTN2, marker 4153), dynactin 2 (p50) (DCTN2, marker 4154), dynactin 4 (p62) (DCTN4, marker 4155), dynactin 5 (p25) (DCTN5, marker 4156), DCN1, defective in cullin neddylation 1, domain containing 1 (DCUN1D1, marker 4157), DCN1, defective in cullin neddylation 1, domain containing 1 (DCUN1D1, marker 4158), DCN1, defective in cullin neddylation 1, domain containing 5 (DCUN1D5, marker 4159), DET1 and DDB1 associated 1 (DDA1, marker 4160), dopa decarboxylase (DDC, marker 4161), DDC antisense RNA 1 (DDC-AS1, marker 4162), DDHD domain containing 1 (DDHD1, marker 4163), DNA-damage inducible 1 homolog 1 (DDI1, marker 4164), DNA-damage inducible 1 homolog 2 (DDI2, marker 4165), dendrin (DDN, marker 4166), D-aspartate oxidase (DDO, marker 4167), D-aspartate oxidase (DDO, marker 4168), DDR1 antisense RNA 1 (head to head) (DDR1-AS1, marker 4169), DDR1 antisense RNA 1 (head to head) (DDR1-AS1, marker 4170),discoidin domain receptor tyrosine kinase 2 (DDR2, marker 4171), DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 (DDX10, marker 4172), DDX11 antisense RNA 1 (DDX11-AS1, marker 4173), DEAD (Asp-Glu-Ala-Asp) box polypeptide 19A (DDX19A, marker 4174), DEAD (Asp-Glu-Ala-Asp) box polypeptide 19B (DDX19B, marker 4175), DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 (DDX28, marker 4176), DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 (DDX31, marker 4177), DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked (DDX3X, marker 4178), DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked (DDX3X, marker 4179), DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked (DDX3Y, marker 4180), DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked (DDX3Y, marker 4181), DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked (DDX3Y, marker 4182), DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked (DDX3Y, marker 4183), DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 (DDX4, marker 4184), DEAD (Asp-Glu-Ala-Asp) box helicase 42 (DDX42, marker 4185), DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 (DDX43, marker 4186), DEAD (Asp-Glu-Ala-Asp) box polypeptide 49 (DDX49,Marker 4187), DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 (DDX50, marker 4188), DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 (DDX51, marker 4189), DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 (DDX51, marker 4190), DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 (DDX52, marker 4191), DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 (DDX53, marker 4192), DEAD (Asp-Glu-Ala-Asp) box helicase 56 (DDX56, marker 4193), DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like (DDX60L, marker 4194), DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like (DDX60L, marker 4195), DEAF1 transcription factor (DEAF1, marker 4196), deleted in esophageal cancer 1 (1-Dec, marker 4197), DEF6 guanine nucleotide exchange factor (DEF6, marker 4198), DEF6 guanine nucleotide exchange factor (DEF6, marker 4199), defensin, alpha 1 / / / defensin, alpha 1B / / / defensin, alpha 3, neutrophil-specific (DEFA1 / / / DEFA1B / / / DEFA3, marker 4200), defensin, alpha 4, corticostatin (DEFA4, marker 4201), defensin, alpha 5, Paneth cell-specific (DEFA5, marker 4202), defensin, alpha 6, Paneth cell-specific (DEFA6, marker 4203), defensin, beta 1 (DEFB1, marker 4204),defensin, beta 103A / / / defensin, beta 103B (DEFB103A / / / DEFB103B, marker 4205), defensin, beta 104A / / / defensin, beta 104B (DEFB104A / / / DEFB104B, marker 4206), defensin, beta 105A / / / defensin, beta 105B (DEFB105A / / / DEFB105B, marker 4207), defensin, beta 106A / / / defensin, beta 106B (DEFB106A / / / DEFB106B, marker 4208), defensin, beta 107A / / / defensin, beta 107B (DEFB107A / / / DEFB107B, marker 4209), defensin, beta 108B (DEFB108B, marker 4210), defensin, beta 114 (DEFB114, marker 4211), defensin, beta 118 (DEFB118, marker 4212), defensin, beta 119 (DEFB119, marker 4213), defensin, beta 119 (DEFB119, marker 4214), defensin, beta 121 (DEFB121, marker 4215), defensin, beta 122 (pseudogene) (DEFB122, marker 4216), defensin, beta 123 (DEFB123, marker 4217), defensin, beta 124 (DEFB124, marker 4218), defensin, beta 125 (DEFB125, marker 4219), defensin, beta 126 (DEFB126, marker 4220), defensin, beta 126 (DEFB126, marker 4221), defensin, beta 127 (DEFB127, marker 4222), defensin, beta 129 (DEFB129, marker 4223), defensin, beta 132 (DEFB132, marker 4224), defensin, beta 4A / / / defensin,beta 4B(DEFB4A / / / DEFB4B,マカー4225),defensin, theta 1 pseudogene / / / defensin, theta 1 pseudogene 2(DEFT1P / / / DEFT1P2,マーー4226),delta(4)-desaturase, sphingolipid 2(DEGS2,マーカー4227),DENN / MADD domain containing 1B(DENND1B,マカー4228),DENN / MADD domain containing 1B(DENND1B,マーー4229),DENN / MADD domain containing 1B(DENND1B,ーカー4230),DENN / MADD domain containing 1C(DENND1C,マカー4231),DENN / MADD domain containing 2C(DENND2C,マーカー4232),DENN / MADD domain containing 2D(DENND2D,マーカー4233),DENN / MADD domain containing 2D(DENND2D,マーー4234),DENN / MADD domain containing 3(DENND3,マーカー4235),DENN / MADD domain containing 3(DENND3,マーー4236),DENN / MADD domain containing 4A(DENND4A,マカー4237),DENN / MADD domain containing 4C(DENND4C,マーー4238),DENN / MADD domain containing 5B(DENND5B,マーー4239),DENN / MADD domain containing 6B(DENND6B,マカー4240),DENN / MADD domain containing 6B(DENND6B,マーカー4241),DENN / MADD domain containing 6B(DENND6B,ーー4242),DEPDC1 antisense RNA 1(DEPDC1-AS1,ーー4243),DEP domain containing 4(DEPDC4,ーカ4244),DEP domain containing 4 (DEPDC4, marker 4245), DEP domain containing MTOR-interacting protein (DEPTOR, marker 4246), derlin 1 (DERL1, marker 4247), derlin 3 (DERL3, marker 4248), derlin 3 (DERL3, marker 4249), desmin (DES, marker 4250), desmin (DES, marker 4251), desmin / / / SPT20 homolog, SAGA complex component (DES / / / SUPT20H, marker 4252), deafness, autosomal recessive 31 (DFNB31, marker 4253), DiGeorge syndrome critical region gene 10 (non-protein codon, ng) (DGCR10, marker 4254), DiGeorge syndrome critical region gene 12 (non-protein coding) (DGCR12, marker 4255), DiGeorge syndrome critical region gene 12 (non-protein coding) (DGCR12, marker 4256), DiGeorge syndrome critical region gene 14 (DGCR14, marker 4257), DiGeorge syndrome critical region gene 14 (DGCR14, marker 4258), DiGeorge syndrome critical region gene 14 (DGCR14, marker 4259), DiGeorge syndrome critical region gene 5 (non-protein coding) (DGCR5, marker 4260), DiGeorge syndrome critical region gene 5 (non-protein coding) (DGCR5, marker 4261), DiGeorge syndrome critical region gene 5 (non-protein coding) (DGCR5, marker 4262), DiGeorge syndrome Critical region gene 5 (non-protein coding) (DGCR5, marker 4263), DiGeorge syndrome critical region gene 5 (non-protein coding) / / / uncharacterized LOC100287576 (DGCR5 / / / LOC100287576, marker 4264), DiGeorge syndrome critical region gene 6-like (DGCR6L, marker 4265), DiGeorge syndrome critical region gene 7 (DGCR7, marker 4266), DiGeorge syndrome critical region gene 7 (DGCR7, marker 4267),DiGeorge syndrome critical region gene 9 (non-protein coding) (DGCR9, marker 4268), diacylglycerol kinase alpha (DGKA, marker 4269), diacylglycerol kinase, beta 90kDa (DGKB, marker 4270), diacylglycerol kinase, beta 90kDa (DGKB, marker 4271), diacylglycerol kinase, epsilon 64kDa (DGKE, marker 4272), diacylglycerol kinase, epsilon 64kDa (DGKE, marker 4273), diacylglycerol kinase, epsilon 64kDa (DGKE, marker 4274), diacylglycerol kinase, epsilon 64kDa (DGKE, marker 4275), diacylglycerol kinase gamma (DGKG, marker 4276), diacylglycerol kinase gamma (DGKG, marker 4277), diacylglycerol kinase, eta (DGKH, marker 4278), diacylglycerol kinase, eta (DGKH, marker 4279), diacylglycerol kinase, iota (DGKI, marker 4280), diacylglycerol kinase, iota / / / uncharacterized LOC100128727 (DGKI / / / LOC100128727, marker 4281), diacylglycerol kinase theta (DGKQ, marker 4282), diacylglycerol kinase, zeta (DGKZ, marker 4283), deoxyguanosine kinase (DGUOK, marker 4284), dihydrodiol dehydrogenase (dimeric) (DHDH, marker 4285), desert hedgehog (DHH, marker 4286), dihydroorotate dehydrogenase (quinone)(DHODH, marker 4287),Dihydroorotate dehydrogenase (quinone) (DHODH, marker 4288), dehydrogenase / reductase (SDR family) member 12 (DHRS12, marker 4289), dehydrogenase / reductase (SDR family) member 12 (DHRS12, marker 4290), dehydrogenase / reductase (SDR family) member 2 (DHRS2, marker 4291), DHRS4-AS1 (marker 4291), dehydrogenase / reductase (SDR family) member 7 (DHRS7, marker 4293), dehydrogenase / reductase (SDR family) member 7 (DHRS7, marker 4294), dehydrogenase / reductase (SDR family) member 7C (DHRS7C, marker 4295), dehydrogenase / reductase (SDR family) member 9 (DHRS9, marker 4296), dehydrogenase / reductase (SDR family) member 9 (DHRS9, marker 4297), dehydrogenase / reductase (SDR family) member 9 (DHRS9, marker 4298), DEAH (Asp-Glu-Ala-His) box helicase 30 (DHX30, marker 4299), DEAH (Asp-Glu-Ala-His) box helicase 30 (DHX30, marker 4300), DEAH (Asp-Glu-Ala-His) box polypeptide 34 (DHX34, marker 4301), DEAH (Asp-Glu-Ala-His) box polypeptide 35 (DHX35, marker 4302), DEAH (Asp-Glu-Ala-His) box polypeptide 36 (DHX36, marker 4303), DEAH (Asp-Glu-Ala-Asp / His) box polypeptide 57 (DHX57, marker 4304),DEXH (Asp-Glu-X-His) box polypeptide 58 (DHX58, marker 4305), DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8, marker 4306), diaphanous-related formin 1 (DIAPH1, marker 4307), DIAPH2 antisense RNA 1 (DIAPH2-AS1, marker 4308), DIAPH2 antisense RNA 1 (DIAPH2-AS1, marker 4309), diaphanous-related formin 3 (DIAPH3, marker 4310), diaphanous-related formin 3 (DIAPH3, marker 4311), DIAPH3 antisense RNA 1 (DIAPH3-AS1, marker 4312), DIAPH3 antisense RNA 1 (DIAPH3-AS1, marker 4313), DIAPH3 antisense RNA 1 (DIAPH3-AS1, marker 4314), dicer 1, ribonuclease type III (DICER1, marker 4315), dicer 1, ribonuclease type III (DICER1, marker 4316), dicer 1, ribonuclease type III (DICER1, marker 4317), DICER1 antisense RNA 1 (DICER1-AS1, marker 4318), DIM1 dimethyladenosine transferase 1 homolog (DIMT1, marker 4319), deiodinase, iodothyronine, type I (DIO1, marker 4320), deiodinase, iodothyronine, type II (DIO2, marker 4321), deiodinase, iodothyronine, type II (DIO2, marker 4322), deiodinase, iodothyronine, type II (DIO2, marker 4323), deiodinase, iodothyronine, type II (DIO2, marker 4324), deiodinase, iodothyronine,type II (DIO2, marker 4325), DIO2 antisense RNA 1 (DIO2-AS1, marker 4326), DIO3 opposite strand / antisense RNA (head to head) (DIO3OS, marker 4327), DIO3 opposite strand / antisense RNA (head to head) (DIO3OS, marker 4328), DIO3 opposite strand / antisense RNA (head to head) (DIO3OS, marker 4329), disco-interacting protein 2 homolog A (DIP2A, marker 4330), disco-interacting protein 2 homolog A (DIP2A, marker 4331), disco-interacting protein 2 homolog A (DIP2A, marker 4332), disco-interacting protein 2 homolog A (DIP2A, marker 4333), disco-interacting protein 2 homolog A (DIP2A, marker 4334), disco-interacting protein 2 homolog B (DIP2B, marker 4335), disco-interacting protein 2 homolog B (DIP2B, marker 4336), DIRAS family, GTP-binding RAS-like 1 (DIRAS1, marker 4337), DIRAS family, GTP-binding RAS-like 2 (DIRAS2, marker 4338), DIRAS family, GTP-binding RAS-like 2 (DIRAS2, marker 4339), DIRAS family, GTP-binding RAS-like 3 (DIRAS3, marker 4340), disrupted in renal carcinoma 1 (DIRC1, marker 4341), disrupted in renal carcinoma 3 (DIRC3, marker 4342), DIS3 homolog,exosome endoribonuclease and 3'-5' exoribonuclease (DIS3, marker 4343), disrupted in schizophrenia 1 (DISC1, marker 4344), disrupted in schizophrenia 1 (DISC1, marker 4345), disrupted in schizophrenia 1 (DISC1, marker 4346), disrupted in schizophrenia 1 / / / TSNAX-DISC1 readthrough (NMD candidate) (DISC1 / / / TSNAX-DISC1, marker 4347), disrupted in schizophrenia 1 / / / TSNAX-DISC1 readthrough (NMD candidate) (DISC1 / / / TSNAX-DISC1, marker 4348), dispatched homolog 2 (Drosophila) (DISP2, marker 4349), dispatched homolog 2 (Drosophila) / / / proline / histidine / glycine-rich 1 (DISP2 / / / PHGR1, marker 4350), uncharacterized LOC26102 (DKFZP434A062, marker 4351), uncharacterized LOC26102 (DKFZP434A062, marker 4352), uncharacterized LOC26077 (DKFZP434H168, marker 4353), uncharacterized LOC26070 (DKFZP434K028, marker 4354), uncharacterized LOC26082 (DKFZP434L187, marker 4355), uncharacterized LOC26082 (DKFZP434L187, marker 4356), uncharacterized LOC26082 / / / uncharacterized LOC105370751 (DKFZP434L187 / / / LOC105370751, marker 4357), uncharacterized protein DKFZp761C1711 (DKFZP761C1711,marker 4358), uncharacterized protein DKFZp761C1711 (DKFZP761C1711, marker 4359), uncharacterized DKFZp434E1119 (DKFZp434E1119, marker 4360), uncharacterized LOC93429 (DKFZp434J0226, marker 4361), uncharacterized protein DKFZp434L192 (DKFZp434L192, marker 4362), uncharacterized LOC401282 (DKFZp451B082, marker 4363), uncharacterized LOC84237 (DKFZp547J222, marker 4364), uncharacterized LOC84237 (DKFZp547J222, marker 4365), uncharacterized DKFZp779M0652 (DKFZp779M0652, marker 4366), Dickkopf WNT signaling pathway inhibitor 2 (DKK2, marker 4367), Dickkopf WNT signaling pathway inhibitor 3 (DKK3, marker 4368), Dickkopf WNT signaling pathway inhibitor 4 (DKK4, marker 4369), Dickkopf-like 1 (DKKL1, marker 4370), DLC1 Rho GTPase activating protein (DLC1, marker 4371), DLC1 Rho GTPase activating protein (DLC1, marker 4372), DLC1 Rho GTPase activating protein (DLC1, marker 4373), deleted in lung and esophageal cancer 1 (DLEC1, marker 4374), deleted in lung and esophageal cancer 1 (DLEC1, marker 4375), deleted in lung and esophageal cancer 1 (DLEC1, marker 4376),deleted in lymphocytic leukemia 2 (non-protein coding) (DLEU2, marker 4377), deleted in lymphocytic leukemia 2 (non-protein coding) (DLEU2, marker 4378), deleted in lymphocytic leukemia 2 (non-protein coding) (DLEU2, marker 4379), deleted in lymphocytic leukemia 2 (non-protein coding) (DLEU2, marker 4380), deleted in lymphocytic leukemia 2 (non-protein coding) (DLEU2, marker 4381), deleted in lymphocytic leukemia, 7 (DLEU7, marker 4382), deleted in lymphocytic leukemia, 7 (DLEU7, marker 4383), DLEU7 antisense RNA 1 (DLEU7-AS1, marker 4384), discs large homolog 1 (Drosophila)(DLG1, marker 4385), discs, large homolog 1 (Drosophila)(DLG1, marker 4386), DLG1 antisense RNA 1(DLG1-AS1, marker 4387), discs, large homolog 2 (Drosophila)(DLG2, marker 4388), discs, large homolog 2 (Drosophila)(DLG2, marker 4389), DLG3 antisense RNA 1(DLG3-AS1, marker 4390), discs, large homolog 4 (Drosophila)(DLG4, marker 4391), DLG5 antisense RNA 1(DLG5-AS1, marker 4392), DLG5 antisense RNA 1(DLG5-AS1, marker 4393), discs, large (Drosophila) homolog-associated protein 1(DLGAP1, marker 4394), discs,large (Drosophila) homolog-associated protein 1 (DLGAP1, marker 4395), discs, large (Drosophila) homolog-associated protein 1 (DLGAP1, marker 4396), discs, large (Drosophila) homolog-associated protein 1 (DLGAP1, marker 4397), DLGAP1 antisense RNA 3 (DLGAP1-AS3, marker 4398), discs, large (Drosophila) homolog-associated protein 2 (DLGAP2, marker 4399), discs, large (Drosophila) homolog-associated protein 2 (DLGAP2, marker 4400), DLGAP2 antisense RNA 1 (DLGAP2-AS1, marker 4401), discs, large (Drosophila) homolog-associated protein 3 (DLGAP3, marker 4402), DLGAP4 antisense RNA 1 (DLGAP4-AS1, marker 4403), delta-like 1 (Drosophila) (DLL1, marker 4404), delta-like 3 (Drosophila) (DLL3, marker 4405), delta-like 3 (Drosophila) (DLL3, marker 4406), delta-like 3 (Drosophila) (DLL3, marker 4407), delta-like 4 (Drosophila) (DLL4, marker 4408), distal-less homeobox 1 (DLX1, marker 4409), distal-less homeobox 1 (DLX1, marker 4410), distal-less homeobox 2 (DLX2, marker 4411), distal-less homeobox 4 (DLX4, marker 4412), distal-less homeobox 4 (DLX4, marker 4413), distal-less homeobox 6 (DLX6, marker 4414),Distal-less homeobox 6 (DLX6, marker 4415), distal-less homeobox 6 (DLX6, marker 4416), DLX6 antisense RNA 1 (DLX6-AS1, marker 4417), diencephalon / mesencephalon homeobox 1 (DMBX1, marker 4418), DNA meiotic recombinase 1 (DMC1, marker 4419), dystrophin (DMD, marker 4420), dystrophin (DMD, marker 4421), dimethylglycine dehydrogenase (DMGDH, marker 4422), dimethylglycine dehydrogenase (DMGDH, marker 4423), dentin matrix acidic phosphoprotein 1 (DMP1, marker 4424), dentin matrix acidic phosphoprotein 1 (DMP1, marker 4425), dystrophia myotonica-protein kinase (DMPK, marker 4426), doublesex and mab-3 related transcription factor 1 (DMRT1, marker 4427), doublesex and mab-3 related transcription factor 2 (DMRT2, marker 4428), doublesex and mab-3 related transcription factor, 2 (DMRT2, marker 4429), doublesex and mab-3 related transcription factor 3 (DMRT3, marker 4430), DMRT-like family B with proline-rich C-terminal, 1 (DMRTB1, marker 4431), DMRT-like family C1 / / / DMRT-like family C1B (DMRTC1 / / / DMRTC1B, marker 4432), DMRT-like family C1 / / / DMRT-like family C1B (DMRTC1 / / / DMRTC1B, marker 4433), DMRT-like family C2 (DMRTC2, marker 4434), dematin actin binding protein (DMTN, marker 4435), Dmx-like 2 (DMXL2, marker 4436), dynein, axonemal, assembly factor 1 (DNAAF1, marker 4437), dynein, axonemal, assembly factor 1 (DNAAF1, marker 4438), dynein, axonemal, assembly factor 3 (DNAAF3, marker 4439), dynein, axonemal, heavy chain 1 (DNAH1, marker 4440), dynein, axonemal, heavy chain 1 (DNAH1, marker 4441), dynein, axonemal, heavy chain 1 (DNAH1, marker 4442), dynein, axonemal, heavy chain 1 (DNAH1, marker 4443), dynein, axonemal, heavy chain 1 (DNAH1, marker 4444), dynein, axonemal, heavy chain 1 (DNAH1, marker 4445), dynein, axonemal, heavy chain 1 (DNAH1, marker 4446), dynein, axonemal, heavy chain 1 (DNAH1, marker 4447), dynein, axonemal, heavy chain 1 (DNAH1, marker 4448),Dynein, axonemal, heavy chain 1 (DNAH1, marker 4449), dynein, axonemal, heavy chain 1 (DNAH1, marker 4450), dynein, axonemal, heavy chain 1 (DNAH1, marker 4451), dynein, axonemal, heavy chain 1 (DNAH1, marker 4452), dynein, axonemal, heavy chain 10 (DNAH10, marker 4453), dynein, axonemal, heavy chain 10 (DNAH10, marker 4454), dynein, axonemal, heavy chain 10 (DNAH10, marker 4455), dynein, axonemal, heavy chain 11 (DNAH11, marker 4456), dynein, axonemal, heavy chain 11 (DNAH11, marker 4457), dynein, axonemal, heavy chain 11 (DNAH11, marker 4458), dynein, axonemal, heavy chain 12 (DNAH12, marker 4459), dynein, axonemal, heavy chain 12 (DNAH12, marker 4460), dynein, axonemal, heavy chain 14 (DNAH14, marker 4461), dynein, axonemal, heavy chain 14 (DNAH14, marker 4462), dynein, axonemal, heavy chain 14 (DNAH14, marker 4463), dynein, axonemal, heavy chain 17 (DNAH17, marker 4464), dynein, axonemal, heavy chain 17 (DNAH17, marker 4465), DNAH17 antisense RNA 1 (DNAH17-AS1, marker 4466), dynein, axonemal, heavy chain 2 (DNAH2, marker 4467), dynein, axonemal, heavy chain 2 (DNAH2, marker 4468), dynein, axonemal,heavy chain 3 (DNAH3, marker 4469), dynein, axonemal, heavy chain 3 (DNAH3, marker 4470), dynein, axonemal, heavy chain 3 (DNAH3, marker 4471), dynein, axonemal, heavy chain 3 (DNAH3, marker 4472), dynein, axonemal, heavy chain 5 (DNAH5, marker 4473), dynein, axonemal, heavy chain 6 (DNAH6, marker 4474), dynein, axonemal, heavy chain 6 (DNAH6, marker 4475), dynein, axonemal, heavy chain 6 (DNAH6, marker 4476), dynein, axonemal, heavy chain 6 (DNAH6, marker 4477), dynein, axonemal, heavy chain 6 (DNAH6, marker 4478), dynein, axonemal, heavy chain 6 (DNAH6, marker 4479), dynein, axonemal, heavy chain 6 (DNAH6, marker 4480), dynein, axonemal, heavy chain 7 (DNAH7, marker 4481), dynein, axonemal, heavy chain 7 (DNAH7, marker 4482), dynein, axonemal, heavy chain 7 (DNAH7, marker 4483), dynein, axonemal, heavy chain 8 (DNAH8, marker 4484), dynein, axonemal, heavy chain 9 (DNAH9, marker 4485), dynein, axonemal, heavy chain 9 (DNAH9, marker 4486), dynein, axonemal, heavy chain 9 (DNAH9, marker 4487), dynein, axonemal, intermediate chain 1 (DNAI1, marker 4488), dynein, axonemal, intermediate chain 2(DNAI2,dynein, axonemal, intermediate chain 2 (DNAI2, marker 4490), DnaJ (Hsp40) homolog, subfamily A, member 4 (DNAJA4, marker 4491), DnaJ (Hsp40) homolog, subfamily B, member 12 (DNAJB12, marker 4492), DnaJ (Hsp40) homolog, subfamily B, member 13 (DNAJB13, marker 4493), DnaJ (Hsp40) homolog, subfamily B, member 7 (DNAJB7, marker 4494), DnaJ (Hsp40) homolog, subfamily B, member 8 (DNAJB8, marker 4495), DNAJB8 antisense RNA 1 (DNAJB8-AS1, marker 4496), DnaJ (Hsp40) homolog, subfamily C, member 10 (DNAJC10, marker 4497), DnaJ (Hsp40) homolog, Subfamily C, member 12 (DNAJC12, marker 4498), DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12, marker 4499), DnaJ (Hsp40) homolog, subfamily C, member 13 (DNAJC13, marker 4500), DnaJ (Hsp40) homolog, subfamily C, member 16 (DNAJC16, marker 4501), DnaJ (Hsp40) homolog, subfamily C, member 2 (DNAJC2, marker 4502), DnaJ (Hsp40) homolog, subfamily C, member 21 (DNAJC21, marker 4503), DnaJ (Hsp40) homolog, subfamily C, member 21 (DNAJC21, marker 4504), DnaJ (Hsp40) homolog, subfamily C, member 21 (DNAJC21, marker 4505),DnaJ (Hsp40) homolog, subfamily C, member 22 (DNAJC22, marker 4506), DnaJ (Hsp40) homolog, subfamily C, member 22 (DNAJC22, marker 4507), DnaJ (Hsp40) homolog, subfamily C, member 24 (DNAJC24, marker 4508), DnaJ (Hsp40) homolog, subfamily C, member 27 (DNAJC27, marker 4509), DnaJ (Hsp40) homolog, subfamily C, member 27 (DNAJC27, marker 4510), DNAJC27 antisense RNA 1 (DNAJC27-AS1, marker 4511), DnaJ (Hsp40) homolog, subfamily C, member 28 (DNAJC28, marker 4512), DNAJC3 antisense RNA 1 (head to head) (DNAJC3-AS1, marker 4513), DnaJ (Hsp40) homolog, subfamily C, member 30 (DNAJC30, marker 4514), DnaJ (Hsp40) homolog, subfamily C, member 4 (DNAJC4, marker 4515), DnaJ (Hsp40) homolog, subfamily C, member 4 (DNAJC4, marker 4516), DnaJ (Hsp40) homolog, subfamily C, member 4 (DNAJC4, marker 4517), DnaJ (Hsp40) homolog, subfamily C, member 5 beta (DNAJC5B, marker 4518), DnaJ (Hsp40) homolog, subfamily C, member 5 beta (DNAJC5B, marker 4519), DnaJ (Hsp40) homolog, subfamily C, member 5 gamma (DNAJC5G, marker 4520), DnaJ (Hsp40) homolog, subfamily C, member 6 (DNAJC6, marker 4521),DNAJC9 antisense RNA 1 (DNAJC9-AS1, marker 4522), dynein, axonemal, light chain 1 (DNAL1, marker 4523), dynein, axonemal, light chain 1 (DNAL1, marker 4524), deoxyribonuclease I (DNASE1, marker 4525), deoxyribonuclease I (DNASE1, marker 4526), ​​deoxyribonuclease I (DNASE1, marker 4527), deoxyribonuclease I (DNASE1, marker 4528), deoxyribonuclease I (DNASE1, marker 4529), deoxyribonuclease I-like 2 (DNASE1L2, marker 4530), deoxyribonuclease I-like 3 (DNASE1L3, marker 4531), deoxyribonuclease I-like 3 (DNASE1L3, marker 4532), deoxyribonuclease II beta (DNASE2B, marker 4533), dynein heavy chain domain 1 (DNHD1, marker 4534), dynein heavy chain domain 1 (DNHD1, marker 4535), dynein heavy chain domain 1 (DNHD1, marker 4536), dynein heavy chain domain 1 (DNHD1, marker 4537), dynamin 1 (DNM1, marker 4538), dynamin 1-like (DNM1L, marker 4539), dynamin 1 pseudogene 35 (DNM1P35, marker 4540), dynamin 1 pseudogene 41 (DNM1P41, marker 4541), dynamin 1 pseudogene 46 (DNM1P46, marker 4542), dynamin 2 (DNM2, marker 4543), dynamin 2 (DNM2, marker 4544), dynamin 3 (DNM3, marker 4545), DNM3 opposite strand / antisense RNA (DNM3OS, marker 4546),DNM3 opposite strand / antisense RNA (DNM3OS, marker 4547), dynamin binding protein (DNMBP, marker 4548), DNA (cytosine-5-)-methyltransferase 3-like (DNMT3L, marker 4549), aspartyl aminopeptidase (DNPEP, marker 4550), 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1, marker 4551), DNA nucleotidylexotransferase (DNTT, marker 4552), DNA nucleotidylexotransferase (DNTT, marker 4553), DNA nucleotidylexotransferase (DNTT, marker 4554), double C2-like domains, alpha (DOC2A, marker 4555), double C2-like domains, beta (DOC2B, marker 4556), double C2-like domains, beta(DOC2B, marker 4557), dedicator of cytokinesis 1(DOCK1, marker 4558), dedicator of cytokinesis 1(DOCK1, marker 4559), dedicator of cytokinesis 10(DOCK10, marker 4560), dedicator of cytokinesis 10(DOCK10, marker 4561), dedicator of cytokinesis 2(DOCK2, marker 4562), dedicator of cytokinesis 4(DOCK4, marker 4563), dedicator of cytokinesis 4(DOCK4, marker 4564), DOCK4 antisense RNA 1(DOCK4-AS1, marker 4565), dedicator of cytokinesis 5(DOCK5, marker 4566), dedicator of cytokinesis 5(DOCK5, marker 4567), dedicator of cytokinesis 5(DOCK5, marker 4568),dedicator of cytokinesis 5 (DOCK5, marker 4569), dedicator of cytokinesis 5 (DOCK5, marker 4570), dedicator of cytokinesis 6 (DOCK6, marker 4571), dedicator of cytokinesis 7 (DOCK7, marker 4572), dedicator of cytokinesis 8 (DOCK8, marker 4573), dedicator of cytokinesis 8 (DOCK8, marker 4574), dedicator of cytokinesis 8 (DOCK8, marker 4575), dedicator of cytokinesis 9 (DOCK9, marker 4576), dedicator of cytokinesis 9 (DOCK9, marker 4577), dedicator of cytokinesis 9 (DOCK9, marker 4578), dedicator of cytokinesis 9 (DOCK9, marker 4579), dedicator of cytokinesis 9 (DOCK9, marker 4580), DOCK9 antisense RNA 2 (head to head) (DOCK9-AS2, marker 4581), deoxyhypusine hydroxylase / monooxygenase (DOHH, marker 4582), docking protein 2 (DOK2, marker 4583), docking protein 3 (DOK3, marker 4584), docking protein 3 (DOK3, marker 4585), docking protein 6 (DOK6, marker 4586), docking protein 6 (DOK6, marker 4587), docking protein 6 (DOK6, marker 4588), dopey family member 1 (DOPEY1, marker 4589), dopey family member 1 (DOPEY1, marker 4590), dopey family member 2 (DOPEY2, marker 4591), DOT1-like histone H3K79 methyltransferase (DOT1L, marker 4592),Diffuse panbronchiolitis critical region 1 (DPCR1, marker 4593), diffuse panbronchiolitis critical region 1 (DPCR1, marker 4594), dipeptidase 1 (renal) (DPEP1, marker 4595), dipeptidase 2 (DPEP2, marker 4596), dipeptidase 3 (DPEP3, marker 4597), D4, zinc and double PHD fingers family 1 (DPF1, marker 4598), D4, zinc and double PHD fingers, family 3 (DPF3, marker 4599), D4, zinc and double PHD fingers, family 3 (DPF3, marker 4600), D4, zinc and double PHD fingers, family 3 (DPF3, marker 4601), D4, zinc and double PHD fingers, family 3 (DPF3, marker 4602), diphthamide biosynthesis 3 pseudogene 1 (DPH3P1, marker 4603), diphthamine biosynthesis 6 (DPH6, marker 4604), DPH6 antisense RNA 1 (head to head) (DPH6-AS1, marker 4605), DPP10 antisense RNA 3 (DPP10-AS3, marker 4606), dipeptidyl-peptidase 6 (DPP6, marker 4607), dipeptidyl-peptidase 6 (DPP6, marker 4608), dipeptidyl-peptidase 7 (DPP7, marker 4609), dipeptidyl-peptidase 9 (DPP9, marker 4610), dipeptidyl-peptidase 9 (DPP9, marker 4611), developmental pluripotency associated 4 (DPPA4, marker 4612), developmental pluripotency associated 5 (DPPA5, marker 4613),dermatopontin (DPT, marker 4614), dermatopontin (DPT, marker 4615), dermatopontin (DPT, marker 4616), dpy-19-like 1 (C. elegans) (DPY19L1, marker 4617), dpy-19-like 1 (C. elegans) (DPY19L1, marker 4618), dpy-19-like 1 (C. elegans) (DPY19L1, marker 4619), DPY19L1 pseudogene 1 (DPY19L1P1, marker 4620), DPY19L2 pseudogene 2 (DPY19L2P2, marker 4621), DPY19L2 pseudogene 3 (DPY19L2P3, marker 4622), DPY19L2 pseudogene 4 (DPY19L2P4, marker 4623), dihydropyrimidine dehydrogenase (DPYD, marker 4624), dihydropyrimidine dehydrogenase (DPYD, marker 4625), dihydropyrimid, ine dehydrogenase (DPYD, marker 4626), dihydropyrimidinase (DPYS, marker 4627), dihydropyrimidinase-like 3 (DPYSL3, marker 4628), dihydropyrimidinase-like 4 (DPYSL4, marker 4629), DEAQ box RNA-dependent ATPase 1 (DQX1, marker 4630), down-regulator of transcription 1 (DR1, marker 4631), downregulated RNA in cancer, inhibitor of cell invasion and migration (DRAIC, marker 4632), downregulated RNA in cancer, inhibitor of cell invasion and migration (DRAIC, marker 4633), dynein regulatory complex subunit 1 (DRC1, marker 4634), dynein regulatory complex subunit 3 (DRC3, marker 4635), dynein regulatory complex subunit 3 (DRC3, marker 4636), dynein regulatory complex subunit 7 (DRC7, marker 4637), dopamine receptor D1 (DRD1, marker 4638), dopamine receptor D2 (DRD2, marker 4639), dopamine receptor D2 (DRD2, marker 4640), dopamine receptor D3 (DRD3, marker 4641), dopamine receptor D3 (DRD3, marker 4642), dopamine receptor D4 (DRD4, marker 4643), dopamine receptor D5 (DRD5, marker 4644), aspartate-rich 1 (DRICH1, marker 4645), aspartate-rich 1 (DRICH1, marker 4646), dystrophin-related protein 2 (DRP2, marker 4647),Dystrophin-related protein 2 (DRP2, marker 4648), dystrophin-related protein 2 (DRP2, marker 4649), desmocollin 1 (DSC1, marker 4650), desmocollin 2 (DSC2, marker 4651), desmocollin 3 (DSC3, marker 4652), desmocollin 3 (DSC3, marker 4653), Down syndrome cell adhesion molecule (DSCAM, marker 4654), Down syndrome cell adhesion molecule (DSCAM, marker 4655), Down syndrome cell adhesion molecule (DSCAM, marker 4656), DSCAM antisense RNA 1 (DSCAM-AS1, marker 4657), Down syndrome cell adhesion molecule like 1 (DSCAML1, marker 4658), Down syndrome cell adhesion molecule like 1 (DSCAML1, marker 4659), DNA replication and sister chromatid cohesion 1 (DSCC1, marker 4660), Down syndrome critical region 10 (non-protein coding) (DSCR10, marker 4661), Down syndrome critical region 4 (DSCR4, marker 4662), Down syndrome critical region 8 (DSCR8, marker 4663), Down syndrome critical region 9 (non-protein coding) (DSCR9, marker 4664), dermatan sulfate epimerase (DSE, marker 4665), dermatan sulfate epimerase (DSE, marker 4666), dermatan sulfate epimerase-like (DSEL, marker 4667), desmoglein 1 (DSG1, marker 4668),DSG2 antisense RNA 1 (DSG2-AS1, marker 4669), desmoglein 3 (DSG3, marker 4670), desmoglein 3 (DSG3, marker 4671), desmoglein 4 (DSG4, marker 4672), dentin sialophosphoprotein (DSPP, marker 4673), dystonin (DST, marker 4674), dystonin (DST, marker 4675), dystonin (DST, marker 4676), dystonin (DST, marker 4677), dystonin (DST, marker 4678), dual serine / threonine and tyrosine protein kinase (DSTYK, marker 4679), D-tyrosyl-tRNA deacylase 1 (DTD1, marker 4680), death domain containing 1 (DTHD1, marker 4681), dystrobrevin, alpha (DTNA, marker 4682), dystrobrevin beta (DTNB, marker 4683), dystrobrevin beta (DTNB, marker 4684), dystrobrevin binding protein 1 (DTNBP1, marker 4685), DTW domain containing 1 (DTWD1, marker 4686), DTW domain containing 1 (DTWD1, marker 4687), DTW domain containing 1 (DTWD1, marker 4688), deltex 1, E3 ubiquitin ligase (DTX1, marker 4689), deltex 3, E3 ubiquitin ligase (DTX3, marker 4690), deltex 3, E3 ubiquitin ligase (DTX3, marker 4691), deltex 3, E3 ubiquitin ligase (DTX3, marker 4692), deltex 3, E3 ubiquitin ligase (DTX3, marker 4693), deoxythymidylate kinase (DTYMK, marker 4694), deoxythymidylate kinase (DTYMK,marker 4695), dual oxidase 1 (DUOX1, marker 4696), dual oxidase 1 (DUOX1, marker 4697), dual oxidase 1 (DUOX1, marker 4698), dual oxidase 2 (DUOX2, marker 4699), dual oxidase maturation factor 1 (DUOXA1, marker 4700), dual oxidase maturation factor...

Claims

【Claim 1】 To human adipose-derived mesenchymal stem cells that have lost their proliferative ability through subculture, introduce reprogramming factors (OCT4, SOX2, KLF4, GLIS1) by gene transfer, after the gene transfer, from the cell population having proliferative ability, by performing subculture 5 or more times, obtain cells in which the expression of NANOG, OCT4, and SOX2 genes is significantly lower than that in ES / iPS cells, and in which CD29, CD90, CD44, CD73, CD105, CD55, CD59, CD71, CD166, IGF1, HGF, FGF2, VEGFA, and EGF genes are expressed. A method for producing human mesenchymal tissue-specific stem / progenitor cells, characterized by the above.

Images